CURRICULUM VITAE

**University of Pittsburgh**

**School of Medicine**

**BIOGRAPHICAL**

**Name: Jerry Vockley, M.D., Ph.D.** **Birth Date:** 5/24/1956

**Business Address** University of Pittsburgh School of Medicine **E-Mail Address:** Jerry.vockley@chp.edu

Children’s Hospital of Pittsburgh of UPMC

Department of Medical Genetics

4401 Penn Avenue

Pittsburgh, PA 15224

**Business Phone:** (412) 692-7746 **Business Fax:** (412) 692-7816

# EDUCATION AND TRAINING

**UNDERGRADUATE:**

9/1974 – 5/1978 Carnegie Mellon University B.S. Biology

Pittsburgh, PA

**GRADUATE:**

7/1978 – 5/1984 University of Pennsylvania M.D., Ph.D. Harry Harris, M.D. (Thesis advisor)

School of Medicine Medicine, Genetics

**POST GRADUATE:**

6/1984 – 6/1987 University of ColoradoInternship and ResidenceEva Sujansky, M.D**.**

Health Science Center Pediatrics

7/1987 – 6/1991 Yale University Fellowship Kay Tanaka, M.D. (Research advisor)

School of Medicine Pediatrics and Human Genetics

**APPOINTMENTS AND POSITIONS**

**ACADEMIC:**

6/1990 – 6/1991Yale University School of MedicineInstructor of Pediatrics and Human Genetics

7/1991 – 12/1995 Mayo Clinic Assistant Professor of Medical Genetics

1/1996 – 12/1999 Mayo Clinic Associate Professor of Medical Genetics

1/2000 – 12/2003 Mayo Clinic Professor of Medical Genetics

1/2000 – 12/2003 Mayo Clinic Chair, Department of Medical Genetics

1/2004 ­ present UPMC Pittsburgh Children’s Hospital Chief of Genetic and Genomic Medicine

University of Pittsburgh School of Medicine Professor of Pediatrics

University of Pittsburgh Graduate School Professor of Human Genetics

of Public Health

6/2015-present UPMC Children’s Hospital of Pittsburgh Director, Center for Rare Disease Therapies

11/2015-presemt University of Pittsburgh Cleveland Family Endowed Chair in Pediatric

Research

## CERTIFICATION AND LICENSURE

**SPECIALTY CERTIFICATION:**

**Certifying Board Certificate Number Month/Year**

American Board of Pediatrics 041677 6/1989

American Board of Medical Genetics 870745 1/1990

Clinical Genetic

Biochemical/molecular

**MEDICAL OR OTHER PROFESSIONAL LICENSURE:**

**Licensing Board/State** PA MD423265 11/2005

**DEA** Federal **Certificate Number** BV10054935/31/2005

## MEMBERSHIPS IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

**Organization**

American College of Medical Genetics and Genomics: Board of Directors 2021-2027

American College of Pediatrics

American Society for Clinical Investigation

Society for Inherited Metabolic Disorders: Board of Directors (1999-current); President Elect (2003-2004); President (2005- 2007)

American Society of Human Genetics

American Academy of Pediatrics

American Association for the Advancement of Science

Society for the Study of Inborn Errors of Metabolism

International Network for Fatty Acid Oxidation and Research: Founder and Chair

Association for Clinical Translational Science

**HONORS**

**Title of Award/Honor Month/Year**

T. Denny Sanford Visiting Lecturer 4/2023

Elected Fellow of the American Association for the Advancement of Science 6/2021

Organic Acidemia Association Lifetime Service Award 3/2021

Keynote Speaker, National PKU Alliance Annual Meeting 6/2020

Keynote Speaker, International Conference on Genetic and Metabolic Diseases (Cairo) 3/2020

Emmanuel Shapira Award. Molecular Genetics and Metabolism, Top Publication 2019 2/2020

Plenary Speaker, International Inborn Errors or Metabolism and Nutrition Congress (Istanbul) 4/2019

University of Pittsburgh Faculty Innovator 10/2019

Keynote Speaker, Jinan University Grand Rounds, China 11/2018

Invited Faculty, Recordati Course on IEMs, Rio de Janeiro 10/2018

Garrod Award (SSIEM, Best article published in JIMD for 2017) 10/2018

Invited Faculty, SSIEM Academy 4/2016-Present

Award for Excellence in Patient Experience, Wolff Center at UPMC 11/2017

Plenary Lecture. International Paediatric Medical Congress. Dubai, UAE. 11/2017

Mansen Visiting Professor. Boston Children’s Hospital. (Pediatric Grand Rounds) 10/2017

Plenary Lecture (2). International Congress of Inborn Errors of Metabolism, Rio de Janeiro. 9/2017

Haworth Visiting Professor, University of Manitoba and Children’s Hospital of Manitoba 4/2017

Pittsburgh Magazine “Top Doc” Award 2007-2020

Keynote speaker, 4th Annual Plain Population Translational Medicine Meeting 8/2016

Chair, International Network for Fatty Acid Oxidation Research and Management (INFORM) Annual Meeting 6/2016-Present

Aaron Michael Graham Memorial Lectureship, Children’s Hospital of Los Angeles 2/2016

Distinguished Editor, NIH Director’s New Innovator Award Editorial Board 1/2016

Postdoctoral trainee Emir Tas, 2016 Fellow Basic Research Award, Society for Pediatric Research 3/2016

March of Dimes Champion for Babies Award 10/2015

Founder and Chair, International Network for Fatty Acid Oxidation Disorders Research and Management 2014- Present

Ron Scott Memorial Lecturer, University of Washington, Seattle 2014

Program Chair, United Mitochondrial Disease Foundation Annual Meeting. 2014

Faculty Honors University of Pittsburgh, Pittsburgh 2014

Founding Faculty Member Asia Pacific Inborn Errors of Metabolism Academy 2014

Pediatric Grand Rounds Lecture, Children’s Hospital, University of Edmonton 2013

Chair, Sterol and Isoprenoid Research Collaborative Annual Meeting 2013

Chair, American College of Medical Genetics PKU Guideline Workgroup 2012-13

Chair, American College of Medical Genetics Therapeutics Committee 2012- Current

Postdoctoral Trainee Dr. Kristen Suhrie winner of Neil Buist outstanding trainee Award at SIMD annual meeting 2011

Pediatric Grand Rounds Lecture, Children’s Hospital, Halifax, Canada 2011

Pediatric Grand Rounds Lecture, University of California at San Diego 2010

Session chair SSIEM annual meeting (Istanbul) 9/2010

Michael Palmerie Memorial Lecturer, Children’s Hospital of Pittsburgh 7/2010

Plenary Session Chair Xth International Congress on IEMs, San Diego 9/2009

Keynote speaker, SSIEM annual meeting Garrod Day Celebration (Lisbon) 9/2008

Member HRSA Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children 2007-2011

Chair, HRSA Advisory Committee Technical Subcommittee 2007-2011

Chair International Organizing Committee Xth International Congress on IEMs, San Diego 2007- 2009

Member ACMG National Clinical Trial Collaborative Working Group 2006-Current

Member, PA State Newborn Screening Advisory Committee 2006-2010

Postdoctoral Trainee Dr. Miao He winner of Neil Buist outstanding trainee Award at SIMD annual meeting 2007

Past-President SIMD 2007-2009

Donough O’Brien Presidential Lecturer, SIMD Annual Meeting, Nashville, TN 2007

Founder and Managing Editor North American Metabolic Academy 2006- Current

Facilitator, HRSA evidence process working group 2006

Invited speaker and plenary session chair, IXth International Congress on Inborn Errors of Metabolism, Tokyo 2006

Member International Organizing Committee IXth International Congress on Inborn Errors of Metabolism, Tokyo 2006

Invited Speaker, Genetic Metabolic Dietician International Conference, Atlanta 2006

Invited Speaker, International Workshop on Fatty Acid Oxidation, Amsterdam 2005

President Society for Inherited Metabolic Disorders (SIMD) 2005-2007

Nominated to Board of Directors, American Board of Medical Genetics 2005

Elected to Pediatric Academic Society 2004

Research Educator of the Year, Mayo Clinic 2001

Elected to American Society for Clinical Investigation 1999

Young Investigator Award, Society for Inherited Metabolic Disorders 1989, 1990

Selected James Hudson Brown-Alexander B. Coxe Fellow, Yale School of Med. 1989

PHS Individual National Research Service Award, Yale School of Med. 1989

Medical Scientist Training Program Award, Univ. Penn. 1978-1984

University Honors, Carnegie-Mellon University 1974-1978

United States Steel Scholar, Carnegie-Mellon University 1974-1978

**PUBLICATIONS**

1. **Refereed articles**

1. Ray K, **Vockley J**, Harris H. (1984). Epitopes of human intestinal alkaline phosphatases, defined by monoclonal antibodies. *FEBS Letters.* **174:** 294-9.

2. **Vockley J**, Bednarz K, Harris H. (1984). Purification of monoclonal antibodies to human alkaline phosphatases by antigen-immunoaffinity chromatography: comparisons of their molar binding values. *J Immunol Methods.* **74:** 23-30.

3. **Vockley J**, D'Souza MP, Foster CJ, Harris H. (1984). Structural analysis of human adult and fetal alkaline phosphatases by cyanogen bromide peptide mapping. *Proc Natl Acad Sci U S A.* **81:** 6120-3. PMC391871.

4. **Vockley J**, Harris H. (1984). Purification of human adult and foetal intestinal alkaline phosphatases by monoclonal antibody immunoaffinity chromatography. *Biochemical Journal.* **217:** 535-41. PMC1153246.

5. **Vockley J**, Meyer LJ, Harris H. (1984). Differentiation of human adult and fetal intestinal alkaline phosphatases with monoclonal antibodies. *American Journal of Human Genetics.* **36:** 987-1000. PMC1684528.

6. Matsubara Y, Indo Y, Naito E, Ozasa H, Glassberg R, **Vockley J**, Ikeda Y, Kraus J, Tanaka K. (1989). Molecular cloning and nucleotide sequence of cDNAs encoding the precursors of rat long chain acyl-coenzyme A, short chain acyl-coenzyme A, and isovaleryl-coenzyme A dehydrogenases. Sequence homology of four enzymes of the acyl-CoA dehydrogenase family. *Journal of Biological Chemistry.* **264:** 16321-31.

7. **Vockley J**, Inserra JA, Breg WR, Yang-Feng TL. (1991). "Pseudomosaicism" for 4p- in amniotic fluid cell culture proven to be true mosaicism after birth. *American Journal of Medical Genetics.* **39:** 81-3.

8. **Vockley J**, Parimoo B, Tanaka K. (1991). Molecular characterization of four different classes of mutations in the isovaleryl-CoA dehydrogenase gene responsible for isovaleric acidemia. *American Journal of Human Genetics.* **49:** 147-57. PMC1683224.

9. Nagao M, **Vockley J**, Parimoo B, Tanaka K. (1992). Processing error of type-2 variant isovaleryl-CoA dehydrogenase precursor is caused by inefficient binding to the mitochondrial import receptor. *Progress in clinical and biological research.* **375:** 541-51.

10. **Vockley J**, Nagao M, Parimoo B, Tanaka K. (1992). The variant human isovaleryl-CoA dehydrogenase gene responsible for type II isovaleric acidemia determines an RNA splicing error, leading to the deletion of the entire second coding exon and the production of a truncated precursor protein that interacts poorly with mitochondrial import receptors. *Journal of Biological Chemistry.* **267:** 2494-501.

11. **Vockley J**, Parimoo B, Nagao M, Tanaka K. (1992). Identification of the molecular defects responsible for the various genotypes of isovaleric acidemia. *Progress in clinical and biological research.* **375:** 533-40.

12. **Vockley J**, Vockley CM, Lin SP, Tuchman M, Wu TC, Lin CY, Seashore MR. (1992). Normal N-acetylglutamate concentration measured in liver from a new patient with N-acetylglutamate synthetase deficiency: physiologic and biochemical implications. *Biochemical Medicine and Metabolic Biology.* **47:** 38-46.

13. Yokota I, Saijo T, **Vockley J**, Tanaka K. (1992). Impaired tetramer assembly of variant medium-chain acyl-coenzyme A dehydrogenase with a glutamate or aspartate substitution for lysine 304 causing instability of the protein. *Journal of Biological Chemistry.* **267:** 26004-10.

14. Kogekar N, Teebi AS, **Vockley J**. (1993). Sandrow syndrome of mirror hands and feet and facial abnormalities. *American Journal of Medical Genetics.* **46:** 126-8.

15. Wolfe L, Jethva R, Oglesbee D, **Vockley J**. Short-Chain Acyl-CoA Dehydrogenase Deficiency. in GeneReviews((R)) Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, Eds. Seattle (WA), 1993), .

16. Kim J-JP, Wang M, Paschke R, Djordjevic S, Bennett DW, **Vockley J**. Three dimensional structures of acyl-CoA dehydrogenases: structural basis of substrate specificity. in Flavins and Flavoproteins 1993 Yagi K, Eds. (Walter deGruyter, New York, 1994), pp. 273-82.

17. Rozen R, **Vockley J**, Zhou L, Milos R, Willard J, Fu K, Vicanek C, Low-Nang L, Torban E, Fournier B. (1994). Isolation and expression of a cDNA encoding the precursor for a novel member (ACADSB) of the acyl-CoA dehydrogenase gene family. *Genomics.* **24:** 280-7.

18. **Vockley J**. (1994). The changing face of disorders of fatty acid oxidation. *Mayo Clin Proc.* **69:** 249-57.

19. Battaile KP, Kim J-J, **Vockley J**. (1995). Identification of the catalytic residue and characterization of the substrate binding pocket of rat SCAD by *in vitro* mutagenesis and x-ray crystallography. *Am J Hum Genet.* **57:** A175.

20. Lindor NM, Karnes PS, Michels VV, Dewald GW, Goerss J, Jalal S, Jenkins RB, **Vockley J**, Thibodeau SN. (1995). Uniparental disomy in congenital disorders: a prospective study. *American Journal of Medical Genetics.* **58:** 143-6.

21. Mattson LR, Lindor NM, Goldman DH, Goodwin JT, Groover RV, **Vockley J**. (1995). Central Pontine Myelinolysis As a Complication Of Partial Ornithine Carbamoyl Transferase Deficiency. *American Journal of Medical Genetics.* **60:** 210-3.

22. Mohsen AW, **Vockley J**. (1995). Identification of the active site catalytic residue in human isovaleryl-CoA dehydrogenase. *Biochemistry.* **34:** 10146-52.

23. Battaile KP, Mohsen AW, **Vockley J**. (1996). Functional role of the active site glutamate-368 in rat short chain acyl-CoA dehydrogenase. *Biochemistry.* **35:** 15356-63.

24. Ushikubo S, Aoyama T, Kamijo T, Wanders RJA, Rinaldo P, **Vockley J**, Hashimoto T. (1996). Molecular characterization of mitochondrial trifunctional protein deficiency - formation of the enzyme complex is important for stabilization of both alpha- and beta-subunits. *American Journal of Human Genetics.* **58:** 979-88.

25. Willard J, Vicanek C, Battaile KP, Van Veldhoven PP, Fauq AH, Rozen R, **Vockley J**. (1996). Cloning of a cDNA for short/branched chain acyl-Coenzyme A dehydrogenase from rat and characterization of its tissue expression and substrate specificity. *Archives of Biochemistry and Biophysics.* **331:** 127-33.

26. Dakoji S, Shin I, Battaile KP, **Vockley J**, Liu HW. (1997). Redesigning the active-site of an acyl-CoA dehydrogenase: new evidence supporting a one-base mechanism. *Bioorg Med Chem.* **5:** 2157-64.

27. Schaller RA, Mohsen AW, **Vockley J**, Thorpe C. (1997). Mechanism-based inhibitor discrimination in the acyl-CoA dehydrogenases. *Biochemistry.* **36:** 7761-8.

28. Thorpe C, Schaller RA, Mohsen A-W, **Vockley J** The acyl-CoA dehydrogenases: Some mechanistic aspects (University of Calgary Press,, Calgary, Canada, 1997).

29. Tiffany KA, Roberts DL, Wang M, Paschke R, Mohsen AWA, **Vockley J**, Kim JJP. (1997). Structure of human isovaleryl-coA dehydrogenase at 2.6 angstrom resolution - basis for substrate specificity. *Biochemistry.* **36:** 8455-64.

30. Tiffany KA, Wang M, Paschke R, Mohsen A-W, **Vockley J**, Kim JJ. (1997). Structural basis for substrate specificity in acyl-CoA dehydrogenases: What makes isovaleryl-CoA dehydrogenase specific for a branched chain substrate? *Flavins and Flavoproteins 1996.* 649-52.

31. Battaile KP, McBurney M, Van Veldhoven PP, **Vockley J**. (1998). Human long chain, very long chain and medium chain acyl-CoA dehydrogenases are specific for the S-enantiomer of 2- methylpentadecanoyl-CoA. *Biochimica et Biophysica Acta.* **1390:** 333-8.

32. Binzak B, Willard J, **Vockley J**. (1998). Identification of the catalytic residue of human short/branched chain acyl-CoA dehydrogenase by in vitro mutagenesis. *Biochimica et Biophysica Acta.* **1382:** 137-42.

33. Kurtz DM, Rinaldo P, Rhead WJ, Tian L, Millington DS, **Vockley J**, Hamm DA, Brix AE, Lindsey JR, Pinkert CA, O'Brien WE, Wood PA. (1998). Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation. *Proc Natl Acad Sci U S A.* **95:** 15592-7. PMC28088.

34. Mohsen AW, Anderson BD, Volchenboum SL, Battaile KP, Tiffany K, Roberts D, Kim JJ, **Vockley J**. (1998). Characterization of molecular defects in isovaleryl-CoA dehydrogenase in patients with isovaleric acidemia. *Biochemistry.* **37:** 10325-35.

35. O'Sullivan DA, Torres VE, de Groen PC, Batts KP, King BF, **Vockley J**. (1998). Hepatic lymphangiomatosis mimicking polycystic liver disease. *Mayo Clin Proc.* **73:** 1188-92.

36. Schievink WI, Wijdicks EF, Michels VV, **Vockley J**, Godfrey M. (1998). Heritable connective tissue disorders in cervical artery dissections: a prospective study. *Neurology.* **50:** 1166-9.

37. Babovic-Vuksanovic D, Patterson MC, Schwenk WF, O'Brien JF, **Vockley J**, Freeze HH, Mehta DP, Michels VV. (1999). Severe hypoglycemia as a presenting symptom of carbohydrate-deficient glycoprotein syndrome. *Journal of Pediatrics.* **135:** 775-81.

38. Mathur A, Sims HF, Gopalakrishnan D, Gibson B, Rinaldo P, **Vockley J**, Hug G, Strauss AW. (1999). Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. *Circulation.* **99:** 1337-43.

39. Mohsen A-W, **Vockley J**. Biochemical characteristics of recombinant human isovaleryl-CoA dehydrogenase pre-treated with ethylenediaminetetraacetate. in Flavins and Flavoproteins 1999 Ghisla S, Kroneck P, Macheroux P, Sund H, Eds. (Rudolf Weber, New York, 1999), pp. 515-8.

40. Moolenaar SH, Poggi-Bach J, Engelke UF, Corstiaensen JM, Heerschap A, de Jong JG, Binzak BA, **Vockley J**, Wevers RA. (1999). Defect in dimethylglycine dehydrogenase, a new inborn error of metabolism: NMR spectroscopy study. *Clinical Chemistry.* **45:** 459-64.

41. Tein I, Haslam RH, Rhead WJ, Bennett MJ, Becker LE, **Vockley J**. (1999). Short-chain acyl-CoA dehydrogenase deficiency: a cause of ophthalmoplegia and multicore myopathy. *Neurology.* **52:** 366-72.

42. Binzak BA, **Vockley J**G, Jenkins RB, **Vockley J**. (2000). Structure and analysis of the human dimethylglycine dehydrogenase gene. *Mol Genet Metab.* **69:** 181-7.

43. Gibson KM, Burlingame TG, Hogema B, Jakobs C, Schutgens RB, Millington D, Roe CR, Roe DS, Sweetman L, Steiner RD, Linck L, Pohowalla P, Sacks M, Kiss D, Rinaldo P, **Vockley J**. (2000). 2-Methylbutyryl-coenzyme A dehydrogenase deficiency: a new inborn error of L-isoleucine metabolism. *Pediatric Research.* **47:** 830-3.

44. Lea W, Abbas AS, Sprecher H, **Vockley J**, Schulz H. (2000). Long-chain acyl-CoA dehydrogenase is a key enzyme in the mitochondrial β-oxidation of unsaturated fatty acids. *Bba-Mol Cell Biol L.* **1485:** 121-8.

45. Reinard T, Janke V, Willard J, Buck F, Jacobsen H-J, **Vockley J**. (2000). Cloning of a gene for an acyl-CoA dehydrogenase from Pisum sativum L. and purification and characterization of its product as an isovaleryl-CoA dehydrogenase. *J Biol Chem.* **275:** 33738-43.

46. Treacy EP, Lambert DM, Barnes R, Boriack RL, **Vockley J**, O'Brien LK, Jones PM, Bennett MJ. (2000). Short-chain hydroxyacyl-coenzyme A dehydrogenase deficiency presenting as unexpected infant death: A family study. *Journal of Pediatrics.* **137:** 257-9.

47. **Vockley J**, Mohsen al WA, Binzak B, Willard J, Fauq A. (2000). Mammalian branched-chain acyl-CoA dehydrogenases: molecular cloning and characterization of recombinant enzymes. *Methods Enzymol.* **324:** 241-58.

48. **Vockley J**, Rinaldo P, Bennett MJ, Matern D, Vladutiu GD. (2000). Synergistic heterozygosity: disease resulting from multiple partial defects in one or more metabolic pathways. *Mol Genet Metab.* **71:** 10-8.

49. **Vockley J**, Rogan PK, Anderson BD, Willard J, Seelan RS, Smith DI, Liu W. (2000). Exon skipping in IVD RNA processing in isovaleric acidemia caused by point mutations in the coding region of the IVD gene. *American Journal of Human Genetics.* **66:** 356-67. PMC1288088.

50. Volchenboum SL, **Vockley J**. (2000). Mitochondrial import and processing of wild type and type III mutant isovaleryl-CoA dehydrogenase. *Journal of Biological Chemistry.* **275:** 7958-63.

51. Binzak BA, Wevers RA, Moolenaar SH, Lee YM, Hwu WL, Poggi-Bach J, Engelke UF, Hoard HM, **Vockley J**G, **Vockley J**. (2001). Cloning of dimethylglycine dehydrogenase and a new human inborn error of metabolism, dimethylglycine dehydrogenase deficiency. *American Journal of Human Genetics.* **68:** 839-47. PMC1275637.

52. Corydon MJ, **Vockley J**, Rinaldo P, Rhead WJ, Kjeldsen M, Winter V, Riggs C, Babovic-Vuksanovic D, Smeitink J, De Jong J, Levy H, Sewell AC, Roe C, Matern D, Dasouki M, Gregersen N. (2001). Role of common gene variations in the molecular pathogenesis of short-chain acyl-CoA dehydrogenase deficiency. *Pediatric Research.* **49:** 18-23.

53. Cox KB, Hamm DA, Millington DS, Matern D, **Vockley J**, Rinaldo P, Pinkert CA, Rhead WJ, Lindsey JR, Wood PA. (2001). Gestational, pathologic and biochemical differences between very long-chain acyl-CoA dehydrogenase deficiency and long-chain acyl-CoA dehydrogenase deficiency in the mouse. *Human Molecular Genetics.* **10:** 2069-77.

54. Hoard HM, Benson LM, **Vockley J**, Naylor S. (2001). Microelectrospray ionization analysis of noncovalent interactions within the electron transferring flavoprotein. *Biochemical and Biophysical Research Communications.* **282:** 297-305.

55. Matern D, Hart P, Murtha AP, **Vockley J**, Gregersen N, Millington DS, Treem WR. (2001). Acute fatty liver of pregnancy associated with short-chain acyl-coenzyme A dehydrogenase deficiency. *Journal of Pediatrics.* **138:** 585-8.

56. Mohsen AW, Navarette B, **Vockley J**. (2001). Identification of Caenorhabditis elegans isovaleryl-CoA dehydrogenase and structural comparison with other acyl-CoA dehydrogenases. *Mol Genet Metab.* **73:** 126-37.

57. Volchenboum SL, Mohsen AW, Kim JJ, **Vockley J**. (2001). Arginine 387 of human isovaleryl-CoA dehydrogenase plays a crucial role in substrate/product binding. *Mol Genet Metab.* **74:** 226-37.

58. Willard JM, Reinard T, Mohsen A, **Vockley J**. (2001). Cloning of genomic and cDNA for mouse isovaleryl-CoA dehydrogenase (IVD) and evolutionary comparison to other known IVDs. *Gene.* **270:** 253-7.

59. Battaile KP, Molin-Case J, Paschke R, Wang M, Bennett D, **Vockley J**, Kim JJ. (2002). Crystal structure of rat short chain acyl-CoA dehydrogenase complexed with acetoacetyl-CoA: comparison with other acyl-CoA dehydrogenases. *Journal of Biological Chemistry.* **277:** 12200-7.

60. Nguyen TV, Andresen BS, Corydon TJ, Ghisla S, Abd-El Razik N, Mohsen AW, Cederbaum SD, Roe DS, Roe CR, Lench NJ, **Vockley J**. (2002). Identification of isobutyryl-CoA dehydrogenase and its deficiency in humans. *Mol Genet Metab.* **77:** 68-79.

61. Nguyen TV, Riggs C, Babovic-Vuksanovic D, Kim YS, Carpenter JF, Burghardt TP, Gregersen N, **Vockley J**. (2002). Purification and characterization of two polymorphic variants of short chain acyl-CoA dehydrogenase reveal reduction of catalytic activity and stability of the Gly185Ser enzyme. *Biochemistry.* **41:** 11126-33.

62. **Vockley J**, Singh RH, Whiteman DA. (2002). Diagnosis and management of defects of mitochondrial beta-oxidation. *Current opinion in clinical nutrition and metabolic care.* **5:** 601-9.

63. **Vockley J**, Whiteman DA. (2002). Defects of mitochondrial beta-oxidation: a growing group of disorders. *Neuromuscular disorders : NMD.* **12:** 235-46.

64. He M, Burghardt TP, **Vockley J**. (2003). A novel approach to the characterization of substrate specificity in short/branched chain Acyl-CoA dehydrogenase. *Journal of Biological Chemistry.* **278:** 37974-86.

65. Koeberl DD, Young SP, Gregersen NS, **Vockley J**, Smith WE, Benjamin DK, Jr., An Y, Weavil SD, Chaing SH, Bali D, McDonald MT, Kishnani PS, Chen YT, Millington DS. (2003). Rare disorders of metabolism with elevated butyryl- and isobutyryl-carnitine detected by tandem mass spectrometry newborn screening. *Pediatric Research.* **54:** 219-23.

66. Matern D, He M, Berry SA, Rinaldo P, Whitley CB, Madsen PP, van Calcar SC, Lussky RC, Andresen BS, Wolff JA, **Vockley J**. (2003). Prospective diagnosis of 2-methylbutyryl-CoA dehydrogenase deficiency in the Hmong population by newborn screening using tandem mass spectrometry. *Pediatrics.* **112:** 74-8.

67. Nishigaki Y, Tadesse S, Bonilla E, Shungu D, Hersh S, Keats BJ, Berlin CI, Goldberg MF, **Vockley J**, DiMauro S, Hirano M. (2003). A novel mitochondrial tRNA(Leu(UUR)) mutation in a patient with features of MERRF and Kearns-Sayre syndrome. *Neuromuscular disorders : NMD.* **13:** 334-40.

68. Pedersen CB, Bross P, Winter VS, Corydon TJ, Bolund L, Bartlett K, **Vockley J**, Gregersen N. (2003). Misfolding, degradation, and aggregation of variant proteins. The molecular pathogenesis of short chain acyl-CoA dehydrogenase (SCAD) deficiency. *Journal of Biological Chemistry.* **278:** 47449-58.

69. Rao KS, Albro M, **Vockley J**, Frerman FE. (2003). Mechanism-based inactivation of human glutaryl-CoA dehydrogenase by 2-pentynoyl-CoA: rationale for enhanced reactivity. *Journal of Biological Chemistry.* **278:** 26342-50.

70. Seidel J, Streck S, Bellstedt K, Vianey-Saban C, Pedersen CB, **Vockley J**, Korall H, Roskos M, Deufel T, Trefz KF, Sewell AC, Kauf E, Zintl F, Lehnert W, Gregersen N. (2003). Recurrent vomiting and ethylmalonic aciduria associated with rare mutations of the short-chain acyl-CoA dehydrogenase gene. *J Inherit Metab Dis.* **26:** 37-42.

71. Battaile KP, Nguyen TV, **Vockley J**, Kim JJ. (2004). Structures of isobutyryl-CoA dehydrogenase and enzyme-product complex: comparison with isovaleryl- and short-chain acyl-CoA dehydrogenases. *Journal of Biological Chemistry.* **279:** 16526-34.

72. Chu G, Kerr JP, Mitton B, Egnaczyk GF, Vazquez JA, Shen M, Kilby GW, Stevenson TI, Maggio JE, **Vockley J**, Rapundalo ST, Kranias EG. (2004). Proteomic analysis of hyperdynamic mouse hearts with enhanced sarcoplasmic reticulum calcium cycling. *FASEB J.* **18:** 1725-7.

73. Ensenauer R, **Vockley J**, Willard JM, Huey JC, Sass JO, Edland SD, Burton BK, Berry SA, Santer R, Grunert S, Koch HG, Marquardt I, Rinaldo P, Hahn S, Matern D. (2004). A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric acidemia diagnosed by newborn screening. *American Journal of Human Genetics.* **75:** 1136-42. PMC1182150.

74. Hoard-Fruchey HM, Goetzman E, Benson L, Naylor S, **Vockley J**. (2004). Mammalian electron transferring flavoprotein.flavoprotein dehydrogenase complexes observed by microelectrospray ionization-mass spectrometry and surface plasmon resonance. *Journal of Biological Chemistry.* **279:** 13786-91. PMID: 14744856.

75. Nasser I, Mohsen AW, Jelesarov I, **Vockley J**, Macheroux P, Ghisla S. (2004). Thermal unfolding of medium-chain acyl-CoA dehydrogenase and iso(3)valeryl-CoA dehydrogenase: study of the effect of genetic defects on enzyme stability. *Biochimica et Biophysica Acta.* **1690:** 22-32.

76. Yu W, Liang X, Ensenauer RE, **Vockley J**, Sweetman L, Schulz H. (2004). Leaky beta-oxidation of a trans-fatty acid: incomplete beta-oxidation of elaidic acid is due to the accumulation of 5-trans-tetradecenoyl-CoA and its hydrolysis and conversion to 5-trans-tetradecenoylcarnitine in the matrix of rat mitochondria. *Journal of Biological Chemistry.* **279:** 52160-7.

77. Ensenauer R, He M, Willard JM, Goetzman ES, Corydon TJ, Vandahl BB, Mohsen AW, Isaya G, **Vockley J**. (2005). Human acyl-CoA dehydrogenase-9 plays a novel role in the mitochondrial beta-oxidation of unsaturated fatty acids. *Journal of Biological Chemistry.* **280:** 32309-16.

78. Goetzman ES, Mohsen AW, Prasad K, **Vockley J**. (2005). Convergent evolution of a 2-methylbutyryl-CoA dehydrogenase from isovaleryl-CoA dehydrogenase in Solanum tuberosum. *Journal of Biological Chemistry.* **280:** 4873-9.

79. Saenger AK, Nguyen TV, **Vockley J**, Stankovich MT. (2005). Thermodynamic regulation of human short-chain acyl-CoA dehydrogenase by substrate and product binding. *Biochemistry.* **44:** 16043-53.

80. Saenger AK, Nguyen TV, **Vockley J**, Stankovich MT. (2005). Biochemical and electrochemical characterization of two variant human short-chain acyl-CoA dehydrogenases. *Biochemistry.* **44:** 16035-42.

81. Schowalter DB, Matern D, **Vockley J**. (2005). In vitro correction of medium chain acyl CoA dehydrogenase deficiency with a recombinant adenoviral vector. *Mol Genet Metab.* **85:** 88-95.

82. Schuler AM, Gower BA, Matern D, Rinaldo P, **Vockley J**, Wood PA. (2005). Synergistic heterozygosity in mice with inherited enzyme deficiencies of mitochondrial fatty acid beta-oxidation. *Mol Genet Metab.* **85:** 7-11.

83. Tolwani RJ, Hamm DA, Tian L, Sharer JD, **Vockley J**, Rinaldo P, Matern D, Schoeb TR, Wood PA. (2005). Medium-chain acyl-CoA dehydrogenase deficiency in gene-targeted mice. *PLoS Genet.* **1:** e23. PMC1189074.

84. Conlon TJ, Walter G, Owen R, Cossette T, Erger K, Gutierrez G, Goetzman E, Matern D, **Vockley J**, Flotte TR. (2006). Systemic correction of a fatty acid oxidation defect by intramuscular injection of a recombinant adeno-associated virus vector. *Human Gene Therapy.* **17:** 71-80.

85. Goetzman ES, He M, Nguyen TV, **Vockley J**. (2006). Functional analysis of acyl-CoA dehydrogenase catalytic residue mutants using surface plasmon resonance and circular dichroism. *Mol Genet Metab.* **87:** 233-42.

86. Merritt JL, 2nd, Matern D, **Vockley J**, Daniels J, Nguyen TV, Schowalter DB. (2006). In vitro characterization and in vivo expression of human very-long chain acyl-CoA dehydrogenase. *Mol Genet Metab.* **88:** 351-8.

87. Strauss KA, Mazariegos GV, Sindhi R, Squires R, Finegold DN, Vockley G, Robinson DL, Hendrickson C, Virji M, Cropcho L, Puffenberger EG, McGhee W, Seward LM, Morton DH. (2006). Elective liver transplantation for the treatment of classical maple syrup urine disease. *Am J Transplant.* **6:** 557-64.

88. **Vockley J**, Ensenauer R. (2006). Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. *Am J Med Genet C Semin Med Genet.* **142C:** 95-103. PMC2652706.

89. Burton BK, Grange DK, Milanowski A, Vockley G, Feillet F, Crombez EA, Abadie V, Harding CO, Cederbaum S, Dobbelaere D, Smith A, Dorenbaum A. (2007). The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. *J Inherit Metab Dis.* **30:** 700-7.

90. Goetzman ES, Wang Y, He M, Mohsen AW, Ninness BK, **Vockley J**. (2007). Expression and characterization of mutations in human very long-chain acyl-CoA dehydrogenase using a prokaryotic system. *Mol Genet Metab.* **91:** 138-47. PMC2702680.

91. He M, Rutledge SL, Kelly DR, Palmer CA, Murdoch G, Majumder N, Nicholls RD, Pei Z, Watkins PA, **Vockley J**. (2007). A new genetic disorder in mitochondrial fatty acid beta-oxidation: ACAD9 deficiency. *American Journal of Human Genetics.* **81:** 87-103. PMC1950923.

92. Lee YW, Lee DH, **Vockley J**, Kim ND, Lee YK, Ki CS. (2007). Different spectrum of mutations of isovaleryl-CoA dehydrogenase (IVD) gene in Korean patients with isovaleric acidemia. *Mol Genet Metab.* **92:** 71-7. PMC4136440.

93. Oglesbee D, He M, Majumder N, **Vockley J**, Ahmad A, Angle B, Burton B, Charrow J, Ensenauer R, Ficicioglu CH, Keppen LD, Marsden D, Tortorelli S, Hahn SH, Matern D. (2007). Development of a newborn screening follow-up algorithm for the diagnosis of isobutyryl-CoA dehydrogenase deficiency. *Genet Med.* **9:** 108-16.

94. Rapaka RR, Goetzman ES, Zheng M, **Vockley J**, McKinley L, Kolls JK, Steele C. (2007). Enhanced defense against Pneumocystis carinii mediated by a novel dectin-1 receptor Fc fusion protein. *J Immunol.* **178:** 3702-12.

95. Sathanoori M, Hu J, Murthy V, Byrnes A, **Vockley J**, Safier R, Bedoyan J, Jalal SM, Huber H, Surti U. (2007). Cryptic duplication of 12q24.33 --> qter in a child with Angelman syndrome-simultaneous occurrence of two unrelated cytogenetic events. *American journal of medical genetics Part A.* **143A:** 985-94.

96. van Calcar SC, Gleason LA, Lindh H, Hoffman G, Rhead W, Vockley G, Wolff JA, Durkin MS. (2007). 2-methylbutyryl-CoA dehydrogenase deficiency in Hmong infants identified by expanded newborn screen. *WMJ.* **106:** 12-5.

97. **Vockley J**. (2007). Newborn screening: After the thrill is gone. *Mol Genet Metab.* **92:** 6-12. PMC2768350.

98. Wolfe LA, Finegold DN, **Vockley J**, Walters N, Chambaz C, Suormala T, Koch HG, Matern D, Barshop BA, Cropcho LJ, Baumgartner MR, Gibson KM. (2007). Potential misdiagnosis of 3-methylcrotonyl-coenzyme A carboxylase deficiency associated with absent or trace urinary 3-methylcrotonylglycine. *Pediatrics.* **120:** e1335-40.

99. Beattie SG, Goetzman E, Conlon T, Germain S, Walter G, Campbell-Thompson M, Matern D, **Vockley J**, Flotte TR. (2008). Biochemical correction of short-chain acyl-coenzyme A dehydrogenase deficiency after portal vein injection of rAAV8-SCAD. *Human Gene Therapy.* **19:** 579-88. PMC2940548.

100. Beattie SG, Goetzman E, Tang Q, Conlon T, Campbell-Thompson M, Matern D, **Vockley J**, Flotte TR. (2008). Recombinant adeno-associated virus-mediated gene delivery of long chain acyl coenzyme A dehydrogenase (LCAD) into LCAD-deficient mice. *J Gene Med.* **10:** 1113-23. PMC4319113.

101. Bonilla Guerrero R, Wolfe LA, Payne N, Tortorelli S, Matern D, Rinaldo P, Gavrilov D, Melan M, He M, Steinberg SJ, Raymond GV, **Vockley J**, Gibson KM. (2008). Essential fatty acid profiling for routine nutritional assessment unmasks adrenoleukodystrophy in an infant with isovaleric acidaemia. *J Inherit Metab Dis.* **31 Suppl 2:** S453-6.

102. Feillet F, Clarke L, Meli C, Lipson M, Morris AA, Harmatz P, Mould DR, Green B, Dorenbaum A, Giovannini M, Foehr E, Sapropterin Research GV, J). (2008). Pharmacokinetics of sapropterin in patients with phenylketonuria. *Clinical Pharmacokinetics.* **47:** 817-25.

103. Horbinski C, Carter EM, Heard PL, Sathanoori M, Hu J, **Vockley J**, Gunn S, Hale DE, Surti U, Cody JD. (2008). Molecular and clinical characterization of a recurrent cryptic unbalanced t(4q;18q) resulting in an 18q deletion and 4q duplication. *American journal of medical genetics Part A.* **146A:** 2898-904. PMC2584776.

104. Jethva R, Bennett MJ, **Vockley J**. (2008). Short-chain acyl-coenzyme A dehydrogenase deficiency. *Molecular Genetics & Metabolism.* **95:** 195-200.

105. Lee P, Treacy EP, Crombez E, Wasserstein M, Waber L, Wolff J, Wendel U, Dorenbaum A, Bebchuk J, Christ-Schmidt H, Seashore M, Giovannini M, Burton BK, Morris AA, Sapropterin Research GV, J). (2008). Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. *American journal of medical genetics Part A.* **146A:** 2851-9.

106. McAndrew RP, **Vockley J**, Kim JJ. (2008). Molecular basis of dimethylglycine dehydrogenase deficiency associated with pathogenic variant H109R. *J Inherit Metab Dis.* **31:** 761-8. PMC2828353.

107. McAndrew RP, Wang Y, Mohsen AW, He M, **Vockley J**, Kim JJ. (2008). Structural basis for substrate fatty acyl chain specificity: crystal structure of human very-long-chain acyl-CoA dehydrogenase. *Journal of Biological Chemistry.* **283:** 9435-43. PMC2431035.

108. Pedersen CB, Kolvraa S, Kolvraa A, Stenbroen V, Kjeldsen M, Ensenauer R, Tein I, Matern D, Rinaldo P, Vianey-Saban C, Ribes A, Lehnert W, Christensen E, Corydon TJ, Andresen BS, Vang S, Bolund L, **Vockley J**, Bross P, Gregersen N. (2008). The ACADS gene variation spectrum in 114 patients with short-chain acyl-CoA dehydrogenase (SCAD) deficiency is dominated by missense variations leading to protein misfolding at the cellular level. *Human Genetics.* **124:** 43-56.

109. Tein I, Elpeleg O, Ben-Zeev B, Korman SH, Lossos A, Lev D, Lerman-Sagie T, Leshinsky-Silver E, **Vockley J**, Berry GT, Lamhonwah AM, Matern D, Roe CR, Gregersen N. (2008). Short-chain acyl-CoA dehydrogenase gene mutation (c.319C>T) presents with clinical heterogeneity and is candidate founder mutation in individuals of Ashkenazi Jewish origin. *Mol Genet Metab.* **93:** 179-89.

110. **Vockley J**. (2008). Metabolism as a complex genetic trait, a systems biology approach: implications for inborn errors of metabolism and clinical diseases. *J Inherit Metab Dis.* **31:** 619-29. PMC4319114.

111. Swigonova Z, Mohsen AW, **Vockley J**. (2009). Acyl-CoA dehydrogenases: Dynamic history of protein family evolution. *J Mol Evol.* **69:** 176-93. PMC4136416.

112. Talkowski ME, McClain L, Allen T, Bradford LD, Calkins M, Edwards N, Georgieva L, Go R, Gur R, Gur R, Kirov G, Chowdari K, Kwentus J, Lyons P, Mansour H, McEvoy J, O'Donovan MC, O'Jile J, Owen MJ, Santos A, Savage R, Toncheva D, Vockley G, Wood J, Devlin B, Nimgaonkar VL. (2009). Convergent patterns of association between phenylalanine hydroxylase variants and schizophrenia in four independent samples. *American journal of medical genetics Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.* **150B:** 560-9. PMC2738981.

113. Trefz FK, Burton BK, Longo N, Casanova MM, Gruskin DJ, Dorenbaum A, Kakkis ED, Crombez EA, Grange DK, Harmatz P, Lipson MH, Milanowski A, Randolph LM, **Vockley J**, Whitley CB, Wolff JA, Bebchuk J, Christ-Schmidt H, Hennermann JB, Sapropterin Study G. (2009). Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. *Journal of Pediatrics.* **154:** 700-7.

114. Trefz FK, Burton BK, Longo N, Casanova MMP, Gruskin DJ, Dorenbaum A, Kakkis ED, Crombez EA, Grange DK, Harmatz P, Lipson MH, Milanowski A, Randolph LM, **Vockley J**, Whitley CB, Wolff JA, Bebchuk J, Christ-Schmidt H, Hennermann JB. (2009). Efficacy of Sapropterin Dihydrochloride in Increasing Phenylalanine Tolerance in Children with Phenylketonuria: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study. *Journal of Pediatrics.* **154:** 700-7.e1.

115. Alfardan J, Mohsen AW, Copeland S, Ellison J, Keppen-Davis L, Rohrbach M, Powell BR, Gillis J, Matern D, Kant J, **Vockley J**. (2010). Characterization of new ACADSB gene sequence mutations and clinical implications in patients with 2-methylbutyrylglycinuria identified by newborn screening. *Mol Genet Metab.* **100:** 333-8. PMC2906669.

116. Goodpaster BH, Delany JP, Otto AD, Kuller L, **Vockley J**, South-Paul JE, Thomas SB, Brown J, McTigue K, Hames KC, Lang W, Jakicic JM. (2010). Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. *JAMA.* **304:** 1795-802. PMC3082279.

117. Hathaway SC, Friez M, Limbo K, Parker C, Salomons GS, **Vockley J**, Wood T, Abdul-Rahman OA. (2010). X-linked creatine transporter deficiency presenting as a mitochondrial disorder. *J Child Neurol.* **25:** 1009-12.

118. Maher AC, Akhtar M, **Vockley J**, Tarnopolsky MA. (2010). Women have higher protein content of beta-oxidation enzymes in skeletal muscle than men. *PLoS One.* **5:** e12025. PMC2917369.

119. Maher AC, Mohsen AW, **Vockley J**, Tarnopolsky MA. (2010). Low expression of long-chain acyl-CoA dehydrogenase in human skeletal muscle. *Mol Genet Metab.* **100:** 163-7. PMC3974577.

120. Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, **Vockley J**, Toledo FG, DeLany JP. (2010). Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. *Obesity (Silver Spring).* **18:** 1695-700. PMC3984458.

121. Skilling H, Coen PM, Fairfull L, Ferrell RE, Goodpaster BH, **Vockley J**, Goetzman ES. (2010). Brown adipose tissue function in short-chain acyl-CoA dehydrogenase deficient mice. *Biochemical and Biophysical Research Communications.* **400:** 318-22. PMC2946480.

122. Soltys KA, Soto-Gutierrez A, Nagaya M, Baskin KM, Deutsch M, Ito R, Shneider BL, Squires R, **Vockley J**, Guha C, Roy-Chowdhury J, Strom SC, Platt JL, Fox IJ. (2010). Barriers to the successful treatment of liver disease by hepatocyte transplantation. *J Hepatol.* **53:** 769-74. PMC2930077.

123. **Vockley J**, Vockley CM. (2010). Clinical trials: curing a critical deficiency in metabolic medicine. *Mol Genet Metab.* **99:** 244-5.

124. Wang Y, Mohsen AW, Mihalik SJ, Goetzman ES, **Vockley J**. (2010). Evidence for physical association of mitochondrial fatty acid oxidation and oxidative phosphorylation complexes. *Journal of Biological Chemistry.* **285:** 29834-41. PMC2943265.

125. Wolfe LA, He M, **Vockley J**, Payne N, Rhead W, Hoppel C, Spector E, Gernert K, Gibson KM. (2010). Novel ETF dehydrogenase mutations in a patient with mild glutaric aciduria type II and complex II-III deficiency in liver and muscle. *J Inherit Metab Dis.* **33 Suppl 3:** S481-7. PMC3970109.

126. Ensenauer R, Hartl D, **Vockley J**, Roscher AA, Fuchs U. (2011). Efficient and gentle siRNA delivery by magnetofection. *Biotech Histochem.* **86:** 226-31. PMC4321792.

127. He M, Kratz LE, Michel JJ, Vallejo AN, Ferris L, Kelley RI, Hoover JJ, Jukic D, Gibson KM, Wolfe LA, Ramachandran D, Zwick ME, **Vockley J**. (2011). Mutations in the human SC4MOL gene encoding a methyl sterol oxidase cause psoriasiform dermatitis, microcephaly, and developmental delay. *Journal of Clinical Investigation.* **121:** 976-84. PMC3049385.

128. He M, Pei Z, Mohsen AW, Watkins P, Murdoch G, Van Veldhoven PP, Ensenauer R, **Vockley J**. (2011). Identification and characterization of new long chain acyl-CoA dehydrogenases. *Mol Genet Metab.* **102:** 418-29. PMC3073726.

129. Homayoun H, Khavandgar S, Hoover JM, Mohsen AW, **Vockley J**, Lacomis D, Clemens PR. (2011). Novel mutation in MYH7 gene associated with distal myopathy and cardiomyopathy. *Neuromuscular disorders : NMD.* **21:** 219-22.

130. Luis PB, Ruiter JP, Ijlst L, Tavares de Almeida I, Duran M, Mohsen AW, **Vockley J**, Wanders RJ, Silva MF. (2011). Role of isovaleryl-CoA dehydrogenase and short branched-chain acyl-CoA dehydrogenase in the metabolism of valproic acid: implications for the branched-chain amino acid oxidation pathway. *Drug Metabolism and Disposition.* **39:** 1155-60. PMC3127238.

131. Pan L, McKain BW, Madan-Khetarpal S, McGuire M, Diler RS, Perel JM, **Vockley J**, Brent DA. (2011). GTP-cyclohydrolase deficiency responsive to sapropterin and 5-HTP supplementation: relief of treatment-refractory depression and suicidal behaviour. *BMJ case reports.* **2011:** PMC3116226.

132. Shellmer DA, DeVito Dabbs A, Dew MA, Noll RB, Feldman H, Strauss KA, Morton DH, **Vockley J**, Mazariegos GV. (2011). Cognitive and adaptive functioning after liver transplantation for maple syrup urine disease: a case series. *Pediatr Transplant.* **15:** 58-64. PMC3050647.

133. Shneider BL, **Vockley J**, Mazariegos GV. (2011). Trading places: liver transplantation as a treatment, not a cure, for metabolic liver disease. *Liver Transpl.* **17:** 628-30.

134. Wolfe L, Jethva R, Oglesbee D, **Vockley J**, in GeneReviews((Internet)) Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, Eds. (University of Washington, Seattle, Seattle (WA), 2011 (updated 2018)), pp. Available at: https://www.ncbi.nlm.nih.gov/books/NBK63582/.

135. Graves JA, Wang Y, Sims-Lucas S, Cherok E, Rothermund K, Branca MF, Elster J, Beer-Stolz D, Van Houten B, **Vockley J**, Prochownik EV. (2012). Mitochondrial structure, function and dynamics are temporally controlled by c-Myc. *PLoS One.* **7:** e37699. PMC3357432.

136. Grunert SC, Wendel U, Lindner M, Leichsenring M, Schwab KO, **Vockley J**, Lehnert W, Ensenauer R. (2012). Clinical and neurocognitive outcome in symptomatic isovaleric acidemia. *Orphanet J Rare Dis.* **7:** 9. PMC3292949.

137. Knerr I, Weinhold N, **Vockley J**, Gibson KM. (2012). Advances and challenges in the treatment of branched-chain amino/keto acid metabolic defects. *J Inherit Metab Dis.* **35:** 29-40. PMC4136412.

138. Kormanik K, Kang H, Cuebas D, **Vockley J**, Mohsen AW. (2012). Evidence for involvement of medium chain acyl-CoA dehydrogenase in the metabolism of phenylbutyrate. *Mol Genet Metab.* **107:** 684-9. PMC3504130.

139. Longo N, Burton BK, Harding CO, Hillman R, Grange DK, **Vockley J**, Wasserstein M, Thomas J, Goodin K, Hostutler R, Gu K, Walling J, Sile S. (2012). Hypophenylalaninemia in adult phenylketonuria patients treated with rAvPAL-PEG. *Molecular Genetics and Metabolism.* **105:** 335.

140. Mazariegos GV, Morton DH, Sindhi R, Soltys K, Nayyar N, Bond G, Shellmer D, Shneider B, **Vockley J**, Strauss KA. (2012). Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience. *Journal of Pediatrics.* **160:** 116-21 e1. PMC3671923.

141. Michaliszyn SF, Sjaarda LA, Mihalik SJ, Lee S, Bacha F, Chace DH, De Jesus VR, **Vockley J**, Arslanian SA. (2012). Metabolomic profiling of amino acids and beta-cell function relative to insulin sensitivity in youth. *J Clin Endocrinol Metab.* **97:** E2119-24. PMC3485593.

142. Mihalik SJ, Michaliszyn SF, de las Heras J, Bacha F, Lee S, Chace DH, DeJesus VR, **Vockley J**, Arslanian SA. (2012). Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. *Diabetes Care.* **35:** 605-11. PMC3322714.

143. Mokhtarani M, Diaz GA, Rhead W, Lichter-Konecki U, Bartley J, Feigenbaum A, Longo N, Berquist W, Berry SA, Gallagher R, Bartholomew D, Harding CO, Korson MS, McCandless SE, Smith W, **Vockley J**, Bart S, Kronn D, Zori R, Cederbaum S, Dorrani N, Merritt JL, 2nd, Sreenath-Nagamani S, Summar M, Lemons C, Dickinson K, Coakley DF, Moors TL, Lee B, Scharschmidt BF. (2012). Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders. *Mol Genet Metab.* **107:** 308-14. PMC3608516.

144. Schiff M, Benit P, Jacobs HT, **Vockley J**, Rustin P. (2012). Therapies in inborn errors of oxidative metabolism. *Trends Endocrinol Metab.* **23:** 488-95. PMC4135311.

145. Wolfe LA, Morava E, He M, **Vockley J**, Gibson KM. (2012). Heritable disorders in the metabolism of the dolichols: A bridge from sterol biosynthesis to molecular glycosylation. *Am J Med Genet C Semin Med Genet.* **160C:** 322-8. PMC3995744.

146. Arnold GL, **Vockley J**. (2013). Introduction: Neurodevelopmental issues in inborn errors of metabolism. *Dev Disabil Res Rev.* **17:** 185-6.

147. Belachew D, Kazmerski T, Libman I, Goldstein AC, Stevens ST, Deward S, **Vockley J**, Sperling MA, Balest AL. (2013). Infantile hypophosphatasia secondary to a novel compound heterozygous mutation presenting with pyridoxine-responsive seizures. *JIMD Rep.* **11:** 17-24. PMC3755558.

148. Bharathi SS, Zhang Y, Mohsen AW, Uppala R, Balasubramani M, Schreiber E, Uechi G, Beck ME, Rardin MJ, **Vockley J**, Verdin E, Gibson BW, Hirschey MD, Goetzman ES. (2013). Sirtuin 3 (SIRT3) protein regulates long-chain acyl-CoA dehydrogenase by deacetylating conserved lysines near the active site. *Journal of Biological Chemistry.* **288:** 33837-47. PMC3837126.

149. Camp KM, Lloyd-Puryear MA, Yao L, Groft SC, Parisi MA, Mulberg A, Gopal-Srivastava R, Cederbaum S, Enns GM, Ershow AG, Frazier DM, Gohagan J, Harding C, Howell RR, Regan K, Stacpoole PW, Venditti C, **Vockley J**, Watson M, Coates PM. (2013). Expanding research to provide an evidence base for nutritional interventions for the management of inborn errors of metabolism. *Mol Genet Metab.* **109:** 319-28. PMC4131198.

150. Diaz GA, Krivitzky LS, Mokhtarani M, Rhead W, Bartley J, Feigenbaum A, Longo N, Berquist W, Berry SA, Gallagher R, Lichter-Konecki U, Bartholomew D, Harding CO, Cederbaum S, McCandless SE, Smith W, Vockley G, Bart SA, Korson MS, Kronn D, Zori R, Merritt JL, 2nd, S CSN, Mauney J, Lemons C, Dickinson K, Moors TL, Coakley DF, Scharschmidt BF, Lee B. (2013). Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. *Hepatology.* **57:** 2171-9. PMC3557606.

151. Hillman R, Peck D, Grange DK, Fong CT, Burton BK, **Vockley J**, Yano S, Violet S, Cohen-Pfeffer J. (2013). Use of sapropterin dihydrochloride in 20 pregnant women with phenylketonuria prior to or during pregnancy: An interim report of the PKU moms sub-registry. *Journal of Inherited Metabolic Disease.* **36:** S92.

152. Hillman R, Peck D, Grange DK, Fong CT, Burton BK, **Vockley J**, Yano S, Violet S, Cohen-Pfeffer J. (2013). Breasr milk and plasma pterin levels and offspring outcomes of 25 pregnancies in women exposed to sapropterin dihydrochloride prior to or during pregnancy: An interim report of the PKU moms sub-registry. *Journal of Inherited Metabolic Disease.* **36:** S120.

153. Pan L, **Vockley J**. (2013). Neuropsychiatric Symptoms in Inborn Errors of Metabolism: Incorporation of Genomic and Metabolomic Analysis into Therapeutics and Prevention. *Current genetic medicine reports.* **1:** 65-70. PMC3603703.

154. Sarin M, Wang Y, Zhang F, Rothermund K, Zhang Y, Lu J, Sims-Lucas S, Beer-Stolz D, Van Houten BE, **Vockley J**, Goetzman ES, Graves JA, Prochownik EV. (2013). Alterations in c-Myc phenotypes resulting from dynamin-related protein 1 (Drp1)-mediated mitochondrial fission. *Cell death & disease.* **4:** e670. PMC3702284.

155. Schiff M, Mohsen AW, Karunanidhi A, McCracken E, Yeasted R, **Vockley J**. (2013). Molecular and cellular pathology of very-long-chain acyl-CoA dehydrogenase deficiency. *Mol Genet Metab.* **109:** 21-7. PMC3628282.

156. Sundaram SS, Alonso EM, Haber B, Magee JC, Fredericks E, Kamath B, Kerkar N, Rosenthal P, Shepherd R, Limbers C, Varni JW, Robuck P, Sokol RJ, Childhood Liver Disease R, Education, Network (Vockley, J). (2013). Health related quality of life in patients with biliary atresia surviving with their native liver. *Journal of Pediatrics.* **163:** 1052-7 e2. PMC4014354.

157. Tuerck J, Wilcken B, Webster DR, Forsman I, Kemper AR, Millington D, Ostrup J, Therrell BL, Torresani T, **Vockley J**. (2013). Newborn Screening Follow-up Guideline—Second Edition; CLSI document NBS02-A2. *Clinical and Laboratory Standards Institute.* **33:** 6 Wayne, PA.

158. Van Calcar SC, Baker MW, Williams P, Jones SA, Xiong B, Thao MC, Lee S, Yang MK, Rice GM, Rhead W, **Vockley J**, Hoffman G, Durkin MS. (2013). Prevalence and mutation analysis of short/branched chain acyl-CoA dehydrogenase deficiency (SBCADD) detected on newborn screening in Wisconsin. *Mol Genet Metab.* **110:** 111-5. PMC5006389.

159. **Vockley J**, Chapman KA, Arnold GL. (2013). Development of clinical guidelines for inborn errors of metabolism: commentary. *Mol Genet Metab.* **108:** 203-5. PMID23428739.

160. Waisbren SE, Landau Y, Wilson J, **Vockley J**. (2013). Neuropsychological outcomes in fatty acid oxidation disorders: 85 cases detected by newborn screening. *Dev Disabil Res Rev.* **17:** 260-8. PMC4137760.

161. Camp KM, Parisi MA, Acosta PB, Berry GT, Bilder DA, Blau N, Bodamer OA, Brosco JP, Brown CS, Burlina AB, Burton BK, Chang CS, Coates PM, Cunningham AC, Dobrowolski SF, Ferguson JH, Franklin TD, Frazier DM, Grange DK, Greene CL, Groft SC, Harding CO, Howell RR, Huntington KL, Hyatt-Knorr HD, Jevaji IP, Levy HL, Lichter-Konecki U, Lindegren ML, Lloyd-Puryear MA, Matalon K, MacDonald A, McPheeters ML, Mitchell JJ, Mofidi S, Moseley KD, Mueller CM, Mulberg AE, Nerurkar LS, Ogata BN, Pariser AR, Prasad S, Pridjian G, Rasmussen SA, Reddy UM, Rohr FJ, Singh RH, Sirrs SM, Stremer SE, Tagle DA, Thompson SM, Urv TK, Utz JR, van Spronsen F, **Vockley J**, Waisbren SE, Weglicki LS, White DA, Whitley CB, Wilfond BS, Yannicelli S, Young JM. (2014). Phenylketonuria Scientific Review Conference: state of the science and future research needs. *Mol Genet Metab.* **112:** 87-122. 24667081.

162. Chaly Y, Fu Y, Marinov A, Hostager B, Yan W, Campfield B, Kellum JA, Bushnell D, Wang Y, **Vockley J**, Hirsch R. (2014). Follistatin-like protein 1 enhances NLRP3 inflammasome-mediated IL-1beta secretion from monocytes and macrophages. *European journal of immunology.* **44:** 1467-79. PMC4004659.

163. Dobrowolski SF, Lyons-Weiler J, Biery A, Spridik K, **Vockley J**, Kranik E, Skvorak K, Sultana T. (2014). Methylome repatterning in a mouse model of Maternal PKU Syndrome. *Mol Genet Metab.* **113:** 194-9.

164. Edmunds LR, Sharma L, Kang A, Lu J, **Vockley J**, Basu S, Uppala R, Goetzman ES, Beck ME, Scott D, Prochownik EV. (2014). c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate.[Erratum appears in J Biol Chem. 2015 Aug 14;290(33):20100; PMID: 26276854]. *Journal of Biological Chemistry.* **289:** 25382-92.

165. Goetzman ES, Alcorn JF, Bharathi SS, Uppala R, McHugh KJ, Kosmider B, Chen R, Zuo YY, Beck ME, McKinney RW, Skilling H, Suhrie KR, Karunanidhi A, Yeasted R, Otsubo C, Ellis B, Tyurina YY, Kagan VE, Mallampalli RK, **Vockley J**. (2014). Long-chain acyl-CoA dehydrogenase deficiency as a cause of pulmonary surfactant dysfunction. *Journal of Biological Chemistry.* **289:** 10668-79. PMC4036448.

166. Grange DK, Hillman RE, Burton BK, Yano S, **Vockley J**, Fong CT, Hunt J, Mahoney JJ, Cohen-Pfeffer JL. (2014). Sapropterin dihydrochloride use in pregnant women with phenylketonuria: an interim report of the PKU MOMS sub-registry. *Mol Genet Metab.* **112:** 9-16.

167. Grange DK, Hillman RE, Burton BK, Yano S, **Vockley J**, Fong CT, Hunt J, Mahoney JJ, Cohen-Pfeffer JL, Phenylketonuria Demographics O, Safety r, Maternal Phenylketonuria Observational Program s-r. (2014). Sapropterin dihydrochloride use in pregnant women with phenylketonuria: an interim report of the PKU MOMS sub-registry. *Mol Genet Metab.* **112:** 9-16. 24667082.

168. He M, Smith LD, Chang R, Li X, **Vockley J**. (2014). The role of sterol-C4-methyl oxidase in epidermal biology. *Biochimica et Biophysica Acta.* **1841:** 331-5. PMC3943829.

169. Longo N, Harding CO, Burton BK, Grange DK, **Vockley J**, Wasserstein M, Rice GM, Dorenbaum A, Neuenburg JK, Musson DG, Gu Z, Sile S. (2014). Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. *Lancet.* **384:** 37-44. PMC4447208.

170. Mazariegos G, Shneider B, Burton B, Fox IJ, Hadzic N, Kishnani P, Morton DH, McIntire S, Sokol RJ, Summar M, White D, Chavanon V, **Vockley J**. (2014). Liver transplantation for pediatric metabolic disease. *Mol Genet Metab.* **111:** 418-27. 24495602.

171. Ng VL, Haber BH, Magee JC, Miethke A, Murray KF, Michail S, Karpen SJ, Kerkar N, Molleston JP, Romero R, Rosenthal P, Schwarz KB, Shneider BL, Turmelle YP, Alonso EM, Sherker AH, Sokol RJ, Childhood Liver Disease RE, Network (Vockley, J). (2014). Medical status of 219 children with biliary atresia surviving long-term with their native livers: results from a North American multicenter consortium. *Journal of Pediatrics.* **165:** 539-46 e2. PMC4144331.

172. Odle J, Adams SH, **Vockley J**. (2014). Carnitine. *Adv Nutr.* **5:** 289-90. PMC4013181.

173. Singh RH, Rohr F, Frazier D, Cunningham A, Mofidi S, Ogata B, Splett PL, Moseley K, Huntington K, Acosta PB, **Vockley J**, Van Calcar SC. (2014). Recommendations for the nutrition management of phenylalanine hydroxylase deficiency. *Genet Med.* **16:** 121-31. PMC3918542.

174. **Vockley J**, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, Mitchell J, Smith WE, Thompson BH, Berry SA. (2014). Phenylalanine hydroxylase deficiency: Diagnosis and management guideline. *Genetics in Medicine.* **16:** 188-200.

175. **Vockley J**, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, Mitchell J, Smith WE, Thompson BH, Berry SA, American College of Medical G, Genomics Therapeutics C. (2014). Phenylalanine hydroxylase deficiency: diagnosis and management guideline. *Genet Med.* **16:** 188-200. 24385074.

176. Wang W, Mohsen AW, Uechi G, Schreiber E, Balasubramani M, Day B, Michael Barmada M, **Vockley J**. (2014). Complex changes in the liver mitochondrial proteome of short chain acyl-CoA dehydrogenase deficient mice. *Mol Genet Metab.* **112:** 30-9. PMC4167795.

177. Dobrowolski SF, Lyons-Weiler J, Spridik K, Biery A, Breck J, **Vockley J**, Yatsenko S, Sultana T. (2015). Altered DNA methylation in PAH deficient phenylketonuria. *Mol Genet Metab.* **115:** 72-7.

178. Edmunds LR, Sharma L, Kang A, Lu J, **Vockley J**, Basu S, Uppala R, Goetzman ES, Beck ME, Scott D, Prochownik EV. (2015). c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate. *Journal of Biological Chemistry.* **290:** 20100. PMC4536417.

179. Haack TB, Staufner C, Kopke MG, Straub BK, Kolker S, Thiel C, Freisinger P, Baric I, McKiernan PJ, Dikow N, Harting I, Beisse F, Burgard P, Kotzaeridou U, Kuhr J, Himbert U, Taylor RW, Distelmaier F, **Vockley J**, Ghaloul-Gonzalez L, Zschocke J, Kremer LS, Graf E, Schwarzmayr T, Bader DM, Gagneur J, Wieland T, Terrile C, Strom TM, Meitinger T, Hoffmann GF, Prokisch H. (2015). Biallelic Mutations in NBAS Cause Recurrent Acute Liver Failure with Onset in Infancy. *American Journal of Human Genetics.* **97:** 163-9. PMC4572578.

180. Lee B, Diaz GA, Rhead W, Lichter-Konecki U, Feigenbaum A, Berry SA, Le Mons C, Bartley JA, Longo N, Nagamani SC, Berquist W, Gallagher R, Bartholomew D, Harding CO, Korson MS, McCandless SE, Smith W, Cederbaum S, Wong D, Merritt JL, 2nd, Schulze A, **Vockley J**, Kronn D, Zori R, Summar M, Milikien DA, Marino M, Coakley DF, Mokhtarani M, Consortium UCD, Scharschmidt BF. (2015). Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder. *Genet Med.* **17:** 561-8. PMC4465427.

181. Mohsen AW, **Vockley J**. (2015). Kinetic and spectral properties of isovaleryl-CoA dehydrogenase and interaction with ligands. *Biochimie.* **108:** 108-19. PMC4280362.

182. Nagamani SC, Diaz GA, Rhead W, Berry SA, Le Mons C, Lichter-Konecki U, Bartley J, Feigenbaum A, Schulze A, Longo N, Berquist W, Gallagher R, Bartholomew D, Harding CO, Korson MS, McCandless SE, Smith W, **Vockley J**, Kronn D, Zori R, Cederbaum S, Merritt JL, 2nd, Wong D, Coakley DF, Scharschmidt BF, Dickinson K, Marino M, Lee BH, Mokhtarani M. (2015). Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials. *Mol Genet Metab.* **116:** 29-34. PMC4804346.

183. Ningappa M, So J, Glessner J, Ashokkumar C, Ranganathan S, Min J, Higgs BW, Sun Q, Haberman K, Schmitt L, Vilarinho S, Mistry PK, **Vockley J**, Dhawan A, Gittes GK, Hakonarson H, Jaffe R, Subramaniam S, Shin D, Sindhi R. (2015). The Role of ARF6 in Biliary Atresia. *PLoS One.* **10:** e0138381. PMC4574480.

184. Prabhu D, Goldstein AC, El-Khoury R, Rak M, Edmunds L, Rustin P, **Vockley J**, Schiff M. (2015). ANT2-defective fibroblasts exhibit normal mitochondrial bioenergetics. *Mol Genet Metab Rep.* **3:** 43-6. PMC4435574.

185. Schiff M, Haberberger B, Xia C, Mohsen AW, Goetzman ES, Wang Y, Uppala R, Zhang Y, Karunanidhi A, Prabhu D, Alharbi H, Prochownik EV, Haack T, Haberle J, Munnich A, Rotig A, Taylor RW, Nicholls RD, Kim JJ, Prokisch H, **Vockley J**. (2015). Complex I assembly function and fatty acid oxidation enzyme activity of ACAD9 both contribute to disease severity in ACAD9 deficiency. *Human Molecular Genetics.* **24:** 3238-47. PMC4424958.

186. **Vockley J**, Marsden D, McCracken E, DeWard S, Barone A, Hsu K, Kakkis E. (2015). Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review. *Mol Genet Metab.* **116:** 53-60. PMC4561603.

187. Bentler K, Zhai S, Elsbecker SA, Arnold GL, Burton BK, **Vockley J**, Cameron CA, Hiner SJ, Edick MJ, Berry SA, Inborn Errors of Metabolism C. (2016). 221 newborn-screened neonates with medium-chain acyl-coenzyme A dehydrogenase deficiency: Findings from the Inborn Errors of Metabolism Collaborative. *Mol Genet Metab.* **119:** 75-82. PMC5031545.

188. Bodian DL, Klein E, Iyer RK, Wong WS, Kothiyal P, Stauffer D, Huddleston KC, Gaither AD, Remsburg I, Khromykh A, Baker RL, Maxwell GL, **Vockley J**G, Niederhuber JE, Solomon BD. (2016). Utility of whole-genome sequencing for detection of newborn screening disorders in a population cohort of 1,696 neonates. *Genet Med.* **18:** 221-30.

189. Camp KM, Krotoski D, Parisi MA, Gwinn KA, Cohen BH, Cox CS, Enns GM, Falk MJ, Goldstein AC, Gopal-Srivastava R, Gorman GS, Hersh SP, Hirano M, Hoffman FA, Karaa A, MacLeod EL, McFarland R, Mohan C, Mulberg AE, Odenkirchen JC, Parikh S, Rutherford PJ, Suggs-Anderson SK, Tang WH, **Vockley J**, Wolfe LA, Yannicelli S, Yeske PE, Coates PM. (2016). Nutritional interventions in primary mitochondrial disorders: Developing an evidence base. *Mol Genet Metab.* **119:** 187-206. PMC5083179.

190. Celik N, Squires RH, **Vockley J**, Sindhi R, Mazariegos G. (2016). Liver transplantation for maple syrup urine disease: A global domino effect. *Pediatr Transplant.* **20:** 350-1.

191. Dobrowolski SF, Lyons-Weiler J, Spridik K, **Vockley J**, Skvorak K, Biery A. (2016). DNA methylation in the pathophysiology of hyperphenylalaninemia in the PAH(enu2) mouse model of phenylketonuria. *Mol Genet Metab.* **119:** 1-7.

192. Edmunds LR, Otero PA, Sharma L, D'Souza S, Dolezal JM, David S, Lu J, Lamm L, Basantani M, Zhang P, Sipula IJ, Li L, Zeng X, Ding Y, Ding F, Beck ME, **Vockley J**, Monga SP, Kershaw EE, O'Doherty RM, Kratz LE, Yates NA, Goetzman EP, Scott D, Duncan AW, Prochownik EV. (2016). Abnormal lipid processing but normal long-term repopulation potential of myc-/- hepatocytes. *Oncotarget.* **7:** 30379-95. PMC5058687.

193. Forsyth R, Vockley CW, Edick MJ, Cameron CA, Hiner SJ, Berry SA, **Vockley J**, Arnold GL, Inborn Errors of Metabolism C. (2016). Outcomes of cases with 3-methylcrotonyl-CoA carboxylase (3-MCC) deficiency - Report from the Inborn Errors of Metabolism Information System. *Mol Genet Metab.* **118:** 15-20. PMC5540133.

194. Ghaloul-Gonzalez L, Goldstein A, Walsh Vockley C, Dobrowolski SF, Biery A, Irani A, Ibarra J, Morton DH, Mohsen AW, **Vockley J**. (2016). Mitochondrial respiratory chain disorders in the Old Order Amish population. *Mol Genet Metab.* **118:** 296-303.

195. Goldstein A, **Vockley J**. (2016). Clinical trials examining treatments for inborn errors of amino acid metabolism. *Expert Opin Orphan D.* **5:** 153-64.

196. Harding C, Amato S, **Vockley J**, Wierenga K, Li H, Bilder D, Burton B, Dimmock D, Longo N, Posner J, Thomas J, Zori R, Rosen O, Greblikas F, Gu K, Li M, Merilainen M, Weng HH, Levy H. (2016). Phase 3 PRISM-1 and PRISM-2 clinical trial results: to evaluate the efficacy and safety of pegvaliase for the treatment of adults with phenylketonuria (PKU). *Journal of Inherited Metabolic Disease.* **39:** S107-S8.

197. Kane MS, Vilboux T, Wolfe LA, Lee PR, Wang Y, Huddleston KC, **Vockley J**G, Niederhuber JE, Solomon BD. (2016). Aberrant splicing induced by the most common EPG5 mutation in an individual with Vici syndrome. *Brain.* **139:** e52. PMC5841196.

198. Longo N, Thomas J, Wasserstein M, Burton B, **Vockley J**, Grange D, Decker C, Weng HH, Li M, Schweighardt B, Zori R. (2016). Evaluation of long-term safety and efficacy of pegvaliase treatment for adults with phenylketonuria: Updated year 4 results. *Journal of Inherited Metabolic Disease.* **39:** S39.

199. McCoin CS, Piccolo BD, Knotts TA, Matern D, **Vockley J**, Gillingham MB, Adams SH. (2016). Unique plasma metabolomic signatures of individuals with inherited disorders of long-chain fatty acid oxidation. *J Inherit Metab Dis.* **39:** 399-408. PMC4851894.

200. Nahabet EH, Gatherwright J, **Vockley J**, Henderson N, Tomei KL, Grigorian AP, Kaminski B, Bass N, Selman WR, Lakin GE. (2016). Postnatal Pancraniosynostosis in a Patient With Infantile Hypophosphatasia. *Cleft Palate Craniofac J.* **53:** 741-4. 26171568.

201. Pena LD, van Calcar SC, Hansen J, Edick MJ, Walsh Vockley C, Leslie N, Cameron C, Mohsen AW, Berry SA, Arnold GL, **Vockley J**. (2016). Outcomes and genotype-phenotype correlations in 52 individuals with VLCAD deficiency diagnosed by NBS and enrolled in the IBEM-IS database. *Mol Genet Metab.* **118:** 272-81. PMC4970910.

202. Shneider BL, Magee JC, Karpen SJ, Rand EB, Narkewicz MR, Bass LM, Schwarz K, Whitington PF, Bezerra JA, Kerkar N, Haber B, Rosenthal P, Turmelle YP, Molleston JP, Murray KF, Ng VL, Wang KS, Romero R, Squires RH, Arnon R, Sherker AH, Moore J, Ye W, **Vockley J**, Sokol RJ, Childhood Liver Disease Research N. (2016). Total Serum Bilirubin within 3 Months of Hepatoportoenterostomy Predicts Short-Term Outcomes in Biliary Atresia. *Journal of Pediatrics.* **170:** 211-7 e1-2. PMC4826612.

203. Shneider BL, Morris A, **Vockley J**. (2016). Possible Phenylacetate Hepatotoxicity During 4-Phenylbutyrate Therapy of Byler Disease. *J Pediatr Gastroenterol Nutr.* **62:** 424-8.

204. Sonnet D, M NOL, M AG, S MN, Mateen S, Hsu Y, K PM, A JL, **Vockley J**, B KK, Ramanathan A. (2016). Metformin inhibits Branched Chain Amino Acid (BCAA) derived ketoacidosis and promotes metabolic homeostasis in MSUD. *Sci Rep.* **6:** 28775. PMC4931503.

205. Staufner C, Haack TB, Kopke MG, Straub BK, Kolker S, Thiel C, Freisinger P, Baric I, McKiernan PJ, Dikow N, Harting I, Beisse F, Burgard P, Kotzaeridou U, Lenz D, Kuhr J, Himbert U, Taylor RW, Distelmaier F, **Vockley J**, Ghaloul-Gonzalez L, Ozolek JA, Zschocke J, Kuster A, Dick A, Das AM, Wieland T, Terrile C, Strom TM, Meitinger T, Prokisch H, Hoffmann GF. (2016). Recurrent acute liver failure due to NBAS deficiency: phenotypic spectrum, disease mechanisms, and therapeutic concepts. *J Inherit Metab Dis.* **39:** 3-16.

206. **Vockley J**, Charrow J, Ganesh J, Eswara M, Diaz GA, McCracken E, Conway R, Enns GM, Starr J, Wang R, Abdenur JE, Sanchez-de-Toledo J, Marsden DL. (2016). Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders. *Mol Genet Metab.* **119:** 223-31. PMC5083220.

207. **Vockley J**, Longo N, Andresen BS, Bennett MJ. Mitochondrial Fatty Acid Oxidation Defects. in Pediatric Endocriniology and Inborn Errors of Metabolism Sarafoglou K, Hoffman GF, Roth K, Eds. (McGraw-Hill Companies, 2016), .

208. Wang W, Palmfeldt J, Mohsen AW, Gregersen N, **Vockley J**. (2016). Fasting Induces Prominent Proteomic Changes in Liver in Very Long Chain Acyl-CoA Dehydrogenase Deficient Mice. *Biochem Biophys Reports.* **8:** 333-9. PMC28955973.

209. Berry SA, Longo N, Diaz GA, McCandless SE, Smith WE, Harding CO, Zori R, Ficicioglu C, Lichter-Konecki U, Robinson B, **Vockley J**. (2017). Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years. *Mol Genet Metab.* **122:** 46-53.

210. Dobrowolski SF, Ghaloul-Gonzalez L, **Vockley J**. (2017). Medium chain acyl-CoA dehydrogenase deficiency in a premature infant. *Pediatr Rep.* **9:** 7045. PMC5733391.

211. Gillingham MB, Heitner SB, Martin J, Rose S, Goldstein A, El-Gharbawy AH, Deward S, Lasarev MR, Pollaro J, DeLany JP, Burchill LJ, Goodpaster B, Shoemaker J, Matern D, Harding CO, **Vockley J**. (2017). Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial. *J Inherit Metab Dis.* **40:** 831-43.

212. Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, Vockley G, Hamazaki T, Lachmann R, Ohashi T, Olivotto I, Sakai N, Deegan P, Dimmock D, Eyskens F, Germain DP, Goker-Alpan O, Hachulla E, Jovanovic A, Lourenco CM, Narita I, Thomas M, Wilcox WR, Bichet DG, Schiffmann R, Ludington E, Viereck C, Kirk J, Yu J, Johnson F, Boudes P, Benjamin ER, Lockhart DJ, Barlow C, Skuban N, Castelli JP, Barth J, Feldt-Rasmussen U. (2017). Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. *Journal of Medical Genetics.* **54:** 288-96. PMC5502308.

213. Pan LA, Martin P, Zimmer T, Segreti AM, Kassiff S, McKain BW, Baca CA, Rengasamy M, Hyland K, Walano N, Steinfeld R, Hughes M, Dobrowolski SK, Pasquino M, Diler R, Perel J, Finegold DN, Peters DG, Naviaux RK, Brent DA, **Vockley J**. (2017). Neurometabolic Disorders: Potentially Treatable Abnormalities in Patients With Treatment-Refractory Depression and Suicidal Behavior. *The American journal of psychiatry.* **174:** 42-50. 27523499.

214. Soltys KA, Setoyama K, Tafaleng EN, Soto Gutierrez A, Fong J, Fukumitsu K, Nishikawa T, Nagaya M, Sada R, Haberman K, Gramignoli R, Dorko K, Tahan V, Dreyzin A, Baskin K, Crowley JJ, Quader MA, Deutsch M, Ashokkumar C, Shneider BL, Squires RH, Ranganathan S, Reyes-Mugica M, Dobrowolski SF, Mazariegos G, Elango R, Stolz DB, Strom SC, Vockley G, Roy-Chowdhury J, Cascalho M, Guha C, Sindhi R, Platt JL, Fox IJ. (2017). Host conditioning and rejection monitoring in hepatocyte transplantation in humans. *J Hepatol.* **66:** 987-1000. PMC5395353.

215. **Vockley J**, Burton B, Berry GT, Longo N, Phillips J, Sanchez-Valle A, Tanpaiboon P, Grunewald S, Murphy E, Humphrey R, Mayhew J, Bowden A, Zhang L, Cataldo J, Marsden DL, Kakkis E. (2017). UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatment. *Mol Genet Metab.* **120:** 370-7.

216. **Vockley J**, Levy H, Amato S, Zori R, Thomas J, Burton B, Harding CO, Longo N, Posner J, Bilder D, Olbertz J, Gu Z, Lau K, Lin M, Larimore K, Dimmock D. (2017). Phase 3 prism-2 long-term extension study evaluating efficacy and safety of pegvaliase for treatment of adults with phenylketonuria. *Journal of Inborn Errors of Metabolism and Screening.* **5:** 128-9.

217. Zori R, Levy H, Longo N, Lau K, Rosen O, Li M, Larimore K, Decker C, Weng H, **Vockley J**. (2017). Phase 2 long-term pegvaliase treatment for adults with phenylketonuria: Updated year 5 safety and efficacy data from the PAL-003 extension. *Journal of Inborn Errors of Metabolism and Screening.* **5:** 130.

218. Berry SA, **Vockley J**, Vinks AA, Dong M, Diaz GA, McCandless SE, Smith WE, Harding CO, Zori R, Ficicioglu C, Lichter-Konecki U, Perdok R, Robinson B, Holt RJ, Longo N. (2018). Pharmacokinetics of glycerol phenylbutyrate in pediatric patients 2months to 2years of age with urea cycle disorders. *Mol Genet Metab.* **125:** 251-7.

219. Bloom K, Mohsen AW, Karunanidhi A, El Demellawy D, Reyes-Mugica M, Wang Y, Ghaloul-Gonzalez L, Otsubo C, Tobita K, Muzumdar R, Gong Z, Tas E, Basu S, Chen J, Bennett M, Hoppel C, **Vockley J**. (2018). Investigating the link of ACAD10 deficiency to type 2 diabetes mellitus. *J Inherit Metab Dis.* **41:** 49-57. PMC5524623.

220. Burton BK, Harding CO, Thomas JA, Longo N, Posner J, Dimmock D, Zori R, Weng HH, Olbertz J, Gershman A, Rosen O, Gupta S, Jones S, Gu Z, **Vockley J**. (2018). Long-term safety of induction, titration, and maintenance dosing of pegvaliase treatment in adults with phenylketonuria. *Journal of Inherited Metabolic Disease.* **41:** S104.

221. Critelli K, McKiernan P, **Vockley J**, Mazariegos G, Squires RH, Soltys K, Squires JE. (2018). Liver Transplantation for Propionic Acidemia and Methylmalonic Acidemia: Perioperative Management and Clinical Outcomes. *Liver Transpl.* **24:** 1260-70.

222. El-Gharbawy A, **Vockley J**. (2018). Inborn Errors of Metabolism with Myopathy: Defects of Fatty Acid Oxidation and the Carnitine Shuttle System. *Pediatric Clinics of North America.* **65:** 317-35.

223. Harding CO, Amato RS, Stuy M, Longo N, Burton BK, Posner J, Weng HH, Merilainen M, Gu Z, Jiang J, **Vockley J**, Investigators P-. (2018). Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trial. *Mol Genet Metab.* **124:** 20-6. PMC6031112.

224. Harding CO, Thomas JA, Burton BK, Zori R, Dimmock D, **Vockley J**, Weng HH, Olbertz J, Gershman A, Rosen O, Jones S, Li M, Longo N. (2018). Characterization of hypophenylalaninemia in pegvaliase treated adults with PKU. *Journal of Inherited Metabolic Disease.* **41:** S104.

225. Karaa A, Haas R, Goldstein A, **Vockley J**, Weaver WD, Cohen BH. (2018). Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. *Neurology.* **90:** e1212-e21. PMC5890606.

226. Leipnitz G, Mohsen AW, Karunanidhi A, Seminotti B, Roginskaya VY, Markantone DM, Grings M, Mihalik SJ, Wipf P, Van Houten B, **Vockley J**. (2018). Evaluation of mitochondrial bioenergetics, dynamics, endoplasmic reticulum-mitochondria crosstalk, and reactive oxygen species in fibroblasts from patients with complex I deficiency. *Sci Rep.* **8:** 1165. PMC5773529.

227. Longo N, Dimmock D, Levy H, Viau K, Bausell H, Bilder DA, Burton B, Gross C, Northrup H, Rohr F, Sacharow S, Sanchez-Valle A, Stuy M, Thomas J, **Vockley J**, Zori R, Harding CO. (2018). Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria. *Genet Med.*

228. Longo N, Zori R, Wasserstein MP, **Vockley J**, Burton BK, Decker C, Li M, Lau K, Jiang J, Larimore K, Thomas JA. (2018). Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study. *Orphanet J Rare Dis.* **13:** 108. PMC6031112.

229. Peters V, **Vockley J**. (2018). Do inborn errors of metabolism confer or impede the risk of diabetes? *J Inherit Metab Dis.* **41:** 1-2.

230. Powis Z, Farwell Hagman KD, Speare V, Cain T, Blanco K, Mowlavi LS, Mayerhofer EM, Tilstra D, Vedder T, Hunter JM, Tsang M, Gonzalez L, **Vockley J**, Tang S. (2018). Exome sequencing in neonates: diagnostic rates, characteristics, and time to diagnosis. *Genet Med.* **20:** 1468-71.

231. Repp BM, Mastantuono E, Alston CL, Schiff M, Haack TB, Rotig A, Ardissone A, Lombes A, Catarino CB, Diodato D, Schottmann G, Poulton J, Burlina A, Jonckheere A, Munnich A, Rolinski B, Ghezzi D, Rokicki D, Wellesley D, Martinelli D, Wenhong D, Lamantea E, Ostergaard E, Pronicka E, Pierre G, Smeets HJM, Wittig I, Scurr I, de Coo IFM, Moroni I, Smet J, Mayr JA, Dai L, de Meirleir L, Schuelke M, Zeviani M, Morscher RJ, McFarland R, Seneca S, Klopstock T, Meitinger T, Wieland T, Strom TM, Herberg U, Ahting U, Sperl W, Nassogne MC, Ling H, Fang F, Freisinger P, Van Coster R, Strecker V, Taylor RW, Haberle J, **Vockley J**, Prokisch H, Wortmann S. (2018). Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective? *Orphanet J Rare Dis.* **13:** 120. PMC6053715.

232. Thomas J, Levy H, Amato S, Vockley G, Zori R, Dimmock D, Harding C, Bilder D, Weng HH, Olbertz J, Merilainen M, Jiang J, Gupta S, Gu Z, Larimore K, Northrup H. (2018). Phase 3 prism clinical trial evaluating efficacy and safety of pegvaliase for treatment of adults with phenylketonuria. *Molecular Genetics and Metabolism.* **123:** 82-3.

233. Thomas J, Levy H, Amato S, **Vockley J**, Zori R, Dimmock D, Harding CO, Bilder DA, Weng HH, Olbertz J, Merilainen M, Jiang J, Larimore K, Gupta S, Gu Z, Northrup H. (2018). Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). *Mol Genet Metab.* **124:** 27-38.

234. van Kuilenburg ABP, Tarailo-Graovac M, Meijer J, Drogemoller B, **Vockley J**, Maurer D, Dobritzsch D, Ross CJ, Wasserman W, Meinsma R, Zoetekouw L, van Karnebeek CDM. (2018). Genome sequencing reveals a novel genetic mechanism underlying dihydropyrimidine dehydrogenase deficiency: A novel missense variant c.1700G>A and a large intragenic inversion in DPYD spanning intron 8 to intron 12. *Human Mutation.* **39:** 947-53.

235. Bell S, Rousseau J, Peng H, Aouabed Z, Priam P, Theroux JF, Jefri M, Tanti A, Wu H, Kolobova I, Silviera H, Manzano-Vargas K, Ehresmann S, Hamdan FF, Hettige N, Zhang X, Antonyan L, Nassif C, Ghaloul-Gonzalez L, Sebastian J, **Vockley J**, Begtrup AG, Wentzensen IM, Crunk A, Nicholls RD, Herman KC, Deignan JL, Al-Hertani W, Efthymiou S, Salpietro V, Miyake N, Makita Y, Matsumoto N, Ostern R, Houge G, Hafstrom M, Fassi E, Houlden H, Klein Wassink-Ruiter JS, Nelson D, Goldstein A, Dabir T, van Gils J, Bourgeron T, Delorme R, Cooper GM, Martinez JE, Finnila CR, Carmant L, Lortie A, Oegema R, van Gassen K, Mehta SG, Huhle D, Abou Jamra R, Martin S, Brunner HG, Lindhout D, Au M, Graham JM, Jr., Coubes C, Turecki G, Gravel S, Mechawar N, Rossignol E, Michaud JL, Lessard J, Ernst C, Campeau PM. (2019). Mutations in ACTL6B Cause Neurodevelopmental Deficits and Epilepsy and Lead to Loss of Dendrites in Human Neurons. *American Journal of Human Genetics.* **104:** 815-34. PMC6507050.

236. Celik N, Kelly B, Soltys K, Squires JE, **Vockley J**, Shellmer DA, Strauss K, McKiernan P, Ganoza A, Sindhi R, Bond G, Mazariegos G, Khanna A. (2019). Technique and outcome of domino liver transplantation from patients with maple syrup urine disease: Expanding the donor pool for live donor liver transplantation. *Clinical transplantation.* **33:** e13721.

237. Celik N, Squires JE, Soltys K, **Vockley J**, Shellmer DA, Chang W, Strauss K, McKiernan P, Ganoza A, Sindhi R, Bond G, Mazariegos G, Khanna A. (2019). Domino liver transplantation for select metabolic disorders: Expanding the living donor pool. *JIMD Rep.* **48:** 83-9. PMC6606984.

238. Coci EG, Gapsys V, Shur N, Shin-Podskarbi Y, de Groot BL, Miller K, **Vockley J**, Sondheimer N, Ganetzky R, Freisinger P. (2019). Pyruvate carboxylase deficiency type A and type C: Characterization of five novel pathogenic variants in PC and analysis of the genotype-phenotype correlation. *Human Mutation.* **40:** 816-27.

239. Diaz GA, Schulze A, Longo N, Rhead W, Feigenbaum A, Wong D, Merritt JL, 2nd, Berquist W, Gallagher RC, Bartholomew D, McCandless SE, Smith WE, Harding CO, Zori R, Lichter-Konecki U, **Vockley J**, Canavan C, Vescio T, Holt RJ, Berry SA. (2019). Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients. *Mol Genet Metab.* **127:** 336-45.

240. Enns GM, Porter MH, Francis-Sedlak M, Burdett A, **Vockley J**. (2019). Perspectives on urea cycle disorder management: Results of a clinician survey. *Mol Genet Metab.* **128:** 102-8.

241. Ferreira CR, van Karnebeek CDM, **Vockley J**, Blau N. (2019). A proposed nosology of inborn errors of metabolism. *Genet Med.* **21:** 102-6. PMC6286709.

242. Ghaloul-Gonzalez L, Mohsen AW, Karunanidhi A, Seminotti B, Chong H, Madan-Khetarpal S, Sebastian J, Vockley CW, Reyes-Mugica M, Vander Lugt MT, **Vockley J**. (2019). Reticular Dysgenesis and Mitochondriopathy Induced by Adenylate Kinase 2 Deficiency with Atypical Presentation. *Sci Rep.* **9:** 15739. PMC6823482.

243. Grings M, Seminotti B, Karunanidhi A, Ghaloul-Gonzalez L, Mohsen AW, Wipf P, Palmfeldt J, **Vockley J**, Leipnitz G. (2019). ETHE1 and MOCS1 deficiencies: Disruption of mitochondrial bioenergetics, dynamics, redox homeostasis and endoplasmic reticulum-mitochondria crosstalk in patient fibroblasts. *Sci Rep.* **9:** 12651. PMC6718683.

244. Hofmann CE, Harmatz P, **Vockley J**, Hogler W, Nakayama H, Bishop N, Martos-Moreno GA, Moseley S, Fujita KP, Liese J, Rockman-Greenberg C, Group ENBS. (2019). Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study. *J Clin Endocrinol Metab.* **104:** 2735-47. PMC6530655.

245. Kernan KF, Ghaloul-Gonzalez L, **Vockley J**, Carcillo JA. (2019). Rapid Whole Genome Sequencing and Fulfilling the Promise of Precision Pediatric Critical Care. *Pediatr Crit Care Med.* **20:** 1085-6.

246. Levy H, Lamppu D, Anastosoaie V, Baker JL, DiBona K, Hawthorne S, Lindenberger J, Kinch D, Seymour A, McIlduff M, Watling S, **Vockley J**. (2019). 5-year retrospective analysis of patients with phenylketonuria (PKU) and hyperphenylalaninemia treated at two specialized clinics. *Mol Genet Metab.*

247. Lichter-Konecki U, **Vockley J**. (2019). Phenylketonuria: Current Treatments and Future Developments. *Drugs.* **79:** 495-500.

248. Longo N, Dimmock D, Levy H, Viau K, Bausell H, Bilder DA, Burton B, Gross C, Northrup H, Rohr F, Sacharow S, Sanchez-Valle A, Stuy M, Thomas J, **Vockley J**, Zori R, Harding CO. (2019). Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria. *Genet Med.* **21:** 1851-67. PMC6752676.

249. McCalley S, Pirman D, Clasquin M, Johnson K, Jin S, **Vockley J**. (2019). Metabolic analysis reveals evidence for branched chain amino acid catabolism crosstalk and the potential for improved treatment of organic acidurias. *Mol Genet Metab.* **128:** 57-61. PMC6864255.

250. McCoin CS, Gillingham MB, Knotts TA, **Vockley J**, Ono-Moore KD, Blackburn ML, Norman JE, Adams SH. (2019). Blood cytokine patterns suggest a modest inflammation phenotype in subjects with long-chain fatty acid oxidation disorders. *Physiol Rep.* **7:** e14037. PMC6434073.

251. McKiernan PJ, Ganoza A, Squires JE, Squires RH, **Vockley J**, Mazariegos G, Soltys K, Sun Q, Sindhi R. (2019). Evolving Trends in Liver Transplant for Metabolic Liver Disease in the United States. *Liver Transpl.* **25:** 911-21.

252. Offiah AC, **Vockley J**, Munns CF, Murotsuki J. (2019). Differential diagnosis of perinatal hypophosphatasia: radiologic perspectives. *Pediatr Radiol.* **49:** 3-22. PMC6313373.

253. Parikh S, Karaa A, Goldstein A, Bertini ES, Chinnery PF, Christodoulou J, Cohen BH, Davis RL, Falk MJ, Fratter C, Horvath R, Koenig MK, Mancuso M, McCormack S, McCormick EM, McFarland R, Nesbitt V, Schiff M, Steele H, Stockler S, Sue C, Tarnopolsky M, Thorburn DR, **Vockley J**, Rahman S. (2019). Diagnosis of 'possible' mitochondrial disease: an existential crisis. *Journal of Medical Genetics.* **56:** 123-30.

254. Peters V, Morath M, Mack M, Liesert M, Buckel W, Hoffmann GF, **Vockley J**, Ghisla S, Zschocke J. (2019). Formation of 3-hydroxyglutaric acid in glutaric aciduria type I: in vitro participation of medium chain acyl-CoA dehydrogenase. *JIMD Rep.* **47:** 30-4. PMC6498835.

255. Polyzos AA, Lee DY, Datta R, Hauser M, Budworth H, Holt A, Mihalik S, Goldschmidt P, Frankel K, Trego K, Bennett MJ, **Vockley J**, Xu K, Gratton E, McMurray CT. (2019). Metabolic Reprogramming in Astrocytes Distinguishes Region-Specific Neuronal Susceptibility in Huntington Mice. *Cell Metab.* **29:** 1258-73 e11. PMC6583797.

256. Richardson R, Apaydin E, Baxi S, **Vockley J**, Akinniranye O, L L, Motala M, Hempel S, in Emerging Technologies and Theapeutics Reports (Patient-Centered Research Institute, 2019), .

257. Roland BP, Richards KR, Hrizo SL, Eicher S, Barile ZJ, Chang TC, Savon G, Bianchi P, Fermo E, Ricerca BM, Tortorolo L, **Vockley J**, VanDemark AP, Palladino MJ. (2019). Missense variant in TPI1 (Arg189Gln) causes neurologic deficits through structural changes in the triosephosphate isomerase catalytic site and reduced enzyme levels in vivo. *Biochim Biophys Acta Mol Basis Dis.* **1865:** 2257-66. PMC6659405.

258. Seminotti B, Leipnitz G, Karunanidhi A, Kochersperger C, Roginskaya VY, Basu S, Wang Y, Wipf P, Van Houten B, Mohsen AW, **Vockley J**. (2019). Mitochondrial energetics is impaired in very long-chain acyl-CoA dehydrogenase deficiency and can be rescued by treatment with mitochondria-targeted electron scavengers. *Human Molecular Genetics.* **28:** 928-41. PMC6400046.

259. **Vockley J**, Burton B, Berry GT, Longo N, Phillips J, Sanchez-Valle A, Tanpaiboon P, Grunewald S, Murphy E, Bowden A, Chen W, Chen CY, Cataldo J, Marsden D, Kakkis E. (2019). Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD). *J Inherit Metab Dis.* **42:** 169-77. PMC6348052.

260. **Vockley J**, Dobrowolski SF, Arnold GL, Guerrero RB, Derks TGJ, Weinstein DA. (2019). Complex patterns of inheritance, including synergistic heterozygosity, in inborn errors of metabolism: Implications for precision medicine driven diagnosis and treatment. *Mol Genet Metab.* **128:** 1-9.

261. Wang Y, Palmfeldt J, Gregersen N, Makhov AM, Conway JF, Wang M, McCalley SP, Basu S, Alharbi H, St Croix C, Calderon MJ, Watkins S, **Vockley J**. (2019). Mitochondrial fatty acid oxidation and the electron transport chain comprise a multifunctional mitochondrial protein complex. *Journal of Biological Chemistry.* **294:** 12380-91. PMC6699831.

262. Zhang Y, Mohsen AW, Kochersperger C, Solo K, Schmidt AV, **Vockley J**, Goetzman ES. (2019). An acyl-CoA dehydrogenase microplate activity assay using recombinant porcine electron transfer flavoprotein. *Analytical Biochemistry.* **581:** 113332. PMC6661201.

1. Apaydin EA, Richardson AS, Baxi S, **Vockley J**, Akinniranye O, Ross R, Larkin J, Motala A, Azhar G, Hempel S. (2020). An evidence map of randomised controlled trials evaluating genetic therapies. *BMJ Evid Based Med.* Epub ahead of print: 10.1136/bmjebm-2020-111448.
2. Bloom K, Karunanidhi A, Tobita K, Hoppel C, Thiels E, Peet E, Wang Y, Basu S, **Vockley J**. (2020). ACAD10 protein expression and Neurobehavioral assessment of Acad10-deficient mice. *PLoS One.* **15:** e0242445. PMC7728233.
3. Burton BK, Longo N, **Vockley J**, Grange DK, Harding CO, Decker C, Li M, Lau K, Rosen O, Larimore K, Thomas J, Pal, Investigators PAL. (2020). Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up. *Mol Genet Metab.* **130:** 239-46. .
4. Dobrowolski SF, Alodaib A, Karunanidhi A, Basu S, Holecko M, Lichter-Konecki U, Pappan KL, **Vockley J**. (2020). Clinical, biochemical, mitochondrial, and metabolomic aspects of methylmalonate semialdehyde dehydrogenase deficiency: Report of a fifth case. *Mol Genet Metab.* **129:** 272-7. .
5. Elizondo G, Matern D, **Vockley J**, Harding CO, Gillingham MB. (2020). Effects of fasting, feeding and exercise on plasma acylcarnitines among subjects with CPT2D, VLCADD and LCHADD/TFPD. *Mol Genet Metab.* **131:** 90-7. PMC8048763.
6. Hillert A, Anikster Y, Belanger-Quintana A, Burlina A, Burton BK, Carducci C, Chiesa AE, Christodoulou J, Dordevic M, Desviat LR, Eliyahu A, Evers RAF, Fajkusova L, Feillet F, Bonfim-Freitas PE, Gizewska M, Gundorova P, Karall D, Kneller K, Kutsev SI, Leuzzi V, Levy HL, Lichter-Konecki U, Muntau AC, Namour F, Oltarzewski M, Paras A, Perez B, Polak E, Polyakov AV, Porta F, Rohrbach M, Scholl-Burgi S, Specola N, Stojiljkovic M, Shen N, Santana-da Silva LC, Skouma A, van Spronsen F, Stoppioni V, Thony B, Trefz FK, **Vockley J**, Yu Y, Zschocke J, Hoffmann GF, Garbade SF, Blau N. (2020). The Genetic Landscape and Epidemiology of Phenylketonuria. *Am J Hum Genet.* **107:** 234-50. PMC7413859.
7. Karaa A, Haas R, Goldstein A, **Vockley J**, Cohen BH. (2020). A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. *J Cachexia Sarcopenia Muscle.* **11:** 909-18. PMC7432581.
8. Koppes EA, Redel BK, Johnson MA, Skvorak KJ, Ghaloul-Gonzalez L, Yates ME, Lewis DW, Gollin SM, Wu YL, Christ SE, Yerle M, Leshinski A, Spate LD, Benne JA, Murphy SL, Samuel MS, Walters EM, Hansen SA, Wells KD, Lichter-Konecki U, Wagner RA, Newsome JT, Dobrowolski SF, **Vockley J**, Prather RS, Nicholls RD. (2020). A porcine model of phenylketonuria generated by CRISPR/Cas9 genome editing. *JCI Insight.* **5:** PMC7605535.
9. Levy H, Lamppu D, Anastosoaie V, Baker JL, DiBona K, Hawthorne S, Lindenberger J, Kinch D, Seymour A, McIlduff M, Watling S, **Vockley J**. (2020). 5-year retrospective analysis of patients with phenylketonuria (PKU) and hyperphenylalaninemia treated at two specialized clinics. *Mol Genet Metab.* **129:** 177-85. .
10. Madsen KL, Buch AE, Cohen BH, Falk MJ, Goldsberry A, Goldstein A, Karaa A, Koenig MK, Muraresku CC, Meyer C, O'Grady M, Scaglia F, Shieh PB, **Vockley J**, Zolkipli-Cunningham Z, Haller RG, Vissing J. (2020). Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trial. *Neurology.* **94:** e687-e98. PMC7176297.
11. McKiernan PJ, Squires JE, Squires RH, **Vockley J**, Mazariegos GV, Soltys K, Ganoza A, Strauss K, Khanna A, Sindhi R. (2020). Liver transplant for inherited metabolic disease among siblings. *Clin Transplant.* **34:** e14090. .
12. Sklirou E, Alodaib AN, Dobrowolski SF, Mohsen AA, **Vockley J**. (2020). Physiological Perspectives on the Use of Triheptanoin as Anaplerotic Therapy for Long Chain Fatty Acid Oxidation Disorders. *Front Genet.* **11:** 598760. PMC7875087.
13. Staufner C, Peters B, Wagner M, Alameer S, Baric I, Broue P, Bulut D, Church JA, Crushell E, Dalgic B, Das AM, Dick A, Dikow N, Dionisi-Vici C, Distelmaier F, Bozbulut NE, Feillet F, Gonzales E, Hadzic N, Hauck F, Hegarty R, Hempel M, Herget T, Klein C, Konstantopoulou V, Kopajtich R, Kuster A, Laass MW, Lainka E, Larson-Nath C, Leibner A, Lurz E, Mayr JA, McKiernan P, Mention K, Moog U, Mungan NO, Riedhammer KM, Santer R, Palafoll IV, **Vockley J**, Westphal DS, Wiedemann A, Wortmann SB, Diwan GD, Russell RB, Prokisch H, Garbade SF, Kolker S, Hoffmann GF, Lenz D. (2020). Defining clinical subgroups and genotype-phenotype correlations in NBAS-associated disease across 110 patients. *Genet Med.* **22:** 610-21. .
14. van Rijt WJ, Jager EA, Allersma DP, Aktuglu Zeybek AC, Bhattacharya K, Debray FG, Ellaway CJ, Gautschi M, Geraghty MT, Gil-Ortega D, Larson AA, Moore F, Morava E, Morris AA, Oishi K, Schiff M, Scholl-Burgi S, Tchan MC, **Vockley J**, Witters P, Wortmann SB, van Spronsen F, Van Hove JLK, Derks TGJ. (2020). Efficacy and safety of D,L-3-hydroxybutyrate (D,L-3-HB) treatment in multiple acyl-CoA dehydrogenase deficiency. *Genet Med.* **22:** 908-16. PMC7200590.
15. **Vockley J**. (2020). Long-chain fatty acid oxidation disorders and current management strategies. *Am J Manag Care.* **26:** S147-S54. .
16. Xiao C, Astiazaran-Symonds E, Basu S, Kisling M, Scaglia F, Chapman KA, Wang Y, **Vockley J**, Ferreira CR. (2020). Mitochondrial energetic impairment in a patient with late-onset glutaric acidemia Type 2. *Am J Med Genet A.* **182:** 2426-31. .
17. Alatibi KI, Hagenbuchner J, Wehbe Z, Karall D, Ausserlechner MJ, **Vockley J**, Spiekerkoetter U, Grunert SC, Tucci S. (2021). Different Lipid Signature in Fibroblasts of Long-Chain Fatty Acid Oxidation Disorders. *Cells.* **10:** 1239. PMC8157847.
18. Alatibi KI, Tholen S, Wehbe Z, Hagenbuchner J, Karall D, Ausserlechner MJ, Schilling O, Grunert SC, **Vockley J**, Tucci S. (2021). Lipidomic and Proteomic Alterations Induced by Even and Odd Medium-Chain Fatty Acids on Fibroblasts of Long-Chain Fatty Acid Oxidation Disorders. *Int J Mol Sci.* **22:** PMC8508682.
19. Arnold GL, Yester J, McCracken E, Feingold BD, **Vockley J**. (2021). Successful orthotopic heart transplantation in CPTII deficiency. *Mol Genet Metab.* **133:** 182-4. .
20. D'Annibale OM, Koppes EA, Alodaib AN, Kochersperger C, Karunanidhi A, Mohsen AW, **Vockley J**. (2021). Characterization of variants of uncertain significance in isovaleryl-CoA dehydrogenase identified through newborn screening: An approach for faster analysis. *Mol Genet Metab.* .
21. Dobrowolski SF, Phua YL, Sudano C, Spridik K, Zinn PO, Wang Y, Bharathi S, **Vockley J**, Goetzman E. (2021). Phenylalanine hydroxylase deficient phenylketonuria comparative metabolomics identifies energy pathway disruption and oxidative stress. *Mol Genet Metab.* .
22. Dobrowolski SF, Sudano C, Phua YL, Tourkova IL, Spridik K, Goetzman ES, **Vockley J**, Blair HC. (2021). Mesenchymal stem cell energy deficit and oxidative stress contribute to osteopenia in the Pah(enu2) classical PKU mouse. *Mol Genet Metab.* **132:** 173-9. .
23. Ewing CB, Soltys KA, Strauss KA, Sindhi R, **Vockley J**, McKiernan P, Squires RH, Bond G, Ganoza A, Khanna A, Mazariegos GV, Squires JE. (2021). Metabolic Control and "Ideal" Outcomes in Liver Transplantation for Maple Syrup Urine Disease. *J Pediatr.* **237:** 59-64 e1. .
24. Glanzel NM, Grings M, da Rosa-Junior NT, de Carvalho LMC, Mohsen AW, Wipf P, Wajner M, **Vockley J**, Leipnitz G. (2021). The mitochondrial-targeted reactive species scavenger JP4-039 prevents sulfite-induced alterations in antioxidant defenses, energy transfer, and cell death signaling in striatum of rats. *J Inherit Metab Dis.* **44:** 481-91. PMC8039837.
25. Jahanshahi M, Gregg K, Davis G, Ndu A, Miller V, **Vockley J**, Ollivier C, Franolic T, Sakai S. (2021). The Use of External Controls in FDA Regulatory Decision Making. *Ther Innov Regul Sci.* **55:** 1019-35. PMC8332598.
26. Maron JL, Kingsmore SF, Wigby K, Chowdhury S, Dimmock D, Poindexter B, Suhrie K, **Vockley J**, Diacovo T, Gelb BD, Stroustrup A, Powell CM, Trembath A, Gallen M, Mullen TE, Tanpaiboon P, Reed D, Kurfiss A, Davis JM. (2021). Novel Variant Findings and Challenges Associated With the Clinical Integration of Genomic Testing: An Interim Report of the Genomic Medicine for Ill Neonates and Infants (GEMINI) Study. *JAMA Pediatr.* **175:** e205906. PMC7885094.
27. Marsden D, Bedrosian CL, **Vockley J**. (2021). Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders. *Genet Med.* **23:** 816-29. PMC8105167.
28. Puurunen MK, **Vockley J**, Searle SL, Sacharow SJ, Phillips JA, 3rd, Denney WS, Goodlett BD, Wagner DA, Blankstein L, Castillo MJ, Charbonneau MR, Isabella VM, Sethuraman VV, Riese RJ, Kurtz CB, Brennan AM. (2021). Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human phase 1/2a study. *Nat Metab.* **3:** 1125-32. .
29. Raghu VK, Carr-Boyd PD, Squires JE, **Vockley J**, Goldaracena N, Mazariegos GV. (2021). Domino transplantation for pediatric liver recipients: Obstacles, challenges, and successes. *Pediatr Transplant.* e14114. .
30. Raimo S, Zura-Miller G, Fezelinia H, Spruce LA, Zakopoulos I, Mohsen AW, **Vockley J**, Ischiropoulos H. (2021). Mitochondrial morphology, bioenergetics and proteomic responses in fatty acid oxidation disorders. *Redox Biol.* **41:** 101923. PMC7970426.
31. Sinsheimer A, Mohsen AW, Bloom K, Karunanidhi A, Bharathi S, Wu YL, Schiff M, Wang Y, Goetzman ES, Ghaloul-Gonzalez L, **Vockley J**. (2021). Development and characterization of a mouse model for Acad9 deficiency. *Mol Genet Metab.* **134:** 156-63.
32. Sood V, Squires JE, Mazariegos GV, **Vockley J**, McKiernan PJ. (2021). Living Related Liver Transplantation for Metabolic Liver Diseases in Children. *J Pediatr Gastroenterol Nutr.* **72:** 11-7.
33. Tcheng M, Cunha VLS, Ahmed N, Liu X, Smith RW, Rea KA, Akhtar TA, D'Alessandro A, Minden MD, **Vockley J**, O'Doherty GA, Lowary TL, Spagnuolo PA. (2021). Structure-activity relationship of avocadyne. *Food & function.* **12:** 6323-33. PMC8312404.
34. Tcheng M, Roma A, Ahmed N, Smith RW, Jayanth P, Minden MD, Schimmer AD, Hess DA, Hope K, Rea KA, Akhtar TA, Bohrnsen E, D'Alessandro A, Mohsen AW, **Vockley J**, Spagnuolo PA. (2021). Very long chain fatty acid metabolism is required in acute myeloid leukemia. *Blood.* **137:** 3518-32. PMC8225921.
35. Vallejo AN, Mroczkowski HJ, Michel JJ, Woolford M, Blair HC, Griffin P, McCracken E, Mihalik SJ, Reyes-Mugica M, **Vockley J**. (2021). Pervasive inflammatory activation in patients with deficiency in very-long-chain acyl-coA dehydrogenase (VLCADD). *Clin Transl Immunology.* **10:** e1304. PMC8236555.
36. **Vockley J**. (2021). View from inside: Rare diseases in the times of COVID19. *J Inherit Metab Dis.* **44:** 2-3. PMC7753813.
37. **Vockley J**, Burton B, Berry G, Longo N, Phillips J, Sanchez-Valle A, Chapman K, Tanpaiboon P, Grunewald S, Murphy E, Lu X, Cataldo J. (2021). Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study. *J Inherit Metab Dis.* **44:** 253-63. PMC7891391.
38. **Vockley J**, Longo N, Madden M, Dwyer L, Mu Y, Chen CY, Cataldo J. (2021). Dietary management and major clinical events in patients with long-chain fatty acid oxidation disorders enrolled in a phase 2 triheptanoin study. *Clin Nutr ESPEN.* **41:** 293-8. .
39. Woerner AC, Gallagher RC, **Vockley J**, Adhikari AN. (2021). The Use of Whole Genome and Exome Sequencing for Newborn Screening: Challenges and Opportunities for Population Health. *Front Pediatr.* **9:** 663752. PMC8326411.
40. Woerner AC, **Vockley J**. (2021). Mitochondrial Disease and Coenzyme Q10 Deficiency: Commentary. *J Pediatr.* **228:** 14-5
41. Wolfe RM, Mohsen AW, Walsh Vockley C, Bertrand CA, Nicholls RD, Heiman P, Seibold LM, **Vockley J**, Ghaloul-Gonzalez L. (2021). Novel GUCY2C variant causing familial diarrhea in a Mennonite kindred and a potential therapeutic approach. *Am J Med Genet A.* **185:** 2046-55. PMC8251925.
42. Xia C, Lou B, Fu Z, Mohsen AW, Shen AL, **Vockley J**, Kim JP. (2021). Molecular mechanism of interactions between ACAD9 and binding partners in mitochondrial respiratory complex I assembly. *iScience.* **24:** 103153. PMC8497999.

305. Apaydin EA, Richardson AS, Baxi S, **Vockley J**, Akinniranye O, Larkin J, Motala A, Hempel S. (2022). Differences in lymphoma patients between chimeric antigen receptor T-cell therapy trials and the general population. *Clin Exp Med.* **22:** 151-5. .

1. Airik M, Phua YL, Huynh AB, McCourt BT, Rush BM, Tan RJ, **Vockley J**, Murray SL, Dorman A, Conlon PJ, Airik R. Persistent DNA damage underlies tubular cell polyploidization and progression to chronic kidney disease in kidneys deficient in the DNA repair protein FAN1. *Kidney Int* **2022**, 102**,** 1042-56. PMC 35931300.
2. Apaydin EA, Richardson AS, Baxi S, **Vockley J**, Akinniranye O, Larkin J, Motala A, Hempel S. Differences in lymphoma patients between chimeric antigen receptor T-cell therapy trials and the general population. *Clin Exp Med* **2022**, 22**,** 151-5. PMC 33997936.
3. Burton BK, Hermida A, Belanger-Quintana A, Bell H, Bjoraker KJ, Christ SE, Grant ML, Harding CO, Huijbregts SCJ, Longo N, McNutt MC, 2nd, Nguyen-Driver MD, Santos Pessoa AL, Rocha JC, Sacharow S, Sanchez-Valle A, Sivri HS, **Vockley J**, Walterfang M, Whittle S, Muntau AC. Management of early treated adolescents and young adults with phenylketonuria: Development of international consensus recommendations using a modified Delphi approach. *Mol Genet Metab* **2022**, 137**,** 114-26. PMC 36027720.
4. Cabrera-Serrano M, Caccavelli L, Savarese M, Vihola A, Jokela M, Johari M, Capiod T, Madrange M, Bugiardini E, Brady S, Quinlivan R, Merve A, Scalco R, Hilton-Jones D, Houlden H, Aydin HI, Ceylaner S, Drewes S, **Vockley J**, Taylor RL, Folland C, Kelly A, Goullee H, Ylikallio E, Auranen M, Tyynismaa H, Udd B, Forrest ARR, Davis MR, Bratkovic D, Manton N, Robertson T, O'Gorman C, McCombe P, Laing NG, Phillips L, de Lonlay P, Ravenscroft G. Bi-allelic loss-of-function OBSCN variants predispose individuals to severe recurrent rhabdomyolysis. *Brain* **2022**, 145**,** 3985-98. PMC 34957489.
5. D'Annibale OM, Koppes EA, Sethuraman M, Bloom K, Mohsen AW, **Vockley J**. Characterization of exonic variants of uncertain significance in very long-chain acyl-CoA dehydrogenase identified through newborn screening. *J Inherit Metab Dis* **2022**, 45**,** 529-40. PMC 35218577.
6. D'Annibale OM, Phua YL, Van't Land C, Karunanidhi A, Dorenbaum A, Mohsen AW, **Vockley J**. Treatment of VLCAD-Deficient Patient Fibroblasts with Peroxisome Proliferator-Activated Receptor delta Agonist Improves Cellular Bioenergetics. *Cells* **2022**, 11**,** PMC 36078043.
7. Dobrowolski SF, Phua YL, Sudano C, Spridik K, Zinn PO, Wang Y, Bharathi S, **Vockley J**, Goetzman E. Comparative metabolomics in the Pah(enu2) classical PKU mouse identifies cerebral energy pathway disruption and oxidative stress. *Mol Genet Metab* **2022**, 136**,** 38-45. PMC 35367142.
8. Dobrowolski SF, Phua YL, Tourkova IL, Sudano C, **Vockley J**, Larrouture QC, Blair HC. Glutamine energy substrate anaplerosis increases bone density in the Pah(enu2) classical PKU mouse in the absence of phenylalanine restriction. *JIMD Rep* **2022**, 63**,** 446-52. PMC 36101821.
9. Dobrowolski SF, Phua YL, **Vockley J**, Goetzman E, Blair HC. Phenylketonuria oxidative stress and energy dysregulation: Emerging pathophysiological elements provide interventional opportunity. *Mol Genet Metab* **2022**, 136**,** 111-7. PMC 35379539.
10. Ehrenberg S, Walsh Vockley C, Heiman P, Ammous Z, Wenger O, **Vockley J**, Ghaloul-Gonzalez L. Natural history of propionic acidemia in the Amish population. *Mol Genet Metab Rep* **2022**, 33**,** 100936. PMC 36393899.
11. Goetzman ES, **Vockley J**. Lysine acylation causes collateral damage in inborn errors of metabolism. *Sci Transl Med* **2022**, 14**,** eabq4863. PMC 35613282.
12. Hansen J, Ramachandran R, **Vockley J**. Survey of Health Care Provider Understanding of Gene Therapy Research for Inherited Metabolic Disorders. *Clin Ther* **2022**, 44**,** 1045-56. PMC 35927093.
13. Heiman P, Mohsen AW, Karunanidhi A, St Croix C, Watkins S, Koppes E, Haas R, **Vockley J**, Ghaloul-Gonzalez L. Mitochondrial dysfunction associated with TANGO2 deficiency. *Sci Rep* **2022**, 12**,** 3045. PMC 35197517.
14. Kahler SG, **Vockley J**. Obituary for Charles Rider Roe, MD. *Journal of Inherited Metabolic Disease* **2022**, 45**,** 379-. PMC 34997769.
15. Karunanidhi A, Van't Land C, Rajasundaram D, Grings M, **Vockley J**, Mohsen AW. Medium branched chain fatty acids improve the profile of tricarboxylic acid cycle intermediates in mitochondrial fatty acid beta-oxidation deficient cells: A comparative study. *J Inherit Metab Dis* **2022**, 45**,** 541-56. PMC 35076099.
16. Kernan KF, Ghaloul-Gonzalez L, **Vockley J**, Lamb J, Hollingshead D, Chandran U, Sethi R, Park HJ, Berg RA, Wessel D, Pollack MM, Meert KL, Hall MW, Newth CJL, Lin JC, Doctor A, Shanley T, Cornell T, Harrison RE, Zuppa AF, Banks R, Reeder RW, Holubkov R, Notterman DA, Dean JM, Carcillo JA. Prevalence of Pathogenic and Potentially Pathogenic Inborn Error of Immunity Associated Variants in Children with Severe Sepsis. *J Clin Immunol* **2022**, 42**,** 350-64. PMC 34973142.
17. Lim CC, **Vockley J**, Ujah O, Kirby RS, Edick MJ, Berry SA, Arnold GL. Outcomes and genotype correlations in patients with mitochondrial trifunctional protein or isolated long chain 3-hydroxyacyl-CoA dehydrogenase deficiency enrolled in the IBEM-IS database. *Mol Genet Metab Rep* **2022**, 32**,** 100884. PMC 35677112.
18. Longo N, Sass JO, Jurecka A, **Vockley J**. Biomarkers for drug development in propionic and methylmalonic acidemias. *J Inherit Metab Dis* **2022**, 45**,** 132-43. PMC 35038174.
19. Pan LA, Segreti AM, Wrobleski J, Shaw A, Hyland K, Hughes M, Finegold DN, Naviaux RK, Brent DA, **Vockley J**, Peters DG. Metabolomic disorders: confirmed presence of potentially treatable abnormalities in patients with treatment refractory depression and suicidal behavior. *Psychological medicine* **2022**, 1-9. PMC 36330595.
20. Raghu VK, Dobrowolski SF, Sindhi R, Strauss KA, Mazariegos GV, **Vockley J**, Soltys K. Domino liver transplant from a donor with maple syrup urine disease into a recipient with phenylketonuria. *Mol Genet Metab Rep* **2022**, 31**,** 100866. PMC 35782613.
21. **Vockley J**, Enns GM, Ramirez AN, Bedrosian CL, Reineking B, Lu X, Ray K, Rahman S, Marsden D. Response to triheptanoin therapy in critically ill patients with LC-FAOD: Report of patients treated through an expanded access program. *Mol Genet Metab* **2022**, 136**,** 152-62. PMC 35459555.
22. Wolfe R, Heiman P, D'Annibale O, Karunanidhi A, Powers A, McGuire M, Seminotti B, Dobrowolski SF, Reyes-Mugica M, Torok KS, Mohsen AW, **Vockley J**, Ghaloul-Gonzalez L. ITCH deficiency clinical phenotype expansion and mitochondrial dysfunction. *Mol Genet Metab Rep* **2022**, 33**,** 100932. PMC 36338154.
23. Airik M, Arbore H, Childs E, Huynh AB, Phua YL, Chen CW, Aird K, Bharathi S, Zhang B, Conlon P, Kmoch S, Kidd K, Bleyer AJ, **Vockley J,** Goetzman E, Wipf P, Airik R. (2023). Mitochondrial ROS Triggers KIN Pathogenesis in FAN1-Deficient Kidneys. *Antioxidants (Basel).* **12:** PMC10135478.
24. DeLany JP, Horgan A, Gregor A, **Vockley J**, Harding CO, Gillingham MB. (2023). Resting and total energy expenditure of patients with long-chain fatty acid oxidation disorders (LC-FAODs). *Mol Genet Metab.* **138:** 107519. PMC9992335.
25. Glanzel NM, Parmeggiani B, Grings M, Seminotti B, Brondani M, Bobermin LD, Ribeiro CAJ, Quincozes-Santos A, **Vockley J**, Leipnitz G. (2023). Myelin Disruption, Neuroinflammation, and Oxidative Stress Induced by Sulfite in the Striatum of Rats Are Mitigated by the pan-PPAR agonist Bezafibrate. *Cells.* **12:** PMC10296939.
26. Karaa A, Bertini E, Carelli V, Cohen BH, Enns GM, Falk MJ, Goldstein A, Gorman GS, Haas R, Hirano M, Klopstock T, Koenig MK, Kornblum C, Lamperti C, Lehman A, Longo N, Molnar MJ, Parikh S, Phan H, Pitceathly RDS, Saneto R, Scaglia F, Servidei S, Tarnopolsky M, Toscano A, Van Hove JLK, Vissing J, Vockley J, Finman JS, Brown DA, Shiffer JA, Mancuso M, Investigators M-T. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. *Neurology.* **101:** e238-e52. PMC10382259.
27. Karunanidhi A, Basu S, Zhao XJ, D'Annibale O, Van't Land C, **Vockley J**, Mohsen AW. (2023). Heptanoic and medium branched-chain fatty acids as anaplerotic treatment for medium chain acyl-CoA dehydrogenase deficiency. *Mol Genet Metab.* **140:** 107689. .
28. Lasio MLD, Leshinski AC, Ducich NH, Flore LA, Lehman A, Shur N, Jayakar PB, Hainline BE, Basinger AA, Wilson WG, Diaz GA, Erbe RW, Koeberl DD, **Vockley J**, Bedoyan JK. (2023). Clinical, biochemical and molecular characterization of 12 patients with pyruvate carboxylase deficiency treated with triheptanoin. *Mol Genet Metab.* **139:** 107605. PMC10330474.
29. Maron JL, Kingsmore S, Gelb BD, **Vockley J**, Wigby K, Bragg J, Stroustrup A, Poindexter B, Suhrie K, Kim JH, Diacovo T, Powell CM, Trembath A, Guidugli L, Ellsworth KA, Reed D, Kurfiss A, Breeze JL, Trinquart L, Davis JM. (2023). Rapid Whole-Genomic Sequencing and a Targeted Neonatal Gene Panel in Infants With a Suspected Genetic Disorder. *JAMA.* **330:** 161-9. PMC10336625.
30. Seminotti B, Grings M, Glanzel NM, **Vockley J**, Leipnitz G. (2023). Peroxisome proliferator-activated receptor (PPAR) agonists as a potential therapy for inherited metabolic disorders. *Biochemical Pharmacology.* **209:** 115433. .
31. Verma A, Lehman AN, Gokcan H, Cropcho L, Black D, Dobrowolski SF, **Vockley J**, Bedoyan JK. (2023). Amino acid ratio combinations as biomarkers for discriminating patients with pyruvate dehydrogenase complex deficiency from other inborn errors of metabolism. *Mol Genet Genomic Med.* e2283. .
32. Vianey-Saban C, Fouilhoux A, **Vockley J**, Acquaviva-Bourdain C, Guffon N. (2023). Improving diagnosis of mitochondrial fatty-acid oxidation disorders. *Eur J Hum Genet.* **31:** 265-72. PMC9995306.
33. **Vockley J**, Aartsma-Rus A, Cohen JL, Cowsert LM, Howell RR, Yu TW, Wasserstein MP, Defay T. (2023). Whole-genome sequencing holds the key to the success of gene-targeted therapies. *Am J Med Genet C Semin Med Genet.* **193:** 19-29. .
34. **Vockley J,** Brunetti-Pierri N, Chung WK, Clarke AJ, Gold N, Green RC, Kagan S, Moroz T, Schaaf CP, Schulz M, De Baere E. (2023). The evolving role of medical geneticists in the era of gene therapy: An urgency to prepare. *Genet Med.* **25:** 100022. .
35. **Vockley J**, Burton B, Jurecka A, Ganju J, Leiro B, Zori R, Longo N. (2023). Challenges and strategies for clinical trials in propionic and methylmalonic acidemias. *Mol Genet Metab.* **139:** 107612. .
36. **Vockley J**, Burton BK, Berry G, Longo N, Phillips J, Sanchez-Valle A, Chapman KA, Tanpaiboon P, Grunewald S, Murphy E, Lu X, Rahman S, Ray K, Reineking B, Pisani L, Ramirez AN. (2023). Triheptanoin for the treatment of long-chain fatty acid oxidation disorders: Final results of an open-label, long-term extension study. *J Inherit Metab Dis.* **46:** 943-55. .
37. **Vockley J**, Defay T, Goldenberg AJ, Gaviglio AM. (2023). Scaling genetic resources: New paradigms for diagnosis and treatment of rare genetic disease. *Am J Med Genet C Semin Med Genet.* **193:** 77-86. PMC10038858.
38. **Vockley J,** Sondheimer N, Puurunen M, Diaz G, Ginevic I, Grange K, Harding C, Northrup H, Phillips J, Searle S, Thomas J, Zori R, Denney W, Ernst S, Humphreys K, McWhorter N, Kurtz C, Brennan A. (2023). Efficacy and Safety of a Synthetic Biotic for Treatment of Phenylketonuria. *Nature Metabolism.* **Accepted for Publication:** .
39. Wang H, Lu J, Stevens T, Roberts A, Mandel J, Avula R, Ma B, Wu Y, Wang J, Land CV, Finkel T, **Vockley J**, Airik M, Airik R, Muzumdar R, Gong Z, Torbenson MS, Prochownik EV. (2023). Premature aging and reduced cancer incidence associated with near-complete body-wide Myc inactivation. *Cell Rep.* **42:** 112830. .
40. Zhao XJ, Mohsen AW, Mihalik S, Solo K, Aliu E, Shi H, Basu S, Kochersperger C, Van't Land C, Karunanidhi A, Coughlan KA, Siddiqui S, Rice LM, Hillier S, Guadagnin E, Giangrande PH, Martini PGV, **Vockley J.** (2023). Synthetic mRNA rescues very long-chain acyl-CoA dehydrogenase deficiency in patient fibroblasts and a murine model. *Mol Genet Metab.* **138:** 106982. PMC9877169.

**Reviews, invited published papers, proceedings of conference and symposia, monographs, books and book chapters**

1. Kim, J-JP, Wang, M, Paschke, R, Djordjevic, S, Bennett, DW and **Vockley, J.** (1994) Three Dimensional Structures of Acyl-CoA Dehydrogenases: Structural basis of Substrate Specificity. in Flavins and Flavoproteins, 1993 (K. Yagi, ed.) Walter deGruyter, New York, 273-282.

2. Thorpe C, Schaller RA, Mohsen A-W, **Vockley J.** (1997). The acyl-CoA dehydrogenases: some mechanistic aspects. in Flavins and Flavoproteins, 1996. Pgs. 597-603. University of Calgary Press, Calgary. Canada.

3. Tiffany KA, Ming W, Paschke R, Mohsen A-W, **Vockley J**, Kim J-JP. (1997). In:Flavins and Flavoproteins, 1996. University of Calgary Press, Calgary. Canada.

1. **Vockley J**. (2010). Defects of β-oxidation. *In:*Modern Nutrition in Health and Disease, 11th edition, (Shils ME, Olson JA, Shihe M and Ross AC, ed). Pp. 1057-1070.Williams and Wilkins, Baltimore, MD.
2. Mohsen A-W, **Vockley J** (1999) Biochemical Characteristics of Recombinant Human Isovaleryl-CoA Dehydrogenase Pre-Treated with Ethylenediaminetetraacetate.In: Flavins and Flavoproteins 1999.Proceedings of the Thirteenth International Symposium, Konstanz (Ghisla S, Kroneck P, Macheroux P, Sund H, Eds), pp. 515-518, Agency for Scientific Publications, Berlin, Germany.
3. **Vockley J.** (2010). Digenic inheritance. Encyclopedia of the Human Genome. *Nature Publishing*.
4. **Vockley J**. (2010). Medium-chain acyl-CoA dehydrogenase deficiency. *Medlink Neurology*. [www.medlink.com](http://www.medlink.com).
5. **Vockley J** (2010). Organic acidemias and disorders of fatty acid oxidation. In: Emery and Rimoin’s Principles and Practice of Medical Genetics, 5th edition (Rimoin, D, eds). Churchill, Livingstone, London.
6. **Vockley J,** (2004) Co-editor.The Vademecum Metabolicum, Manual of Metabolic Paediatrics, 2nd Ed. (Zschocke J, Hoffmann GF,eds) Milupa Metabolics GmbH & Co., Germany.
7. **Vockley J,** Cohen B, and Wang, L-J. (2010). Mitochondrial myopathies. PREP Audio Series. Published by the American Academy of Pediatrics.
8. Wolfe L, Jethva R, Oglesbee D, **Vockley J**, in GeneReviews((Internet)) Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, Eds. (University of Washington, Seattle, Seattle (WA), 2011 (updated 2018), Available at: https://www.ncbi.nlm.nih.gov/books/NBK63582/.
9. **Vockley J**, ZschockeJ, Knerr I, Walsh Vockley C, Gibson KM. (2012). Branched Chain Organic Acidurias. The Online Metabolic and Molecular Basis of Inherited Disease, (Valle D, ed.). McGraw Hill, NY
10. (Zschocke J, Hoffmann GF, eds) Milupa Metabolics GmbH & Co., Germany.
11. **Vockley J,** Arnold G. Guest editor of the Intellectual & Developmental Research Reviews. June 2013
12. **Vockley J.** Organic Acidemias and Disorders of Fatty Acid Oxidation. In Principles and Practice of Medical Genetics 5th edition. (Emory and Rimoin, eds). Harcourt Health Sciences Companies.
13. **Vockley J,** Longo N, Andresen B, and Bennett MJ. Mitochondrial Fatty Acid Oxidation Defects. In Pediatric Endocrinology and Inborn Errors of Metabolism. (Sarafoglou, Hoffman, and Roth eds) McGraw-Hill Professional
14. **Vockley J**, Gillingham MB, Matern D. Mitochondrial Fatty Acid Oxidation Disorders.The Online Metabolic and Molecular Basis of Inherited Disease, (Valle D, ed.). McGraw Hill, NY. 2016
15. **Vockley J**, Gibson KM, Knerr I, Zschocker J. (2016). Branched Chain Organic Acidemias. The Online Metabolic and Molecular Basis of Inherited Disease, 8th Ed. (Valle D, ed.). McGraw Hill, NY
16. **Vockley J.** Inborn Error of Metabolism. Rudolph’s Pediatrics, 23rd edition. Senior Editor Andrew Moyer. (2016)
17. El-Gharbawy A, **Vockley J.** Chapter 14 Non- mitochondrial metabolic diseases. 2016. Cardioskeletal Myopathies in Children and Young Adults 1st Edition. Editors: John Jefferies Burns Blaxall Jeffrey Towbin Jeffrey Robbins ISBN: 9780128000403 eBook ISBN: 9780128005804 Imprint: Academic Press.
18. **Vockley J,** (2020) Co-editor.Vademecum Metabolicum, Diagnosis and Treatment of Inborn Errors of Metabolism, 3rd Ed.
19. Forsythe R and **Vockley J** (2022). Isovaleric acidemia. ApoGeE. <https://apogee-ern-ithaca.edunao.com/mod/page/view.php?id=381>.
20. **Vockley J**, Wolfe L, Renaud DL.Inherited lipid disorders of beta-oxidation. in Modern Nutrition in Health and Disease(Ross AC, Caballero B, Cousins R, Tucker K,Ziegler T, Eds.) Wolters kluwer/LIppincott Williams & Wilkens, Philadelphia, 2022.
21. **Published abstracts (selected from over 1,000)**
22. Roles of Synergistic Heterozygosity and Dietary Fat in Metabolic Crises of Acyl-CoA Dehydrogenase Deficiencies in Mouse Models. (1977).VII International Congress on Inherited Metabolic Disorders. Vienna, Austria. The use of molecular modeling in inborn errors of metabolism.
23. American Society of Human Genetics Annual Meeting. (1998). San Francisco, CA. Splicing mutations in the IVD gene in isovaleric acidemia.
24. American Society of Human Genetics Annual Meeting. (2001).Philadelphia, PA. Short/branched chain acyl-CoA dehydrogenase deficiency.
25. Detection of asymptomatic, putative short-chain acyl-CoA dehydrogenase (SCAD) deficiency by newborn screening. (2000) Presented at the annual meeting of the American Society of Human Genetics.
26. The Acyl-CoA Dehydrogenases and Other Primary Flavoprotein Dehydrogenases Share Binding Motifs with Electron Transferring Flavoprotein. (2002) Presented at Annual Symposium of Society for the Study of Inborn Errors of Metabolism, Dublin, Ireland.
27. The Molecular Basis of SBCAD Deficiency - A Mild Disease? (2002) Presented at annual symposium of Society for the Study of Inborn Errors of Metabolism, Dublin, Ireland.
28. Studies Towards the Treatment of Medium-Chained acyl-CoA Dehydrogenase (MCAD) Deficiency: Metabolic and Cellular Characterization of MCAD Deficiency Human Fibroblasts Transfected with Ad/cmv-mcad. (2003) Presented at American Society of Microbiologists Conference on Gene Therapy: The Next Five Years, Banff, Alberta, Canada.
29. Development of a New Automated Analysis of Mitochondrial Respiratory Chain Complex (RCC) Enzymes. (2003) Presented at annual meeting of American College of Medical Genetics, San Diego, CA
30. Detection of Isobutyryl-CoA Dehydrogenase (IBD) Deficiency by Newborn Screening. (2003) Presented at annual meeting of the American College of Medical Genetics, San Diego, CA.
31. The Differential Diagnosis of Elevated C4- and C5-Acylcarnitines in Newborn Screening By Tandem Mass Spectrometry (2003) Presented at annual meeting of Society for Pediatric Research.
32. A Novel Approach to Reveal Mechanism of the Substrate Specificity in Short/Branched Chain Acyl-CoA Dehydrogenase. (2003) Presented at International Congress on Inborn Errors of Metabolism, Brisbane, Australia.
33. Analysis of Wild Type and Variant Short-Chain Acyl-CoA Dehydrogenase Conformation Change in Response to Enzyme-Substrate Interaction. (2003) Presented at International Congress on Inborn Errors of Metabolism, Brisbane, Australia.
34. Mitochondrial Rotenone-Sensitive NADH COQ Reductase Deficiency Causing Mild SCAD (Short-Chain Acyl-CoA Dehydrogenase) Dysfunction In Vitro Analysis. (2003) Presented at International Congress on Inborn Errors of Metabolism, Brisbane, Australia.
35. Automated Analysis of Respiratory Chain Complex (RCC) Enzyme Activities in Cultured Skin Fibroblasts. (2003) Presented at International Congress on Inborn Errors of Metabolism, Brisbane, Australia.
36. Impaired Protein Folding in SCAD Deficiency: Degradation or Aggregation of Variant Proteins. (2003) Presented at International Congress on Inborn Errors of Metabolism, Brisbane, Australia.
37. Discovery of New Members of the Acyl-CoA Dehydrogenase (ACD) Gene Family. (2003) Presented at annual meeting of American Society of Human Genetics, Los Angeles, CA.
38. Natural History of Isovaleric Acidemia. (2003) Presented at annual meeting of American Society of Human Genetics, Los Angeles, CA.
39. Redefining long chain fat metabolism in humans. (2005). Presented at the annual meeting of the Society for inherited metabolic disorders.
40. Acyl-CoA dehydrogenases: new enzymes and new disorders. (2005). Presented at the international symposium on beta-oxidation. Amsterdam.
41. Mitochondrial -oxidation: new developments.(2006). Presented at the International Congress on Inherited Metabolic Disorders. Chiba. Japan
42. Inborn errors of metabolism and complex patterns of disease. (2007). Presented at the annual meeting of the American College of Medical Genetics. San Diego. CA
43. The latest outcome and clinical trials in PKU treatment. (2008) Presented at the annual meeting of the American College of Medical Genetics. Phoenix. AX.
44. A new inborn error of sterol metabolism. (2008). Presented at the annual meeting of the Society for inherited metabolic disorders. Asilomar. CA
45. New enzymes of long chain fatty acid metabolism. (2009). Plenary Lecture. Presented at the Xth International Congress on Inborn Errors of Metabolism. San Diego, CA.
46. Characterization of a multi-functional protein complex containing the mitochondrial respiratory chain and fatty acid oxidation. (2009). Presented at the Xth International Congress on Inborn Errors of Metabolism. San Diego, CA.
47. New developments in the treatment of fatty acid oxidation disorders. (2010). Presented at the annual meeting of the American College of Medical Genetics, Albuquerque, NM
48. Changes in the mitochondrial proteome in fatty acid oxidation deficient mice. (2010). Presented at the annual meeting of the Society for Inherited Metabolic Disorders. Istanbul.
49. Clinical trials for mitochondrial myopathies. (2011). Invited Plenary lecture. Presented at the United Mitochondrial Disease Foundation 2011 Annual Meeting.
50. Long chain fatty acid oxidation disorders. (2012). Invited Plenary lecture. Presented at the American College of Medical Genetics 2012 Annual Meeting.
51. Personalized medicine and inborn errors of metabolism. (2012). Invited Plenary lecture. Presented at the Society of Inborn Errors of Metabolism 2012 Annual Meeting.
52. Development of a New PKU Guideline. (2013) Invited lecture, American College of Medical Genetics 2013Annual Meeting
53. Moonlighting in mitochondria; ACAD9 plays a duel role in energy metabolism in mitochondria. (2013). Presented at XI th International Congress on Inborn Errors of Metabolism. Barcelona, Spain
54. Molecular Architecture of Mitochondrial Energy Metabolism. Invited Lecture. (2013) XI th International Congress on Inborn Errors of Metabolism. Barcelona, Spain.
55. Novel therapy of long chain fatty acid oxidation disorders using triheptanoin. (2013) XI th International Congress on Inborn Errors of Metabolism. Barcelona, Spain.
56. Infantile hypophosphatasia. (2014) Presented at the American College of Medical Genetics Annual Meeting. Memphis TN
57. Transplant for metabolic disease. (2014)Presented at the Garrod Society Annual Meeting, Ottowa, CA
58. The mitochondrial architecture of energy metabolism. (2014)Keynote Address at the United Mitochondrial Disease Foundation Annual Meeting. Pittsburgh, PA.
59. Results from a randomized trial of triheptanoin compared to MCT oil in patients with long chain fatty acid oxidation defects. (2015). Presented at the Annual Meeting of the Society for Inherited Metabolic Disorders, Salt Lake City, UT
60. Mitochondrial respiratory chain disorders in the Old Order Amish Population. (2015). Presented at the Annual Meeting of the Society for Inherited Metabolic Disorders, Salt Lake City, UT
61. Molecular Architecture of mitochondrial energy metabolism. (2015). Presented at the annual meeting of the Society for the Study of Inherited Metabolic Disorders. Lyon. France.
62. Novel therapies for disorders of fatty acid oxidation. (2016). Presented at the Annual Meeting of the Society for Inherited Metabolic Disorders, Ponte Vedre, FL
63. Advances in fatty acid oxidation research. (2016). Presented at the Annual meeting of the International Network for Fatty Acid Oxidation Research and Management (INFORM). Boston, MA
64. **P**ositive response to Infliximab in a patient with very long-chain acyl-CoA dehydrogenase deficiency. (2017). Presented at the American College of Medical Genetics Annual Meeting. Phoenix, AZ.
65. Elevated superoxide levels, mitochondrial dysfunction, and endoplasmic reticulum-mitochondria crosstalk disruption in ETHE1- and sulfite oxidase-deficient fibroblasts. (2017). Presented at the XII th International Congress on Inborn Errors of Metabolism., Rio de Janeiro.
66. Phase 2 Long-term Pegvaliase Treatment for Adults with Phenylketonuria: Updated Year 5 Safety and Efficacy Data from the PAL-003 Extension. (2017). Presented at the XII th International Congress on Inborn Errors of Metabolism., Rio de Janeiro.
67. Results from a 78-week Single-arm, Open-label Phase 2 Study Evaluating UX007 (Triheptanoin) Treatment in Pediatric and Adult Patients with Moderate to Severe LC-FAOD. (2017). Presented at the XII th International Congress on Inborn Errors of Metabolism., Rio de Janeiro.
68. Treatment of long chain fatty acid oxidation disorders with triheptanoin. (2017) Presented at the annual meeting of the Portuguese Metabolic Society. Evora, Portugal
69. New developments in the treatment of fatty acid oxidation disorders. (2017). Plenary lecture presented at the XII th International Congress on Inborn Errors of Metabolism., Rio de Janeiro.
70. Treatment of inborn errors of metabolism by liver transplant. (2017). Presented at the Recordati Academy. Lille, France.
71. Key Challenges and Unmet Needs in Urea Cycle Disorder (UCD) Management: Results of a Clinician Survey. ACMG Annual Meeting 2018.
72. Results from a 78-week single-arm, open-label phase 2 study to evaluate ux007 in pediatric and adult patients with moderate to severe long-chain fatty acid oxidation disorders (LC-FAOD). SIMD Annual Meeting 2018
73. Mitochondrial targeted antioxidants improve mitochondrial function in very long-chain acyl-coA dehydrogenase deficient fibroblasts. SIMD Annual Meeting 2018
74. Evaluation of mitochondrial dynamics, superoxide production and apoptosis in ETHE1- and sulfite oxidase-deficient fibroblasts. SIMD Annual Meeting 2018
75. Management of hyperammonemia in a patient with TANGO2 mutations suggests a role for defective ureagenesis. SSIEM Annual Meetign 2018
76. Characterization of the significance of newly identified missense mutations in newborn screening: A novel approach for faster analysis. SSIEM Annual Meeting 2018
77. Targeting cardiolipin: a new therapeutic approach to treat long chain hydroxy acyl CoA dehydrogenase and mitochondrial trifunctional protein deficiency. SSIEM Annual Meeting. 2018.
78. Restoration of VLCAD in knockout mice and deficient human fibroblasts using novel mRNA technology: a model to treat fatty acid β-oxidation disorders. SSIEM Annual Meeting 2018
79. Identifying rare metabolic disorders of energy dysfunction in patients with treatment-resistant depression. ACMG Annual Meeting. 2019
80. Long-term Safety of Induction, Titration, and Maintenance Dosing of Pegvaliase Treatment in Adults with Phenylketonuria. ACMG. Annual Meeting. 2019
81. Designer triglycerides: A practical approach to deliver disease-specific alternative fatty acids, bypassing the metabolic block in patients with fatty acids oxidation disorders. ASHG Annual Meeting. 2019
82. Enhancement of bioenergetic parameters in very long chain acyl-CoA dehydrogenase deficient cells treated with trimetazidine. ASHG Annual Meeting. 2019
83. A 5-year retrospective study of individuals with phenylketonuria (PKU) treated at two specialized U.S. clinics. ASHG Annual Meeting. 2019
84. Subgroup Analysis of Pegvaliase in Adults with Phenylketonuria in Phase 3 PRISM Studies: Evaluating Efficacy and Safety Based on Previous Sapropterin Response or Dietary Phenylalanine Intake. SIMD Annual Meeting. 2019
85. IVD deficient fibroblasts show improvement in phenotype with epigallocatechin gallate treatment. SIMD Annual Meeting 2019
86. Treatment of bioenergetic dysfunction in propionic acidemia. SIMD Annual Meeting. 2019
87. A Phase 1/2a, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blind, Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Adult Subjects with Phenylketonuria to Evaluate Safety, Tolerability, Kinetics, and Pharmacodynamics. SSIEM. Annual Meeting. 2019.
88. A comparative multi-omic study to characterize VLCAD patient response to triheptanoin vs. medium chain triglyceride management. SSIEM Annual Meeting. 2019
89. Successful Orthotopic Heart Transplantation in CPTII deficiency. SSIEM Annual Meeting. 2019
90. Interim results from an open-label, long-term extension study to evaluate the safety and efficacy of triheptanoin (UX007) in LC-FAOD. SSIEM Annual Meeting. 2019
91. Fatty acid oxidation-respiratory chain proteins and their interactions are abnormal in end stage cardiomyopathy. SSIEM Annual Meeting. 2019
92. Assessing Referral of Plain Community Members for Genetic Services at UPMC Children’s Hospital of Pittsburgh: A Quality Improvement Study. ACMG Annual Meeting. 2020
93. Long-term follow-up (up to 24 months) of glycerol phenylbutyrate for patients 2 months to 2 years with urea cycle disorders. SIMD Annual Meeting. 2020
94. Phase 3 prism studies: efficacy and safety of pegvaliase 60 mg dose in adult patients with phenylketonuria. SIMD Annual Meeting. 2020
95. Rare metabolic disorders of energy dysfunction in patients with treatment-resistant depression. SIMD Annual Meeting. 2020
96. Interim results from an open-label, long-term extension study to evaluate the safety and efficacy of triheptanoin (UX007) in long-chain fatty acid oxidation disorders (LC-FAODs). SIMD Annual Meeting. 2020
97. Comparison of distal and proximal inhibition of the leucine pathway in IVD deficient cells. SIMD Annual Meeting. 2020
98. Compassionate use of triheptanoin in patients with pyruvate carboxylase deficiency. SIMD Annual Meeting. 2020
99. Potential Therapies for Mitochondrial Bioenergetics Dysfunction in Fibroblasts from a 2-Hydroxyglutaric Aciduria Patient. SIMD Annual Meeting. 2020
100. Metabolic analysis reveals evidence for branched chain amino acid catabolism crosstalk and the potential for improved treatment of organic aciduria. SIMD Annual Meeting. 2020
101. Outcomes and genotype-phenotype correlations in 45 individuals with *HADHA* and *HADHB* mutations diagnosed by NBS and enrolled in the Inborn Errors of Metabolism – Information System database. ACMG 2021 Meeting. Virtual fomrmat
102. **C**linical Outcomes of Major Clinical Events and Emergency Triheptanoin in Critically Ill Patients With Long-chain Fatty Acid Oxidation Disorders. ACMG 2021 Annual Meeting. Virtual format.
103. Phenom: A prospective clinical study on the clinical impact of phenylketonuria in adults. ACMG Annual 2021 Meeting. Virtual format.
104. Comparison of triheptanoin and succinate as anaplerotic treatment in a very long-chain acyl-CoA dehydrogenase deficiency mouse model. SSIEM 2021 Annual Meeting, Sydney Australia
105. Comparison of triheptanoin and succinate as anaplerotic treatment in a very long-chain acyl-CoA dehydrogenase deficiency mouse model. SSIEM 2021 Annual Meeting, Sydney Australia
106. Mitochondrial-targeted reactive oxygen species scavenger JP4-039 prevents oxidative stress in cerebral cortex and striatum of glutaryl-CoA dehydrogenase-deficient mice. SSIEM 2021 Annual Meeting, Sydney Australia
107. Characterization of variants of uncertain significance in isovaleryl-CoA dehydrogenase identified through newborn screening: An approach for faster analysis. SSIEM 2021 Annual Meeting, Sydney Australia.
108. Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria with Live Bacterial Therapeutic SYNB1618. SSIEM 2021 Annual Meeting, Sydney Australia.
109. Restoration of interaction between FAO and ETC proteins in VLCAD and VLCAD-deficient mice mitochondria by addition of recombinant VLCAD. SSIEM 2021 Annual Meeting, Sydney Australia.
110. Defining Therapeutic Options for Combined D,L-2 Hydroxyglutaric Aciduria. SSIEM 2021 Annual Meeting, Sydney Austrailia.
111. Synthetic Messenger RNA Rescues Very Long-Chain Acyl-CoA Dehydrogenase Deficiency in Fibroblasts from Patients and a Murine Model. UMDF 2021 Annual Meeting. Virtual format.
112. Correlation of genotype and molecular phenotype in mitochondrial trifunctional protein deficiency. ACMG 2022 Annual Meeting. Nashville, TN.
113. An open-label, phase 1/2 trial of gene therapy 4D-310 in adult males with Fabry disease. WORLD 2022 Annual Meeting. San Diego, CA.
114. Cardiolipin Remodeling Deregulation and Mitochondrial Bioenergetics Alterations in Trifunctional Protein (TFP) Deficiency. SIMD 2022 Annual Meeting. Orlando, FL
115. Characterization of variants of uncertain significance in very long chain acyl-CoA dehydrogenase identified through newborn screening. SIMD 2022 Annual Meeting. Orlando, FL
116. Improvement in major clinical events (MCEs) in children treated with triheptanoin for long-chain fatty acid oxidation disorders (LC-FAOD). SIMD 2022 Annual Meeting. Orlando, FL
117. Oxidative stress and mitochondrial respiration impairment induced by sulfite in rat brain are prevented by the mitochondria-targeted antioxidant XJB-5-131. SSIEM 2022 Annual Meeting. Freyburg, Germany.
118. Restoring succinyllysine antigenic signal and improving O2 consumption of CPT II deficient cells treated with anaplerotic compounds. SSIEM 2022 Annual Meeting. Freyburg, Germany.
119. A new class of anaplerotic compounds restores cellular lysine succinylation and antigenic signal. SSIEM 2022 Annual Meeting. Freyburg, Germany.
120. An Open-Label Study To Determine The Safety And Tolerability Of 12 Weeks’ Treatment With Oral REN001 In Subjects With Fatty Acid Oxidation Disorders(FAOD). SSIEM 2022 Annual Meeting. Freyburg, Germany.
121. A CRISPR/Cas9 genome-edited PAH-deficient cell line for studying PKU. SSIEM 2022 Annual Meeting. Freyburg, Germany.
122. **Patents Awarded and Pending**
123. Antioxidant Therapy of Inborn Errors of Fatty Acid Oxidation and Oxidative Phosphorylation (5/5/2016)
124. Metabolomics of Treatment Refractory Depression and Suicidal Behavior (2/10/2016)
125. Use of a knock-out Yucatan mini-pig model for characterization and treatment of phenylalanine hydroxylase (PAH) deficiency (phenylketonuria; PKU) (1/8/2016)
126. Novel anaplerotic agents for treatment of disorders of propionate and long chain fat metabolism (12/14/2015)
127. Use of gene transcription modifiers for treatment of rhabdomyolyis due to fatty acid oxidation and of unknown cause (10/8/2015)
128. Treatment of Rhabdomyolysis due to Fatty Acid Oxidation Disorders and Other Causes with Bendavia (10/8/2015)
129. Development of acyl-CoA dehydrogenases micro/nano enzyme assay for clinical diagnosis and newborn screening (6/29/2015)
130. Triheptanoin IND (Awarded 1/19/2011)
131. Treatment of medium chain acyl-CoA dehydrogenase deficiency (Awarded 10/12/2011)

# PROFESSIONAL ACTIVITIES

**TEACHING:**

University of Pittsburgh Graduate School of Public Health, Department of Human Genetics

Lecturer in first year Health Human Genetics course (2005-current)

University of Pittsburgh School of Medicine

Director, UPMC Medical Biochemistry Fellowship (2010-2020)

Lecturer in first year Biochemistry course (2005-current)

Lecturer in first year Medical Genetics course (2007-current)

Lecturer in Molecular Medicine course (2007-2019)

Clinical supervisor Medical Genetics rotation for pediatric residents and genetic counseling students (2004-current)

Mayo Medical and Graduate School Teaching:

Medical Genetics (Medical School 1992)

Cell and Molecular Biology (Medical School 1993)

Biochemistry 8001: Enzyme Kinetics, Mechanism and Structure: Graduate School (1994–97)

Molecular Biology 8102: Regulation of Protein Synthesis: Graduate School (1994–98)

Molecular Biology 8600: Human Genetics: Co-course director, Graduate School (1994, 1995)

Graduate School Core Curriculum: Course director, Molecular Genetics (1999-2003)

Molecular Genetics Journal Club: Course director (1998-2003)

Mayo Clinical Faculty Genome Education Initiative (1999-2002) Program founder.

Doctoral and Postdoctoral (non-clinical) Trainees

Al-Walid A. Mohsen. Postdoctoral Trainee. Mayo Clinic. 1992-1995.

Kevin Pruitt Battaile. Ph.D. Trainee. Mayo Graduate School. 1992-1996.

Samuel L. Volchenboum. M.D., Ph.D. Trainee. Mayo Graduate School. 1993-1998.

Barbara A. Binzak. Ph.D. Trainee. Mayo Graduate School 1994-1999. Selected as outstanding predoctoral trainee at the 1998 annual meeting of the American Society of Human Genetics.

Heidi Hoard. Ph.D. Trainee. Mayo Graduate School 1998-2002. Mayo Clinic Medical School

Tien Nguyen, Ph.D. Postdoctoral Trainee. Mayo Clinic. 1999-2004. Mayo Clinic Medical School

Dusica Babovic-Vuksanovic, M.D. Postdoctoral Trainee. Mayo Clinic 1997-2000.

Miao He, Ph.D. Postdoctoral Trainee. Mayo Clinic. 2000-2006. Selected as outstanding postdoctoral trainee at the 2011 annual meeting of the Society for Metabolic Disorders.

Eric Goetzman, Ph.D., Postdoctoral Trainee, Mayo Clinic. 2001- 2007.

Zuzana Swigonova, Ph.D. Postdoctoral Trainee, University of Plattsburgh, 2005-2007

Kristen Harris Suhrie, M.D., Postdoctoral Fellow in Pediatrics, 2009-2011.

Manuel Schiff, M.D., Postdoctoral Fellow, Fullbright Scholar, 2011-2013.

Kristen Skvorak Postdoctoral Fellow, 2012-current

Heejung Kang. Ph.D. Trainee. University of Pittsburgh Graduate School of Public Health. 2010-2014

Wei Wang, Ph.D. Trainee. University of Pittsburgh Graduate School of Public Health. 2010-2014

Kaitlyn Kormanik Bloom. Ph.D. Trainee. University of Pittsburgh Graduate School of Public Health. 2010-2014

Chikara Otsubo, M.D., Ph.D., Postdoctoral Trainee, University of Pittsburgh, 2013-2016

Lina Ghaloul-Gonzalez, M.D., Postdoctoral Trainee, University of Pittsburgh, 2013-2016

Steve McCalley, Ph.D. Trainee. University of Pittsburgh Graduate School of Public Health. 2014-2018

Andrew Sinsheimer, Ph.D. Trainee. University of Pittsburgh Graduate School of Public Health. 2014-2019

Guilhian Leipnitz, Ph.D., Visiting Scientist, Universidade Federal do Rio Grande do Sul, 2015-2016

Bianca Seminotti, Ph.D., Postdoctoral Trainee, University of Pittsburgh, 2015-2017

Olivia Dannibale, Ph.D. Trainee, University of Pittsburgh Graduate School of Public Health, 2018-2022

Yuleng Phua, Pd.D. Trainee. University of Pittsburgh School of Medicine. 20

Eduardo Vieira Neto, Ph.D., Clinical Biochemical Fellow, University of Pittsburgh School of Medicine, 2019-2022

Frances Johnson, Ph.D. Trainee, University of Pittsburgh Graduate School of Public Health, 2021- current

Justin Dutta, Ph.D. Trainee, University of Pittsburgh Graduate School of Public Health, 2022- current

Suja Somanadhan, Ph.D., Postdoctoral Trainee, Fullbright Scholar, University of Pittsburgh School of Medicine, 2022

Doctoral Candidate Thesis Committees

Kevin Battaile (Biochemistry and Molecular Biology, Mayo Clinic Medical School)

Samuel Volchenboum (Biochemistry and Molecular Biology, Mayo Clinic Medical School)

Barbara Binzak (Biochemistry and Molecular Biology, Mayo Clinic Medical School)

Monique Purdock (Biochemistry and Molecular Biology, Mayo Clinic Medical School)

Brian Johnson (Biochemistry and Molecular Biology, Mayo Clinic Medical School)

Marcie Mikesell (Biochemistry and Molecular Biology, Mayo Clinic Medical School)

Scott Kuhns (Biochemistry and Molecular Biology, Mayo Clinic Medical School)

Lori Lebruska (Biochemistry and Molecular Biology, Mayo Clinic Medical School)

Kurt Krummel (Biochemistry and Molecular Biology, Mayo Clinic Medical School)

Heidi Hoard (Biochemistry and Molecular Biology, Mayo Clinic Medical School)

Heather O’Neil (Biochemistry and Molecular Biology, Mayo Clinic Medical School)

Rachaneekorn Punyashthiti (Molecular Biology, Mayo Clinic Medical School)

Sarah Van Driest (Molecular Biology, Mayo Clinic Medical School)

Kristen Skvorik (Biochemistry, University of Pittsburgh School of Medicine)

Wei Wang (Human Genetics, University of Pittsburgh Graduate School of Public Health)

Heejung Kang (Human Genetics, University of Pittsburgh Graduate School of Public Health)

Kaitlyn Kormanik (Human Genetics, University of Pittsburgh Graduate School of Public Health)

Ryan McAndrew (Biochemistry, Medical College of Wisconsin)

Megan Beck (Human Genetics, University of Pittsburgh Graduate School of Public Health)

Steve McCalley (Human Genetics, University of Pittsburgh Graduate School of Public Health)

Andrew Sinsheimer (Human Genetics, University of Pittsburgh Graduate School of Public Health)

Olivia Dannibale (Human Genetics, University of Pittsburgh Graduate School of Public Health)

Keaton Solo (Human Genetics, University of Pittsburgh Graduate School of Public Health)

National and International Teaching

North American Metabolic Academy (2006- current; Founder and Director)

SSIEM (European) Academy (2012- current; Course faculty)

Asia Pacific Inborn Errors of Metabolism Course (2014-2015; Course faculty)

Recordati Academy (2013-current; Intermittent course faculty)

South American Inborn Errors of Metabolism Course (2014-current; Intermittent course faculty)

**RESEARCH:**

**RESEARCH FUNDING**

**Vockley, Gerard**

**ACTIVE**

**ACTIVE**

\*Title: Characterization of Branched Chain Amino Acid Metabolism and Its Deficiency

Major Goals: The long-range goal of this project is to characterize the metabolism of branched chain acyl-CoAs and to identify the consequences of its failure in humans.

\*Status of Support: Active

Project Number: 5R01DK109907-06

Name of PD/PI: Gerard Vockley (PI)

\*Source of Support: NIDDK

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 07/01/2016 – 02/28/2025

\* Total Award Amount (including Indirect Costs): $4,123,041

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 2.10 calendar |
| 2. 2022 | 2.10 calendar |
| 3. 2023 | 2.10 calendar |
| 4. 2024 | 2.10 calendar |

\*Title: Phase 3 Trial of DCA in PDC Deficiency: (IND 028,625, 02/04/2015)

Major Goals: The primary goal will be based on an improved clinical status, as determined by a novel FDA-approved, Observer Reported Outcome (ObsRO) measure. Our secondary endpoints will include 1) confirmation of better clinical outcome by the Karnofsky/Lansky performance scale of home functionality in children with life- threatening disease; and 2) decreased lactatemia.

\*Status of Support: Active

Project Number: 5R01FD005407-03

Name of PD/PI: Peter Stacpoole (PI)

\*Source of Support: FDA

\*Primary Place of Performance: University of Florida

Project/Proposal Start and End Date: 06/01/2016 – 06/30/2023

\* Total Award Amount (including Indirect Costs): $39,098

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.12 calendar |
| 2. 2022 | 0.12 calendar |

\*Title: Use of a home phenylalanine meter to help manage PKU

Major Goals: Our long-term goal is to create low-cost, effective tools that empower people to take charge of their healthcare though field diagnosis and therapy monitoring, and thereby reduce death, disability, and healthcare costs.

\*Status of Support: Active

Project Number: 5R01NR016991-03

Name of PD/PI: Gerard Vockley (PI)

\*Source of Support: NINR

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 09/01/2017 – 06/30/2022

\* Total Award Amount (including Indirect Costs): 2,376,288.00

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 1.81 calendar |

\*Title: Creating a paper-based phenylalanine test for personalized therapy monitoring by patients with phenylketonuria

Major Goals: The long-range goal of this project is to characterize the metabolism of branched chain acyl-CoAs and to identify the consequences of its failure in humans.

\*Status of Support: Active

Project Number: 1R01HD091175

Name of PD/PI: Elaine Fu (PI)

\*Source of Support: NIDDK

\*Primary Place of Performance: Oregon State University

Project/Proposal Start and End Date: 09/01/2017 – 05/31/2021

\* Total Award Amount (including Indirect Costs): $86,127

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.12 calendar |

\*Title: North American Mitochondrial Disease Consortium

Major Goals: Patient Enrollment in to the NAMDC Patient Registry and Bio-Repository.

\*Status of Support: Active

Project Number: 5U54NS078059-10

Name of PD/PI: Michio Hirano (PI)

\*Source of Support: NINDS

\*Primary Place of Performance: Columbia University

Project/Proposal Start and End Date: 09/30/2011 – 08/31/2024

\* Total Award Amount (including Indirect Costs): $48,035

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.12 calendar |
| 2. 2022 | 0.12 calendar |
| 3. 2023 | 0.12 calendar |

\*Title: Hepatocyte Transplantation for Liver-Based Metabolic Disease

Major Goals: In this study, we will treat patients with liver-based metabolic disease by hepatocyte transplantation with the goal of opening the door for broader use of hepatocyte transplants in the treatment of metabolic liver disease.

\*Status of Support: Active

Project Number: 5R01DK117916-03

Name of PD/PI: Ira Fox (PI), Gerard Vockley (MPI)

\*Source of Support: NIDDK

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 08/10/2018 – 06/30/2024

\* Total Award Amount (including Indirect Costs): $1,268,334

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2020 | 0.91 calendar |
| 2. 2022 | 1.20 calendar |
| 3. 2023 | 1.20 calendar |

\*Title: PKUDOS – PKU Demographics, Outcomes, and Safety Registry

Major Goals: The objective of this study is to evaluate the safety of long-term treatment with Kuvan.

\*Status of Support: Active

Project Number: PKUDOS-01/17869

Name of PD/PI: Gerard Vockley (PI)

\*Source of Support: BioMarin

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 09/26/2008 – 96/26/2023

\* Total Award Amount (including Indirect Costs): $55,700

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.12 calendar |
| 2. 2022 | 0.12 calendar |

\*Title: An Observational, Longitudinal, Prospective, Long-Term Registry of Patients with Hypophosphatasia

Major Goals: This multinational, multicenter, observational, prospective, long-term registry is designed to collect data on epidemiology, HPP history, clinical course, symptoms (including multi-systematic aspects of disease), and burden of disease from patients of all ages who have a diagnosis of HPP.

\*Status of Support: Active

Project Number: ALX-HPP-501/18581

Name of PD/PI: Gerard Vockley (PI)

\*Source of Support: Alexion

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 10/19/2015 – 10/18/2024

\* Total Award Amount (including Indirect Costs): $62,250

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.12 calendar |
| 2. 2022 | 0.12 calendar |
| 3. 2023 | 0.12 calendar |

\*Title: An Open Label Study to Determine the Safety and Tolerability of 12 Weeks Treatment with Oral REN001 in Subjects with Fatty Acid Oxidation Disorders (FAOD)

Major Goals: The objective of this study is to evaluate the safety and tolerability of 12 weeks treatment with REN001 in subjects with FAOD.

\*Status of Support: Active

Project Number: REN001-102/23225

Name of PD/PI: Gerard Vockley (PI)

\*Source of Support: Reneo

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 02/19/19 – 02/18/22

\* Total Award Amount (including Indirect Costs): $157,025

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.12 calendar |

\*Title: Precision Medicine Implementation and Commercialization

Major Goals: Our goal is to build upon previous successes in administering pilot awards to stimulate precision medicine research, and our experience in implementation science (pharmacogenomics) and education (Test2Learn) to focus this proposal on the implementation of genomic sequencing in the neonatal intensive care unit (NICU), the development of healthcare provider genomics education through novel solutions and driving precision medicine initiatives across Pitt and UPMC towards commercialization.

\*Status of Support: Active

Project Number: Not Applicable

Name of PD/PI: Adrian Lee (PI)

\*Source of Support: The Richard King Mellon Foundation

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 05/01/2019 – 04/30/2022

\* Total Award Amount (including Indirect Costs): $449,859

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.12 calendar |

\*Title: A Phase 1/2 Open-Label, Randomized, Concurrently-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-102 in Adult PKU Subjects with PAH Deficiency

Major Goals: The primary objective of the study is to evaluate the safety, tolerability, and efficacy of a single dose of HMI-102 when administered to subjects with phenylalanine hydroxylase (PAH) deficiency.

\*Status of Support: Active

Project Number: Not Applicable

Name of PD/PI: Gerard Vockley (PI)

\*Source of Support: Homology Medicines

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 07/03/2019 – 07/02/2022

\* Total Award Amount (including Indirect Costs): $646,739

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.12 calendar |

\*Title: Rare disease research network: Congenital disorders of glycosylation

Major Goals: The goal of this project is to establish a nation-wide network of regional centers for diagnosis, follow up, treatment and clinical research in CDG in order to be able to improve quality of life and life expectancy in congenital disorders of glycosylation.

\*Status of Support: Active

Project Number: 5U54NS115198-03

Name of PD/PI: Eva Morava-Kozicz (PI)

\*Source of Support: NINDS

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 09/15/2019 - 07/31/2024

\* Total Award Amount (including Indirect Costs): $149,435

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.46 calendar |
| 2. 2022 | 0.60 calendar |
| 3. 2023 | 0.60 calendar |

\*Title: The Natural History of LCHAD Retinopathy

Major Goals: The goal for this study is conducting a prospective deep phenotyping study of LCHAD/TFP deficient retinopathy among 44 patients diagnosed with LCHAD/TFP deficiencies followed over time.

\*Status of Support: Active

Project Number: 5R01HD095968‐02

Name of PD/PI: Melanie Gillingham

\*Source of Support: NICHHD

\*Primary Place of Performance: Oregon Health & Science University

Project/Proposal Start and End Date: 08/01/2019 - 11/31/2023

\* Total Award Amount (including Indirect Costs): $859,285

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.60 calendar |
| 2. 2022 | 0.60 calendar |

\*Title: Precision Medicine in the Diagnosis of Genetic Disorders in Neonates

Major Goals: We hypothesize that TNGS will perform comparably to WGS while providing enhanced detection of copy number variants and genes with high degrees of homology. The impact of TNGS will determined on targeted therapeutics (e.g. medications, diet, surgery, other interventions) enrollment in clinical trials, reduction in diagnostic studies/therapeutics, or initiation of palliative care.

\*Status of Support: Active

Project Number: 5U01TR002271-04

Name of PD/PI: Jonathan Davis

\*Source of Support: NCATS

\*Primary Place of Performance: Tufts Medical Center

Project/Proposal Start and End Date: 08/15/2018 - 07/31/2023

\* Total Award Amount (including Indirect Costs): $326,371

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.60 calendar |
| 2. 2022 | 0.60 calendar |

\*Title: A Prospective Clinical Study of Phenylketonuria (PKU)

Major Goals: The purpose of this study is to learn more about health problems in people with PKU and how we measure these problems over time. This knowledge will help us design future studies to understand whether health problems get better when we test new drugs for PKU.

\*Status of Support: Active

Project Number: Not Applicable

Name of PD/PI: Gerard Vockley

\*Source of Support: BioMarin

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 07/24/2020 - 07/23/2022

\* Total Award Amount (including Indirect Costs): $384,421

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.12 calendar |

\*Title: A Longitudinal, Prospective, Observational Study in Adult Males with Fabry Disease

Major Goals: Characterize FD-specific biomarkers, symptoms and outcomes for use as baseline/external control data in interventional clinical trials and Assess patient-specific variance of cardiac biomarkers (serum, non-invasive imaging, and ECG) associated with cardiac involvement in FD.

\*Status of Support: Active

Project Number: Not Applicable

Name of PD/PI: Gerard Vockley

\*Source of Support: 4D Molecular Therapeutics

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 07/13/2020 - 07/12/2022

\* Total Award Amount (including Indirect Costs):$17,716

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.12 calendar |

\*Title: An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adult Males with Classic Fabry Disease

Major Goals: Evaluate the safety and tolerability of 4D-310 following a single intravenous (IV) dose.

\*Status of Support: Active

Project Number: Not Applicable

Name of PD/PI: Gerard Vockley

\*Source of Support: 4D Molecular Therapeutics

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 11/13/2020 - 11/12/2022

\* Total Award Amount (including Indirect Costs): $247,396

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.12 calendar |

\*Title: An Open-label Study of the Efficacy and Safety of SYNB1618 in Patients with Phenylketonuria (SynPheny-1)

Major Goals: The purpose of this study is to determine the efficacy of SYNB1619 in reducing area under the curve (AUC) for plasma D5-phenylalanine (Phe).

\*Status of Support: Active

Project Number: Not Applicable

Name of PD/PI: Gerard Vockley

\*Source of Support: Synlogic

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 11/20/2020 – 11/19/2022

\* Total Award Amount (including Indirect Costs): $44,607

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.12 calendar |

\*Title: AAV Gene therapy of VLCAD Deficiency

Major Goals: The purpose of this study is to determine the efficacy of SYNB1619 in reducing area under This project analyzes VLCAD deficiency in mice.

\*Status of Support: Active

Project Number: Not Applicable

Name of PD/PI: Gerard Vockley

\*Source of Support: Kriya Pharmaceuticals

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 01/14/2021 – 01/13/2023

\* Total Award Amount (including Indirect Costs): $344,684

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2022 | 0.50 calendar |

\*Title: Novel Mouse Models to Assess AAV Gene Therapy of VLCAD Deficiency

Major Goals: This project assesses AAV Gene Therapy in mice.

\*Status of Support: Active

Project Number: Not Applicable

Name of PD/PI: Gerard Vockley

\*Source of Support: Kriya Pharmaceuticals

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 01/14/2021 – 01/13/2023

\* Total Award Amount (including Indirect Costs): $344,684

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2022 | 0.50 calendar |

\*Title: Enzyme Substitution Therapy of a Porcine Model of PKU

Major Goals: To examine the effectiveness of Nestlé’s novel therapeutic in the minipig disease model of phenylketonuria.

\*Status of Support: Active

Project Number: Not Applicable

Name of PD/PI: Gerard Vockley

\*Source of Support: Nestle

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 11/04/2021 - 11/03/2023

\* Total Award Amount (including Indirect Costs): $800,000

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 1.00 calendar |
| 2. 2022 | 1.00 calendar |

\*Title: A Phase 1/2 Open-label Clinical Study of Hlb-001 Gene Therapy in Pediatric Patients with Methylmalonic Acidemia Characterized by MMUT Mutations

Major Goals: To assess the safety and tolerability of hLB-001 in pediatric patients with methylmalonic acidemia (MMA)

\*Status of Support: Active

Project Number: Not Applicable

Name of PD/PI: Gerard Vockley

\*Source of Support: Logic Bio

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 11/09/2020 – 11/08/2022

\* Total Award Amount (including Indirect Costs): $105,678

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.12 calendar |

**PENDING**

\*Title: Metabolic Engineering for Management of PAH Deficient PKU Osteopenia

Major Goals: We will identify analytes informing bone restoration and therapeutic response that will be assayable within patient collected dried blood spots adding a novel element to this long-established aspect of PKU management.

\*Status of Support: Pending

Project Number: R01 HD105994

Name of PD/PI: Steven Dobrowolski / Harry Blair

\*Source of Support: NIAMSD / NIH

\*Primary Place of Performance: University of Pittsburgh

Project/Proposal Start and End Date: 09/2022 – 08/2027

\* Total Award Amount (including Indirect Costs): $3,258,091

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2022 | 0.30 calendar |
| 2. 2023 | 0.30 calendar |
| 3. 2024 | 0.30 calendar |
| 4. 2025 | 0.30 calendar |
| 5. 2026 | 0.30 Calendar |

**PRIOR FUNDING**

P01 HL59412 (Terry Flotte) 09/01/06 – 08/31/07

NIH (University of Florida)

**Project #2 Gene Therapy using Viral Vector for Lung and Cardiovascular Disease**

The purpose of the study is to provide tandem MS analysis and other biochemical assays crucial for determining the correction of the FAO disorders in cell culture and animal models.

R01 DK054936 (Gerard Vockley) 02/15/99 – 02/28/14

NIH

**Metabolism of Short Chain Acyl-CoA’s and its Deficiency**

The purpose of the study is to identify molecular defects responsible for causing SCAD, SBCAD, and IBD deficiencies, and to characterize the effects of mutations on enzyme function.

R01 DK045482 (Gerard Vockley) 08/01/93 – 04/30/06

NIH

**Molecular Characterization of Acyl-CoA Dehydrogenases**

The purpose of the study is to Investigate important structure/function relationships in the ACD gene family.

BMRN PKU-006 (Gerard Vockley) 01/01/05 – 12/31/07

BioMarin Pharmaceutical Inc.

**A Phase 3, Multicenter, Randomized, Double-blind. Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin 20mg/kg/day to increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted diet.**

The purpose of this diet study is to evaluate the effect of Phenoptin on Phenylalanine tolerance.

BMRN PKU-001 (Vockley) 01/01/05 – 12/31/07

BioMarin Pharmaceutical Inc.

**A Phase 2, Multicenter, Open-Label Study to Evaluate the Response to and Safety of an 8-day Course of Phenoptin Treatment in Subjects with Phenylketonuria Who Have Elevated Phenylalanine Levels.**

The purpose of the study is in support of a Phenoptin’s regulatory approval application submitted to the U.S. Food and Drug Administration.

BMRN PKU-003 (Gerard Vockley) 01/01/05 – 12/31/07

BioMarin Pharmaceutical Inc.

**A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenoptin in Subjects with Phenylketonuria Who Have Elevated Phenylalanine Levels.**

The purpose of the study is in support of a Phenoptin’s regulatory approval application submitted to the U.S. Food and Drug Administration.

U54 RR019455 (Ronald Sokol) 08/01/05 – 07/31/07

NIH

**ACD9 Deficiency: A New Genetic Cause of Acute Liver Failure**

The purpose of the study is to test the hypothesis that ACD9 Deficiency represents a previously unrecognized cause of liver disease, including sudden liver failure in otherwise healthy individuals.

R01 NS051813 (Maureen Durkin) 10/01/06 – 09/30/09

NIH

**Epidemiology of 2-Methylbutyryl-CoA Dehydrogenase Deficiency (SBCADD) in the Hmong-American population of Wisconsin**

My role in this project is to provide molecular and biochemical diagnosis of SBCAD deficiency in patients.

0655512U (Gerard Vockley) 07/01/06 - 06/30/08

American Heart Association

**Cardiomyopathy in β-oxidation defects**

The purpose of this study is to characterize the molecular determinants predictive of the development of cardiomyopathy in very long chain acyl-CoA dehydrogenase deficiency

R01 DK049200 (Vladimir Ritov) 06/01/07 – 05/31/09

NIH

**Mitochondrial Impairment in Muscle Insulin Resistance**

Our first specific aim will be to measure the functional capacity of mitochondria in human skeletal muscle in obesity and type 2 DM. The second specific aim will be to examine the morphology of mitochondria in human skeletal muscle in obesity and type 2 DM. The third specific aim will be to examine the pathogenesis of mitochondrial damage in obesity and type 2 DM. The fourth specific aim will be to assess whether exercise and diet can heal mitochondria in obesity and type 2 DM.

DK078775 (Gerard Vockley) 04/01/08 - 03/31/21

NIH

**Inborn Errors of Long Chain Fat Metabolism**

The goal of this study is to characterize the physiological roles of LCAD, VLCAD, and ACD9 and explore the ramifications of genetic deficiencies of these enzymes in humans and mouse models.

U54 HD061939 (William Rizzo) 09/29/09 – 08/31/20

NIH

**Sterol and Isoprenoid Disease Research Consortium (STAIR)**

The STAIR Consortium was created to study a group of inherited diseases bound by common biochemistry. The consortium will conduct four major clinical trials and a therapeutic trial to evaluate the efficacy of cholesterol therapy in Smith-Lemli-Opitz Syndrome (SLOS). The consortium will support a full-scale training program in the field of sterol and isoprenoid diseases and will share resources with the NIH Rare Diseases Clinical Research Network (RDCRN).

PAL-003(Gerard Vockley) 11/19/09 – 11/18/15

BioMarin

**Phase 2 Ext. Open-Label, Dose-Finding Study to evaluate the Safety, Efficacy and Tolerability of Multiple sub-Q Doses of rAvPAL-PEG in Subjects with PKU.**

The primary objective of the study is: to evaluate the effect of long-term administration of Sc injections of rAvPAL-PEG on blood Phe concentrations in subjects with PKU.

HPN-100-005 (Gerard Vockley) 01/01/10 – 12/31/11

Hyperion Therapeutics

**A Phase 2, Fixed Sequence, Switch-Over Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children 6-17 Years of Age with Urea Cycle Disorders**

The primary objective of the study is: to evaluate the safety and pharmacokinetic (PK) characteristics of HPN-100 as compared to sodium phenylbutyrate (NaPBA) in pediatric subjects with urea cycle disorders (UCDs).

HPN-100-006 (Gerard Vockley) 01/01/10 – 12/31/11

Hyperion Therapeutics

**A Phase 3, Randomized, Double-Blind, Cross-Over, Active-Controlled Study of the Efficacy and Safety of HPN-100, Glyceryl-tri-(4-phenylbutyrate), for the Treatment of Adults with Urea Cycle Disorders (Help UCD)**

The primary objective of the study is: to establish the non-inferiority of HPN-100 as compared to sodium phenylbutyrate (NaPBA) as assessed by venous ammonia.

HPN-100-007 (Gerard Vockley) 01/01/10 – 12/31/11

Hyperion Therapeutics

**A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)**

The primary objective of the study is: to evaluate the long-term safety and it’s control of venous ammonia in the management of urea cycle disorders (UCDs).

N/A (Gerard Vockley) 09/01/10 – 08/31/15

Enobia Pharma

**Safety and Efficacy of ENB-0040 in Infants & Children < 5 with Hypophosphosphatasia**

The primary objective is to study the effect of ENB-0040 treatment on skeletal manifestations of HPP as measured by radiographs.

N/A (Gerard Vockley) 09/26/08 – 09/26/21

BioMarin

**PKUDOS – PKU Demographics, Outcomes, and Safety Registry**

The objective of this study is to evaluate the safety of long-term treatment with Kuvan.

SAP4100033126 (Bret Goodpaster) 09/01/06 – 05/31/10

PA Department of Health

**Determinants and Treatment of Obesity.**

My subsection of this grant focuses on identification of variations in energy metabolism in morbid obesity.

N/A (Gerard Vockley) 03/17/10 – 03/16/12

SHS International

**Safety and Efficacy of Lanaflex II in Improving Plasma Phenylalanine Levels in PKU Subjects who are Non-Compliant with a Phe-Restricted Diet**

The primary objective is to investigate the effects of Lanaflex II in reducing plasma Phe levels.

HPN-100-011 (Gerard Vockley) 02/10/11 – 02/09/13

Hyperion Therapeutics

**Long-Term Use of HPN-100 in Urea Cycle Disorders**

The primary objective of the study is: to follow the subjects’ transition to the study and provide a six month follow up for mental testing, ammonia levels and routine safety screens.

R01 FD003895 (Melanie Gillingham) 05/20/11 – 04/30/15

Oregon Health & Science University

**Triheptanoate Therapy of Long-chain Fatty Acid Oxidation Disorders**

The overall goal of the project is to examine the relationship between Fatty Acid oxidation (FAO) and the Citric Acid Cycle (CAC) in patients with FAO defects and develop novel, improved therapies for their treatment.

PAL-004 (Gerard Vockley) 08/18/11 – 08/17/13 BioMarin

**Phase 2 study to Evaluate the Safety, Efficacy and Tolerability of Sub-Q Doses of rAvPAL-PEG administered Daily in Subjects with PKU.**

The primary objective of the study is to evaluate the effect of daily administration of rAvPAL-PEG on the reduction of blood Phe concentrations in subjects with PKU.

PRISM 165-301 (Gerard Vockley) 05/07/13 – 05/06/15

BioMarin

**Phase 3, Open-Label, Randomized, Multi-Center Study to Assess the Safety and Tolerability of an Induction, Titration and Maintenance Dose regimen of BMN-165 Self-Administered in Adults Not Previously Treated with BMN-165**

The primary objective of the study is to evaluate the effect of treatment with BMN-165 on an adult population.

PRISM 165-302 (Gerard Vockley) 06/25/13 – 09/24/16

BioMarin $1,322,850

**Three-Part, Phase 3, Double-Blind, Placebo-Controlled, Four-arm, Discontinuation Study to Evaluate the Efficiency and Safety of Sub-Cutaneous Injections of BMN-165 Self-Administered**

This is the follow-up study for PRISM 165-302.

N/A (Gerard Vockley) 07/12/13 – 07/11/15

Ultragenyx Pharmaceuticals

**A Retrospective Medical Record Review Study to Assess the Clinical Outcome of Triheptanoin Treatment on Patients Affected by Long-Chain Fatty Oxidation Disorders**

This study is a retrospective chart review of FAOD-affected subjects who participate in the triheptanoin compassionate use program. Based on eligibility criterion data from the medical records will be abstracted to collect the important clinical events, safety events and laboratory results that characterize FAOD as defined in the protocol.

N/A (Gerard Vockley) 08/12/13 – 06/30/20

Ultragenyx Pharmaceuticals

**Dietary Therapy for Inherited Disorders of Energy Metabolism**

The primary hypothesis of this study is that triheptanoin is an effective dietary supplement for the treatment of inherited disorders of energy metabolism in substitute for standard medium chain triglycerides. Efficacy will be evaluated through standard of care clinical and laboratory parameters used to follow patients as part of their metabolic care. This includes monitoring of the known associated complications of these diseases including hypoglycemia, cardiomyopathy and episodes of rhabdomyolysis. Data obtained through this protocol will lead to development of a formal clinical trial for FDA approval of use triheptanoin.

U54 NS078059 (Michio Hirano) 09/30/12 - 08/31/24

NIH/Columbia Univeristy

**North American Mitochondrial Disease Consortium**

Patient Enrollment in to the NAMDC Patient Registry and Bio-Repository.

N/A (Gerard Vockley) 11/12/13 – 05/11/15

Ultragenyx Pharmaceuticals

**An Open-Label Phase 2 Study to Assess the safety and Clinical Effects of UX007 on Long-Chain Fatty Oxidation Disorders (LC-FAOD)**

This study will assess whether UX007 is safe and effective in subjects with LC-FAOD. FAOD is an inherited disorder in which the body is unable to break down fats present in normal foods, which would produce energy. People with FAOD are usually treated by limiting the amount of fat in their diets and then placed on a diet which includes a supplement of medium chain triglycerides (MCT). MCT are shorter length fats that can be normally absorbed by people with LC-FAOD and used to make energy.

N/A (Gerard Vockley) 03/01/14 – 02/28/14

Children’s Research Institute

**N-carbamlyglutamate in the treatment of hyperammonenmia**

The overall objective of this project is to determine whether treatment of acute hyperammonemia with N-carbamyl-L-glutamate (NCG) in propionic academia (PA), methylmalonic academia (MMA), carbamyl phosphate synthetase 1 deficiency (CPSD) and ornithine transcarbalmylsae deficiency (OTCD) changes in the clinical outcome of diseases.

N/A (Gerard Vockley) 03/18/14 – 03/17/16

Shire Human Genetic Therapies, Inc.

**Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric Ear, Nose and Throat (ENT) Surgery (Adenoidectomy and/or Tonsillectomy and/or Tympanostomy) (The HATT Project)**

The primary objective of this study is to evaluate the positive screening rate of MPS II subjects by screening a high-risk male pediatric population who have had or are scheduled for 1 or more specific ENT surgical procedures (adenoidectomy and/or tonsillectomy and/or tympanostomy) and who have a previously repaired or present evidence of an inguinal and/or umbilical hernia. Also, to evaluate the positive screening rate of MPS I and VI in the same high-risk population.

N/A (Gerard Vockley) 04/17/14 – 04/16/16

Wellstat Therapeutics

**Open-Label Study of Uridine Triacetate in Pediatric Patients with Hereditary Orotic Aciduria**

The primary objective is to document the continued clinical benefit of exogenous uridine when patients are

switched from oral administration of uridine to oral administration of uridine triacetate.

N/A (Gerard Vockley) 11/17/14 – 10/31/20

Ultragenyx Pharmaceutical Inc.

**An Open-label Long-Term Safety and Efficacy Extension Study in Subjects with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Previously Enrolled in UX007 or Triheptanoin Studies**

The primary objective of the study is to evaluate the long-term safety and efficacy of UX007 in LC-FAOD subjects. The secondary objectives of the study are to evaluate the effect of UX007 on energy metabolism in LC-FAOD and to evaluate impact of UX007 on clinical events associated with LC-FAOD.

N/A (Gerard Vockley) 01/01/15 – 12/31/16

Ultragenyx Pharmaceutical, Inc.

**ACAD9 and its role in energy metabolism**

The overall aim of this project is to better understand the role of ACAD9 in normal mitochondrial energy metabolism and the physiologic derangements induced by its deficiency.

N/A (Gerard Vockley) 02/01/15 - 01/31/16

National PKU Alliance

**Hepatocyte and Human Amnion Epithelial Cell Transplantation**

Objective: To improve transplant methods, optimize liver environment to maximize cell engraftment, and stabilize PAH to attain the highest enzyme efficiency. When successful, these studies will generate preclinical data relevant to help move AE cell transplant for this disorder from bench to the clinic.

R01 GM108073 (Michael John Palladino) 04/01/15 - 01/31/19

NIH

**Pre-clinical studies of novel mitochondrial gene therapy**

Mitochondrial diseases are devastating untreatable diseases that affect ~1 in 3-5000 humans. We propose preclinical research to develop and demonstrate efficacy of a novel mitochondrial-targeted RNA approach as a viable gene therapy. This approach will be developed and tested in vitro in human cells and in vivo using an established invertebrate genetic model of mitochondrial disease.

AT1001-042 (Gerard Vockley) 05/15/15 – 05/14/19

Amicus Therapeutics

**An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects with Fabry Disease**

The purpose of this study is to investigate the long-term safety and explore the efficacy/pharmacodynamics of migalastat HCl administered 150 mg every other day (QOD).

N/A (Gerard Vockley) 06/25/15 – 06/24/17

ArmaGen

**A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 1-Sulfatese (IDS) Fusion Protein, AGT-182 in Adult Patients with MPS II**

The primary objective of this study is to determine a safe and tolerated dose of AGT-182 in adults with MPS II.

N/A (Gerard Vockley) 06/17/15 – 06/16/17

ArmaGen

**A Phase I Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human**

**Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-181 in Adult Patients with Mucopolysaccharadisosis (MPS 1)**

The objective of this study is to determine a safe and well tolerated dose of AGT-181 in adults with MPS I.

N/A (Gerard Vockley) 07/28/15 – 07/27/18

Reata Pharmaceuticals

**A phase 2 study of the safety, efficacy, and pharmacodynamics of RTA 408 in the treatment of Mitochondrial Myopathy**

This two-part study will evaluate the efficacy, safety, and pharmacodynamics of RTA 408 in the treatment of patients with mitochondrial myopathy.

N/A (Gerard Vockley) 10/07/15 – 10/06/17

Alexion Pharma

**An open-label, multicenter, expanded access program for asfotase alfa treatment for patients with infantile- or juvenile-onset Hypophosphatasia (HPP)**

The primary objective is to assess the safety and tolerability of subcutaneous (SC) injections of asfotase alfa administered 6 times weekly (at a dose of 1 mg/kg) or 3 times weekly (at a dose of 2 mg/kg).

N/A (Gerard Vockley) 10/19/15 – 10/18/20

Alexion

**An Observational, Longitudinal, Prospective, Long-Term Registry of Patients with Hypophosphatasia**

This multinational, multicenter, observational, prospective, long-term registry is designed to collect data on epidemiology, HPP history, clinical course, symptoms (including multi-systematic aspects of disease), and burden of disease from patients of all ages who have a diagnosis of HPP.

N/A (Gerard Vockley) 11/12/15 – 11/11/16

Mitobridge, Inc.

**Evaluation of PPARd modulators in cellular models of FAOD**

We will test Mitobridge-provided PPAR delta modulators in various fatty acid oxidation deficiency (FAOD) patient cell lines. This study will be carried out in two phases; phase 1 will test compounds in four cell lines per disease in three FAOD mutations. Phase 2 will test compounds in ten or more cell lines to achieve sufficient statistical power in focused FAOD mutation(s).

R44 HD088211 (Scott Norton) 09/01/16 - 07/31/20

Baebies, Inc.

**Point-of-Birth Newborn Screening for MCAD/VLCAD and Galactosemia to Eliminate Deadly Delays for Time Critical Conditions**

The project objective is to demonstrate the technical feasibility of using digital microfluidics to detect medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency and galactosemia in whole blood samples for improved newborn screening at point-of-birth.

N/A (Gerard Vockley) 12/20/17 - 12/19/20

Stealth BioTherapeutics

**A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondrial Myopathy Followed by an Open-Label Treatment Extension**

The objectives of this study are divided into two parts. PART 1 is a 24-week, randomized, double-blind, parallel-group, placebo-controlled assessment of the efficacy and safety of single daily subcutaneous (SC) doses of 40 mg elamipretide (vs placebo) administered through the elamipretide delivery system as a

treatment for subjects with primary mitochondrial myopathy (PMM). PART 2 is an up to 144-week, open-label assessment of the long-term safety and tolerability of single daily SC doses of 40 mg elamipretide administered through the elamipretide delivery system in subjects with PMM.

N/A (Gerard Vockley) 03/23/18 – 06/30/18

Homology

**A 5-year retrospective analysis of two cohorts (BCH and Pitt) of Individuals 10-40 with a diagnosis of Hyperphenylalaninemia from two specialized tertiary care clinics**

The goal of this study is to evaluate individuals 10-40 with a diagnosis of Hyperphenylalaninemia.

N/A (Gerard Vockley) 04/19/18 – 04/18/19

Reneo Pharmaceuticals, Inc.

**Reneo Pharmaceuticals Research Collaboration for Laboratory Experiments to Test a Potential Therapy for Patients with Fatty Acid Oxidation Disorders**

This study proposes to test PPAR activators provided by Reneo Pharmaceuticals in a number of vitro assays.

N/A (Gerard Vockley) 04/17/18 – 04/16/19

Reneo Pharmaceuticals, Inc.

**Reneo FAOD Patient Survey**

This study proposes to better understand the FAOD population and to pre-identify patients who might be eligible to participate in a clinical trial of REN001.

N/A (Gerard Vockley) 12/17/18 – 12/31/19

Carnot, LLC

**Treatment of Fatty Acid Oxidation Disorder by cardiolipin binding peptides**

The goal of this project is to examine the status of the TCA cycle in patients with PA and MMA before and after treatment with succinate/citrate, and to examine its effect in cardiomyopathy in patients with PA.

N/A (Gerard Vockley) 12/20/18 – 12/19/19

Synlogic

**A Phase 1/2a, First-in0human, Oral Single and Multiple Dose Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Adult Subjects with Phenylketonuria to Evaluate Safety, Tolerability, Kinetics, and Pharmacodynamics**

The primary objective is to evaluate the safety and tolerability of SYNB1618 following single and multiple doses in health volunteers and subjects diagnosed with PKU.

N/A (Gerard Vockley) 07/01/18 – 12/31/19

Imbria Pharmaceuticals, Inc.

**Anapleurotic therapy for Disorders of Propionate Metabolism**

The goal of this project is to examine the status of the TCA cycle in patients with PA and MMA before and after treatment with succinate/citrate, and to examine its effect in cardiomyopathy in patients with PA.

1. **Seminars and invited lectureships related to your research.**

**Visiting Professor/Named Lecturer**

Rady Children’s Hospital Grand Rounds, San Diego, CA, (2010)

Michael Palmeri Memorial Lectureship, Children’s Hospital of Philadelphia (2011)

Grand Rounds, Halifax Children’s Hospital (2011)

Grand Rounds, University of Edmonton Children’s Hospital (2013)

Grand Rounds, University of British Columbia, Vancouver Children’s Hospital (2014)

Ron Scott Memorial Lecture, University of Washington Children’s Hospital, Seattle (2014)

Aaron Michael Graham Memorial Lectureship, Children’s Hospital of Los Angeles (2016)

Haworth Visiting Professor, University of Manitoba and Children’s Hospital of Manitoba (2017)

Boston Children’s Hospital Grand Rounds (Manton Lecture), Boston, MA (2017)

Franklin and Marshall College. Leadership in Biomedical Research and Medicine Lecture3 (2018)

Brown University Department of Pediatrics Grand Rounds. (2021)

General Hospital Medical Genetics Grand Rounds. (2022)

University of South Florida Department of Genetics Grand Rounds. (2022)

**Invited Presentations at National Meetings (Selected from several hundred)**

1. Society for Inherited Metabolic Disorders Annual Meeting. (1989). Orlando, FL. Molecular Characterization of Type III Isovaleric Acidemia.

2. Society for Inherited Metabolic Disorders Annual Meeting. (1991). Santa Fe, NM. Central Pontine Myelinolysis in Ornithine Transcarbamylase Deficiency.

3. Second International Congress on Disorders of β-Oxidation. (1991). Philadelphia, PA. Molecular Defects in Isovaleric Acidemia.

4. Society for Inherited Metabolic Defects Annual Meeting. (1993). Asilomar, CA. Molecular and Biochemical Characterization of Mutations Responsible for Isovaleric Acidemia.

5. Society for Inherited Metabolic Disorders Annual Meeting. (1995). Perdido Beach, AL. Cloning and Characterization of Short/Branched Chain Acyl-CoA Dehydrogenase.

6. Society for Inherited Metabolic Disorders Annual Meeting. (1996). Cocoyoc, Mexico. Molecular Modeling as an Aid to Study Point Mutations in Isovaleric Acidemia.

7. NIH Workshop on Structural Biology in Inborn Errors of Metabolism. (1996). Bethesda, MD. Structure/Function Relationships in Acyl-CoA Dehydrogenases.

1. March of Dimes and American College of Medical Genetics Annual Meeting. (1998). Los Angeles, CA. Short chain acyl-CoA dehydrogenase deficiency.
2. American Society of Human Genetics Annual Meeting. (1998). San Francisco, CA. Splicing mutations in the IVD gene in isovaleric acidemia.
3. Society for Inherited Metabolic Disorders Annual Meeting. (1999). Lake Lanier, Georgia. New advances in inborn errors of metabolism. Workshop organizer and speaker.
4. American Society of Human Genetics Annual Meeting. (2001).Philadelphia, PA. Short/branched chain acyl-CoA dehydrogenase deficiency.
5. Society for Inherited Metabolic Disorders Annual Meeting (2002). Asilomar, CA. Beyond the human genome project. Workshop chair and speaker.
6. American Society of Human Genetics Annual Meeting. (2002). Baltimore, MD. Isobutyryl-CoA dehydrogenase deficiency.
7. Pediatric Grand Rounds. University of California, Davis. (2003). Davis, CA. Expanded newborn screening for inborn errors of metabolism.
8. Society for Inherited Metabolic Disorders Annual Meeting. Asilomar CA (2005). Redefining long chain fat metabolism in humans.
9. Donough O’Brien Presidential Lecturer, Society for Inherited Metabolic Disorders Annual Meeting. Nashville, TN (2007). Newborn Screening: After the Thrill is Gone.
10. American College of Medical Genetics Annual Meeting, Phoenix AZ. (2007) Inborn errors of metabolism and complex patterns of disease.
11. Society for Inherited Metabolic Disorders Annual Meeting. Asilomar. CA (2008). A new inborn error of sterol metabolism.
12. New developments in the treatment of fatty acid oxidation disorders. (2010). Presented at the annual meeting of the American College of Medical Genetics, Albuquerque, NM
13. Clinical trials for mitochondrial myopathies. **Vockley J** (2011). Invited Plenary lecture. Presented at the United Mitochondrial Disease Foundation 2011 Annual Meeting.
14. Long chain fatty acid oxidation disorders. **Vockley J** (2012). Invited Plenary lecture. Presented at the American College of Medical Genetics 2012 Annual Meeting.
15. Personalized medicine and inborn errors of metabolism. **Vockley J** (2012). Invited Plenary lecture. Presented at the Society of Inborn Errors of Metabolism 2012 Annual Meeting.
16. Development of a New PKU Guideline. **Vockley J.** (2013) Invited lecture, American College of Medical Genetics 2013Annual Meeting
17. Infantile hypophosphatasia. Presented at the American College of Medical Genetics 2014 Annual Meeting. Memphis TN
18. The mitochondrial architecture of energy metabolism. Keynote Address at the United Mitochondrial Disease Foundation Annual Meeting, 2014. Pittsburgh, PA.
19. Results from a randomized trial of triheptanoin compared to MCT oil in patients with long chain fatty acid oxidation defects. (2015). Presented at the Annual Meeting of the Society for Inherited Metabolic Disorders, Salt Lake City, UT
20. Mitochondrial respiratory chain disorders in the Old Order Amish Population. (2015). Presented at the Annual Meeting of the Society for Inherited Metabolic Disorders, Salt Lake City, UT
21. Keynote Speaker, A Plain Population Genome Project, Amish Translational Medicine Meeting. (2016) South Bend, IN
22. Plenary Speaker, Update on the International Network for Fatty Acid Oxidation Research and Management. (2016). Presented at the Annual Meeting of the Society for Inherited Metabolic Disorders, Jacksonville, FL
23. Positive response to Infliximab in a patient with very long-chain acyl-CoA dehydrogenase deficiency. (2017). Presented at the annual meeting of the American College of Medical Genetics and Genomics. Phoenix, AZ
24. Newborn screening for heavy metals. Annual Meeting of the Newborn Screening Translational Research Network. Baltimore, MD. 2017
25. Results from a 78-week single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with moderate to severe long-chain fatty acid oxidation disorders (LC-FAOD). SIMD Annual Meeting. San Diego. 2018
26. Mitochondrial targeted antioxidants improve mitochondrial function in very long-chain acyl-coA dehydrogenase deficient fibroblasts. SIMD Annual Meeting. San Diego. 2018
27. Identifying rare metabolic disorders of energy dysfunction in patients with treatment-resistant depression. ACMG Annual Meeting. 2019
28. Treatment of bioenergetic dysfunction in propionic acidemia. SIMD Annual Meeting. Seattle. 2019
29. Metabolic analysis reveals evidence for branched chain amino acid catabolism crosstalk and the potential for improved treatment of organic aciduria. SIMD Annual Meeting. Virtual presentation. 2020
30. A long day’s journey: new therapies for rare disorders. Brown University Department of Pediatrics Grand Rounds.Virtual presentation. 2021
31. Metabolic imbalance in chronic depression: implications for diagnosis and treatment. Massachusetts General Hospital Medical Genetics Grand Rounds. Virtual presentation. 2022
32. Long chain fatty acid oxidation disorders. University of South Florida Department of Pediatrics Grand Rounds. Virtual presentation. 2022
33. A New Era in Therapies for Genetic Disorders: FAODs. Texas Newborn Screening Program Annual Meeting. Virtual presentation. 2022

**Invited Presentations at International Meetings (Selected from several hundred)**

1. Vth International Congress on Inborn Errors of Metabolism. (1990). Asilomar, CA. Molecular Characterization of Mutations Responsible for Isovaleric Acidemia.

2. VIth International Congress on Inborn Errors of Metabolism. (1994). Milan, Italy. Mutations in Isovaleric Acidemia. Molecular and Biochemical Characterization of Mutations Responsible for Isovaleric Acidemia.

3. International Working Group on Disorders of β-Oxidation. (1995). Aarhus, Denmark. Chair of Session on Structure and Substrate Specificity of Acyl-CoA Dehydrogenases.

4. VII International Congress on Inherited Metabolic Disorders. (1997). Vienna, Austria. The use of molecular modeling in inborn errors of metabolism.

1. SCAD collaborative group workshop. (1999). Aarhus, Denmark. SCAD deficiency.
2. VII International Congress on Inborn Errors of Metabolism. (2000). Cambridge, England. Plenary Session Chair. Workshop chair. Invited lecture on Disorders of ß-Oxidation
3. Annual meeting of the Society for Study of Inherited Metabolic Disorders. (2002). Dublin, Ireland. Workshop chair. Invited presentation on Synergistic Heterozygosity
4. International Working Group on Disorders of ß-Oxidation. (2003). Session chair. Invited presentation on New Disorders of ß-Oxidation.
5. IXth International Congress on Inborn Errors of Metabolism. (2003). Brisbane, Australia. Plenary Session Chair, Disorders of Mitochondrial Energy Metabolism.
6. International Symposium on -oxidation. Amsterdam. (2005). Acyl-CoA dehydrogenases: new enzymes and new disorders.
7. Mitochondrial -oxidation: new developments. (2006). Presented at the International Congress on Inherited Metabolic Disorders. Chiba. Japan
8. Keynote address. Annual meeting of the Society for Study of Inherited Metabolic Disorders. Lisbon. Spain, (2008). Energy metabolism as a complex genetic trait.
9. Tissue specificity of mitochondrial -oxidation. (2008). Fulda. Germany.
10. Xth International Congress on Inborn Errors of Metabolism. San Diego, CA. (2009). Characterization of a multi-functional protein complex containing the mitochondrial respiratory chain and fatty acid oxidation.
11. Presented at the annual meeting of the Society for Inherited Metabolic Disorders Annual Meeting. Istanbul, Turkey. (2010). Changes in the mitochondrial proteome in fatty acid oxidation deficient mice.
12. Presented at the XIth Annual Congress on Inborn Errors of Metabolism, Barcelona, Spain. (2013) The molecular Architecture of Mitochondrial Energy Metabolism
13. Moonlighting in mitochondria; ACAD9 plays a duel role in energy metabolism in mitochondria. (2013). Presented at XI th International Congress on Inborn Errors of Metabolism. Barcelona, Spain
14. Transplant for metabolic disease. Presented at the Garrod Society Annual Meeting, Ottowa, CA
15. Novel therapy of long chain fatty acid oxidation disorders using triheptanoin. **Vockley J.** (2013) XI th International Congress on Inborn Errors of Metabolism. Barcelona, Spain.
16. Emerging clinical trials for fatty acid oxidation disorders. (2015). Presented at the annual meeting of the International Fatty Acid Oxidation Research and Management Network. Lyon. France.
17. Molecular Architecture of mitochondrial energy metabolism. (2015). Presented at the annual meeting of the Society for the Study of Inherited Metabolic Disorders. Lyon. France.
18. Molecular Architecture of mitochondrial energy metabolism. (2015). Presented at the annual meeting of the Society for the Study of Inherited Metabolic Disorders. Lyon. France.
19. Advances in therapy for PKU. (2016). Presented at the Annual Meeting of the Garrod Society, Halifax, Canada
20. Advances in fatty acid oxidation research. (2016). Presented at the annual meeting of the International Network for Fatty Acid Oxidation Research and Management (INFORM). Boston, MA
21. Novel therapies for fatty acid oxidation disorders. (2016). Presented at the annual meeting of the Society for the Study of Inherited Metabolic Disorders. Rome, Italy
22. Triheptanoin in the treatment of long chain fatty acid oxidation disorders: Report of two FDA Phase 2 trial results. (2017). Presented at the annual meeting of the Portuguese Society of Metabolic Disorders. Lisbon, Portugal.
23. Fatty acid oxidation update. (2017). Plenary Lecture. International Congress on Inherited Metabolic Disorders. Rio De Janeiro, Brazil
24. Results from a 78-week Single-arm, Open-label Phase 2 Study to Evaluate UX007 in Pediatric and Adult Patients with Moderate to Severe Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD). (2017). International Congress on Inherited Metabolic Disorders. Rio De Janeiro, Brazil
25. Phase 2 Long-term Pegvaliase Treatment for Adults with Phenylketonuria: Updated Year 5 Safety and Efficacy Data from the PAL-003 Extension. (2017). International Congress on Inherited Metabolic Disorders. Rio De Janeiro, Brazil
26. Endoplasmic reticulum-mitochondria crosstalk and redox homeostasis disruption in very long-chain acyl-CoA dehydrogenase deficient fibroblasts. (2017). International Congress on Inherited Metabolic Disorders. Rio De Janeiro, Brazil
27. Antioxidant therapy as an adjunct for treatment of long chain fatty acid oxidation disorders. (2017). International Congress on Inherited Metabolic Disorders. Rio De Janeiro, Brazil
28. Novel mechanisms of pathogenesis in mitochondrial trifunctional protein deficiency: implications for clinical outcome and treatment. (2017). International Congress on Inherited Metabolic Disorders. Rio De Janeiro, Brazil
29. Elucidating the mitochondrial architecture of branched-chain amino acid metabolism enzymes. (2017). International Congress on Inherited Metabolic Disorders. Rio De Janeiro, Brazil
30. PKU Research Update. (2017). Asia-Pacific PKU Summit. Osaka. Japan.
31. Targeting cardiolipin: a new therapeutic approach to treat long chain hydroxy acyl CoA dehydrogenase and mitochondrial trifunctional protein deficiency. SSIEM Annual Meeting. 2018. Athens, Greece
32. A Phase 1/2a, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blind, Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Adult Subjects with Phenylketonuria to Evaluate Safety, Tolerability, Kinetics, and Pharmacodynamics. SSIEM. Annual Meeting. 2019. Amsterdam, The Netherlands
33. Interim results from an open-label, long-term extension study to evaluate the safety and efficacy of triheptanoin (UX007) in LC-FAOD. SSIEM Annual Meeting. 2019. Amsterdam, The Netherlands
34. Assessing Referral of Plain Community Members for Genetic Services at UPMC Children’s Hospital of Pittsburgh: A Quality Improvement Study. ACMG Annual Meeting. 2020
35. Rare metabolic disorders of energy dysfunction in patients with treatment-resistant depression. SIMD Annual Meeting. 2020
36. Metabolic analysis reveals evidence for branched chain amino acid catabolism crosstalk and the potential for improved treatment of organic aciduria. SIMD Annual Meeting. 2020
37. **C**linical Outcomes of Major Clinical Events and Emergency Triheptanoin in Critically Ill Patients With Long-chain Fatty Acid Oxidation Disorders. ACMG 2021 Annual Meeting. Virtual format.
38. Characterization of variants of uncertain significance in isovaleryl-CoA dehydrogenase identified through newborn screening: An approach for faster analysis. SSIEM 2021 Annual Meeting, Sydney Austrailia.
39. Restoration of interaction between FAO and ETC proteins in VLCAD and VLCAD-deficient mice mitochondria by addition of recombinant VLCAD. SSIEM 2021 Annual Meeting, Sydney Austrailia.
40. Defining Therapeutic Options for Combined D,L-2 Hydroxyglutaric Aciduria. SSIEM 2021 Annual Meeting, Sydney Austrailia.
41. Gene therapy for inborn errors of metabolism: current challenges and opportunities. Middle East Genetic and Metabolic Society. Virtual presentation. 2021
42. Whole genome sequencing for genetic diseases across the age spectrum. Arab Medicine. Virtual presentation. 2021
43. Targeting treatments of rare diseases: Biology comes to life! Arab Pediatrics. Virtual presentation. 2021
44. Advances and Treatments of LCFAODs. Brazilian Society for Inborn Errors of Metabolism. Virtual presentation. 2021
45. Inborn errors of long chain fatty acid oxidation. Taiwan Neurology Society. Virtual presentation. 2021
46. A long day’s journey: new therapies for rare disorders. South American Society for Inborn Errors of Metabolism. Virtual presentation. 2022
47. Moving forward one disease at a time. Irish North/South Rare Disease Day. Virtual presentation. 2022
48. Cardiolipin Remodeling Deregulation and Mitochondrial Bioenergetics Alterations in Trifunctional Protein (TFP) Deficiency. SIMD 2022 Annual Meeting. Orlando, FL
49. Restoring succinyllysine antigenic signal and improving O2 consumption of CPT II deficient cells treated with anaplerotic compounds. SSIEM 2022 Annual Meeting. Freyburg, Germany.
50. A new class of anaplerotic compounds restores cellular lysine succinylation and antigenic signal. SSIEM 2022 Annual Meeting. Freyburg, Germany.
51. A CRISPR/Cas9 genome-edited PAH-deficient cell line for studying PKU. SSIEM 2022 Annual Meeting. Freyburg, Germany.

**3. Other research related activities.** Include editorships, journal refereeing, study section memberships, extra-mural grant reviewing, national course directorships and specialty board memberships.

Meeting Chair. Annual meeting of the International Network for Fatty Acid Oxidation Research and Management. (2020)

Chair DMSB, NIH NIDDK Radiant Project 6/2019-current

Meeting Chair. Annual meeting of the International Network for Fatty Acid Oxidation Research and Management. (2019)

Meeting Chair. Annual meeting of the International Network for Fatty Acid Oxidation Research and Management. (2018)

Meeting Chair. Annual meeting of the International Network for Fatty Acid Oxidation Research and Management. (2017)

Chair, Scientific Advisory Board. Newborn Screening Translational Research Network. (2016-Current)

Member, NIH Director’s Young Investigator Award Second Tier Review Group (NIH). (2016-current)

Member, Undiagnosed Disease Network Metabolomics Core Scientific review committee (NIH). (2015)

Member, Big Data Award ad hoc review committee (NIH) (2014)

Member, NIH Director’s Award review committee (NIH) (2012-current)

Founder and Chair International Network for Fatty Acid Oxidation Disorders Research and Management (INFORM). 2013-current

Program Chair, United Mitochondrial Disease Foundation Annual Meeting (2013)

Chair, Sterol and Isoprenoid Research Collaborative Annual Meeting (2012)

Member, Pioneer Award ad hoc review committee (NIH (2012-2016)

Chair, Metabolomics K Award Study Section (NIH) (2012-Current)

Founder and Managing Editor, North American Metabolic Academy (2006-Current)

Communicating editor, Journal of Inherited Metabolic Disorders (2010-Current)

Assistant editor, Molecular Genetics and Metabolism (2008-Current)

Chair, International Congress of Inherited Metabolic Disorders, (2007-2009)

President, Society for Inherited Metabolic Disorders, 2005-2007

Chair, NIH National Institute of General Medical Sciences Human Mutant Cell Repository Advisory Panel (2003-2004)

Program Committee Member, American College of Medical Genetics, 2002-2005

Program Director, Society for Inherited Metabolic Disorders, 2002-2003

Chair, NIH National Institute of General Medical Sciences Human Mutant Cell Repository Advisory Panel (2005)

Member, NIH National Institute of General Medical Sciences Human Mutant Cell Repository Advisory Panel (2001 - 2005)

Medical Biochemistry Study Section, NIH, permanent member, 1997-2001

Board of Directors, The Metabolic Information Network (1998-2006)

Board of Directors, The Society for Inherited Metabolic Diseases (1998- 2007)

Member, *Ad Hoc* Site Visit Committee Maternal and Child Health Mental Retardation Center (1995)

Member, NIH Medical Biochemistry Study Section, Center for Scientific Review (1997-2001)

Program Chair, Society for Inherited Metabolic Disorders, North American Metabolic Academic Annual Meeting (2011)

**LIST OF CURRENT RESEARCH INTERESTS:**

1. Molecular architecture of mitochondrial energy metabolism
2. Molecular basis of defects of ß-oxidation and energy metabolism
3. Systems biology of energy metabolism
4. Structure/function relationships in acyl-CoA dehydrogenases
5. Gene modifying effects in disorders of energy metabolism
6. Gene therapy of acyl-CoA dehydrogenases
7. Novel therapies for disorders of energy metabolism
8. Novel genetic diagnostic techniques
9. Development of novel therapeutics for inborn errors of metabolism
10. Hepatocyte transplant for inborn errors of metabolism

**SERVICE:**

**1. University and Medical School.** Include committee service and chairmanships, administrative appointments and assignments.

Chair, Pennsylvania Rare Disease Advisory Council, Clinical Research Subcommittee, 2019-Current

Member, Pennsylvania Rare Disease Advisory Council, 2019-Current

Chair, NIH Ad Hoc Review Panel for RFA Center for Identification and Study of Individuals with Atypical Diabetes (3/2018)

Advisory Committee on Lead Exposure and the Hazards of Lead Poisoning in Pennsylvania (2017-Current)

Pennsylvania Birth Defects Registry Committee (2016-Current)

Member, Steering Committee, New York, Mid-Atlantic Regional Newborn Screening Consortium (2016- Current)

Chair, Newborn Screening Translational Research Network Steering Committee (2016-2018)

Member, United Mitochondrial Disease Foundation Scientific and Medical Advisory Board, 2015- Current

Member University of Pittsburgh School of Medicine Tenure Committee (2015- 2017)

Director, Center for Rare Disease Therapeutics, Children’s Hospital of Pittsburgh, (2015-Current)

Member of the Precision Medicine Steering Committee, University of Pittsburgh School of Medicine (2012-Current)

Chief of Medical Genetics, Children’s Hospital of Pittsburgh, (2004-Current)

Chair, Research Committee, Department of Medical Genetics, Mayo Clinic (1992-1998)

Chair, Department of Medical Genetics Staff Search Committee (1998-2002)

Member, Rochester Research Committee (1998-1999)

Chair, Interdepartmental Genetics Society, Mayo Clinic (1993-1997)

Educational Director, Biochemical Disease Detection Laboratory, Mayo Clinic (1994-1998)

Member, M.D, Ph.D. Committee (1997-Present)

Member, Institutional Animal Care and Use Committee, Mayo Clinic (1994-1999)

Vice-Chair, Institutional Animal Care and Use Committee, Mayo Clinic (1997-1998)

Chair, Institutional Animal Care and Use Committee, Mayo Clinic (1998-1999)

Member, Research Web Task Force (1998-1999)

Member, Molecular Medicine Task Force and Search Committee (1994-1998)

Member, Molecular Medicine Executive Committee (1995-1998)

Member, Research Committee, Department of Pediatrics (1994-1996)

Member, Balfour/Kendall Research Award Selection Committee (1994 and 1995)

Member, Eagles Grant Review Committee (1996)

Member, Department of Biochemistry and Molecular Biology Graduate Student Qualifying Examination Committee (1994-1997)

Member, Department of Lab Medicine, Biochemical Genetics Testing Task Force (1995-2004)

Member, Division of Lab Genetics Search and Planning Committee (1998-2004)

Member, Pediatric Council Task Force of Pediatric Research at Mayo (1997)

Member, Medical Chairs Forum, Mayo Clinic (2000-2004)

1. **Community Activities.** Include hospital appointments and consultantships.

Chair, HRSA Secretary’s Advisory Committee on Heritable Diseases in Childhood, Technology Subcommittee. (2010-2014)

Chair, American College of Medical Genetics Committee on Therapeutics (2010-2014)

Member Advisory Board Rare Disease Forum (2018-Current)

Member, Pennsylvania Rare Disease Advisory Council (2018-Current)

Member, Pennsylvania State Birth Defects Surveillance Advisory Board (2017-Current)

Member, Pennsylvania State Birth Defects Lead Advisory Board (2016-2019)

Member, HRSA Secretary’s Advisory Committee on Heritable Diseases in Childhood (2008-2014)

Chair, Pennsylvania State Newborn Screening Advisory Committee (2010-2019)

Member, Pennsylvania State Newborn Screening Advisory Committee (2006-Current)

Member, State of Minnesota Newborn Screening Ad Hoc Advisory Committee (1994-2004)

Medical advisor, Organic Acidemia Family Foundation (1991-Current)

Medical advisor, Fatty Acid Oxidation Family Support Group (1991-Current)

Medical advisor, Saving Lives through Screening Foundation (2004-Current)

Musician, St. Joseph Church Contemporary Music Group (2004-Current)

Assistant Scoutmaster, Boy Scouts of America (1996-2012)

Member, Rochester Catholic Schools Council (2002-2004)

Member, St. John the Evangelist Catholic Church Pastoral Council (2000-2004)

Co-director, St. Joseph Parish, contemporary Choir (2004-current)

Boy Scouts of America Troop 380 Scoutmaster (2012-2016)

Boy Scouts of America, Japeechen District Chair (2019- Current)

Boy Scouts of America, Laurel Highlands Council, Leadership Board (2019-current)

3. **Continuing Medical Education (CME) activities.**

Regular presenter for Children’s Hospital of Pittsburgh outreach CME programs

Course Director, Challenging the Paradigms: Liver Transplantation for Metabolic Disease, May 4-5, 2012, Pittsburgh, PA.

Many others!

Medscape 2020. MMA and PA, Is liver transplant always the best treatment option.

Medscape 2020. Long chain fatty acid oxidation disorders

Touch IME. Long chain fatty acid oxidation disorders: pathophysiology, diagnosis and management

Rockpoint CME. Breaking down long chain fatty acid oxidation disorder treatment. Review of current care and the latest advances

Total CME. 2020. Long chain fatty acid oxidation disorders

TEDx Talk:. 2/2017. A matter of balance: changing the rules in depression treatment